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Breast cancer is the most common cancer in women in Western countries.1 In the Netherlands, 
nearly 17,000 new breast cancer cases were diagnosed in 2016.2 Although the disease affects 
women of all ages, it is more common among older women. Currently, about 40% of all cases 
are in women aged ≥65 years3 and this percentage is expected to increase as the population 
ages.4 Older patients also have a greater breast cancer mortality than younger patients.2,5-7 
Consequently, there has been much concern about how to optimize cancer care for this 
patient population.8 
Despite this significant and growing patient population, little evidence is available to guide the 
management of breast cancer in older patients.9,10 Randomized clinical trials have frequently 
excluded older women based on their age or comorbid conditions.9-11 Consequently, the 
benefits and risks of treatment are often uncertain for older patients and results from trials 
conducted in younger patients can possibly not be extrapolated to the geriatric population. 
In addition, the few older patients that have been included in trials may not reflect the 
older patients in daily clinical practice, as they are generally healthier and might have more 
favourable tumour characteristics.12 
An important aspect in cancer treatment decision-making for older patients, is the patient’s 
preference. Currently, decision-making of breast cancer treatment is often done without the 
input of patients.13,14 Lack of shared decision-making between the clinician and the patient 
could potentially entail a decrease in satisfaction and treatment adherence of the patients.15,16 
Therefore, it is stipulated that shared decision-making should be made a priority in breast 
cancer treatment in older patients,9,10 especially as it is often not clear which treatment 
option is most appropriate.17 Given this background, this thesis is directed towards exploring 
treatment decision-making between clinicians and older patients, with a focus on the 
preferences of the latter. 
Tailoring treatment to the older patient’s context 
Treatment decision-making for older patients is generally complex. Older patients frequently 
suffer from other medical conditions besides breast cancer and may take multiple medications, 
which may place them at increased risk of adverse outcomes.18-20 Further, the older patient 
population is highly heterogeneous,21 with patients of the same chronological age having large 
differences in physiological reserves, life expectancies, physical and cognitive functioning, 
geriatric health conditions, and possibly in preferences. These aspects make it difficult to 
determine the best individual treatment decision.















cancer are not able to recommend treatment options in older breast cancer patients.22 
This means that with the absence of age-specific guidelines, clinicians are left with general 
treatment recommendations. However, for many older patients with breast cancer, the 
general treatment recommendations are difficult to apply to. Since 2007, an international 
group of experts of the European Society of Breast Cancer Specialists and the International 
Society of Geriatric Oncology have put efforts in releasing a set of recommendations for 
the management of breast cancer in older patients.9,10 Their recommendations state that 
treatment plans should not be based solely on the patient’s chronological age alone, but 
be tailored to the individual older patient’s context (e.g., general health status, comorbid 
conditions, and estimated life expectancy). In addition, it is recommended that as evidence 
about the best treatment option is often inconclusive, a shared decision-making approach 
between the clinician and the older patient should be an essential part of this process. 
Shared decision-making 
In recent years, it has become increasingly accepted that it is important to involve patients 
in medical decision-making and to elicit their preferences to make good individualized health 
care decisions.23 Shared decision-making is a process in which clinicians inform patients 
about all possible treatment options and encourage them to consider the potential benefits 
and risks, so that patients can form their preferences. The patient’s preferences are then 
combined with the best available medical evidence to decide which option best suits the 
patient.24 Assessment and prioritization of the patient’s preferences is particularly essential 
in decisions when there is more than one reasonable treatment option from a medical 
standpoint25 or when trade-offs between potential benefits and risks have to be made for 
which patient preferences vary.26 This is the case in the treatment of early-stage breast cancer 
as will be illustrated in following subparagraphs.  
Treatment of early stage breast cancer
The majority of patients with breast cancer are diagnosed with stage 0-II (‘early stage’) 
disease,27,28 which typically refers to small tumours (i.e., a clinical lesion size ≤ 5.0 cm) that 
have not spread beyond the breast or lymph nodes close to the breast.22 Depending on the 
type and extension of the early BC, its treatment often involves a combination of different 
modalities (i.e., primary surgery potentially followed by adjuvant systemic therapies). 
Generally, patients with this diagnosis and their clinicians face a difficult decision-making 
process, which revolves around whether to perform a mastectomy or a breast-conserving 
surgery, potentially followed by adjuvant systemic therapies (hormonal or chemotherapies). 
Each of the abovementioned modalities involves risks and benefits, which clinicians clearly 
need to discuss with the patients, so that they can develop informed treatment preferences.24 
Moreover, as this is a high impact decision-making process, it is preferable to elicit their 
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preferences in the early stages of this process.
Type of surgery
Primary treatment for patients with ductal carcinoma in situ (the most common type of 
stage 0) and stage I-II breast cancer consists of surgery. In most cases, patients of all ages 
are eligible for two surgical treatment options, namely a mastectomy or a breast-conserving 
surgery. Mastectomy involves a surgical procedure in which the breast is removed, while 
breast-conserving surgery is a less invasive procedure, but is followed by radiotherapy. Trials 
comparing the outcomes of both options have shown similar overall survival rates.29-31 However, 
the surgical options are different with respect to cosmetic outcome, local recurrence, and 
use of additional surgery or radiotherapy.32 As there is no best surgical treatment option from 
a medical standpoint, the decision between breast-conserving surgery and mastectomy can 
be made according to the patient’s individual preferences and values. 
Adjuvant systemic therapy
After surgery, the next step in the treatment of stages I and II breast cancer may be 
chemotherapy and/or hormonal therapy. Adjuvant systemic therapy is generally recommended 
for patients with unfavourable tumour characteristics and a 10-year disease recurrence risk 
of ≥25%, and when treatment would result in an absolute benefit of ≥10%.22 Although these 
adjuvant systemic therapies have been shown to reduce breast cancer recurrence,33 each of 
these therapies may cause side effects.34 
In the Dutch treatment guidelines for BC treatment options, decision-making about adjuvant 
hormonal therapy is driven by the hormone receptor status and not by the patient’s age. 
With regard to adjuvant chemotherapy, the benefits of this systemic therapy are less clear for 
patients aged ≥70 years. The guidelines currently recommend that adjuvant chemotherapy 
may be considered for patients aged ≥70 years who are in good general health.22 
In general, older patients diagnosed with early breast cancer may benefit from adjuvant 
systemic therapy,35,36 however the benefits in this patient group may only be marginal. This 
means that both accepting and declining the therapies are clinically possible options. As 
there is no best treatment option, the patient’s informed treatment preference in which the 
benefits and risks are weighed should determine the treatment decision.
Differences in treatment by age
Population-based studies have reported that older patients less often receive standard 
treatment than younger patients. Despite the fact that the decision between breast-
conserving surgery and mastectomy can be made independent of the patient’s age,22 















radiotherapy is more likely to be omitted after breast-conserving surgery in older patients 
and they less frequently receive (guideline recommended) adjuvant chemotherapy than 
younger patients with similar disease severity.35,39,40 After taking into account differences in 
patient and tumour characteristics (e.g., comorbid conditions, tumour size), there was still 
substantial variation between different age groups. This has directed the focus towards the 
preferences of patients and clinicians as potential important determinants of the decision-
making process for older patients.41 
Older patients’ decision-making about breast cancer treatment
Extensive research to date has been performed on the factors that patients with breast 
cancer consider important when facing a decision between breast-conserving surgery with 
radiotherapy and mastectomy.42 Various influencing factors have been found, including fear of 
cancer recurrence43 and the impact of the surgery on body image.44 Studies on the association 
between age and breast cancer treatment have implied that a patient’s preference for a 
specific treatment option or willingness to undergo treatment is influenced by a patient’s 
age.45 For example, it is often believed that older patients may attach less importance to 
body image than younger patients and that they consider several weeks of radiotherapy 
to be a larger burden,46,47 and therefore are more likely to prefer mastectomy over breast-
conserving surgery. It is also often assumed that many older patients judge that the small 
possible survival benefits of adjuvant systemic therapy do not outweigh the possible side 
effects48 and therefore they are more likely to refuse therapy. Also, it is often thought that 
older patients’ preferences may be based on other aspects than prolongation of life only, for 
example, on maintaining mobility and independence and quality of life.47
Older patients’ treatment preferences are however an understudied topic in the field of 
breast cancer,47,49 in particular with regard to their preferences for adjuvant systemic therapy. 
A systematic review of studies on older cancer patients’ preferences found that none of 
the studies focused on adjuvant treatment for breast cancer.49 The few studies that have 
concentrated on older patients with breast cancer involved only patients aged ≥65 or ≥70 
years,50-56 making it hard to decide whether the decision-making process of older patients 
is actually different from that of younger patients. In addition, other studies including 
breast cancer patients of all ages have generally not aimed to determine age-differences in 
treatment preferences or in the reasons for choosing one treatment over the other.57 
Clinicians’ decision-making about breast cancer treatment 
Clinician preference has also been proposed to strongly influence the treatments that older 
patients undergo.58 Firstly, although the majority of patients want to be involved in treatment 
decision-making, it is often suggested that decision-making role preferences differ by patient 
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age. Older patients are thought to more often prefer to leave the decision to their clinician,59-61 
thereby indicating that the treatment decision mainly depends on the clinician’s preference 
rather than on the patient’s preference. Secondly, there are indications that for their older 
patient clinicians often make unilateral decisions with regard to which treatment options 
are relevant based on the patient’s chronological age.62-64 Making decisions without having 
complete information available about the patient (e.g., comorbid conditions, social situation, 
concerns and preferences), may not result in a decision that is right for that particular older 
patient. 
 
Previous research on clinicians’ preferences for treatment of older patients has mainly 
focused on oncologists of one specialty.65 In the Netherlands, it is nowadays standard of care 
that treatment plans are discussed in multidisciplinary team meetings.22 The team constitutes 
of at least a surgical, a radiation and a medical oncologist who collaborate together to come 
to a treatment advice that is in their patient’s best interest. Each of these different specialties 
is expected to approach the same patient from their own perspective, which could result 
in different treatment recommendations.66 This may be particularly present with regard to 
older patients, as clinicians can make different interpretations of the clinical evidence, since 
the benefits to older patients are not clearly defined and since the content of the treatment 
guidelines leaves room for alternative interpretations. Thus, opinions of the specialists 
involved in the treatment of older patients also require examination.
Aims of this thesis 
FOCUS study 
The research in this thesis is part of the FOCUS project (Female breast cancer in the elderly: 
Optimizing Clinical guidelines Using clinico-pathological and molecular data). This project was 
funded by a grant of the Dutch Cancer Society in 2007, and aimed to increase knowledge 
about tumour biology, treatment and survival outcomes of older patients with breast 
cancer.67 Amongst others, this resulted in a data set with detailed treatment and patient-
related information of more than 3,000 female breast cancer patients of ≥65 years and who 
were diagnosed in the South West region of the Netherlands between 1997 and 2004.5-
7,18,20,27,39,68-71 During data collection it became apparent that data about the preferences of 
older patients were largely absent. Consequently, older patients’ preferences was added to 
the FOCUS project as a new research topic. 
This thesis
It is often suggested that older patients may have different preferences and motivations 
than younger patients, because of different life circumstances, values, priorities and medical 















perspectives of younger and older patients. With the addition of data on older patients’ 
treatment preferences and the factors that distinctively affect their preferences, clinicians 
will be able to better inform, support and guide older patients in decision-making. To better 
understand the process of treatment decision-making for older patients, it is also relevant 
to understand the opinions of their clinicians and which factors of the older patient they 
consider important when making treatment recommendations. 
The overall aim of this thesis therefore is to gain a greater understanding of the preferences 
of both older patients with early breast cancer and clinicians with regard to treatment, with 
the first group being the central focus of this thesis. 
Outline of this thesis
The first part of this thesis describes the perspectives of patients with early breast cancer on 
decision-making about surgical and adjuvant systemic therapy. Chapter 2 presents the results 
of a systematic literature review which identified studies on patients’ preferences for surgery 
and adjuvant systemic therapy in early breast cancer. PubMed and EMBASE databases were 
searched up to October 2012. The aim of this systematic review was to provide an overview 
of the factors that affect patients’ preferences for type of surgery and the minimal survival 
benefit that patients require from adjuvant systemic therapy to consider the therapy 
worthwhile. 
Chapter 3 to 5 report on a prospective study which was carried out among patients with 
early-stage breast cancer who were scheduled to undergo primary surgery and who were 
eligible for both breast-conserving surgery and mastectomy. This study had a unique design 
characteristic where preferences were measured before patients had seen a surgical or 
medical oncologist to decide upon a treatment plan. Based on a psychological mechanism 
(i.e., cognitive dissonance reduction or post-hoc justification), individuals may have a strong 
preference for the treatment they are recommended.72 To minimize the impact of this 
phenomenon, we conducted this study in patients who had not yet been informed about 
their clinician’s advice. 
Chapter 3 describes the preferences for type of surgery of both younger and older patients, 
and the factors they consider important when making the decision between breast-conserving 
surgery with radiotherapy versus mastectomy. Secondarily, older patients’ preferences for 
breast reconstruction following mastectomy are compared to those of younger patients. In 
Chapter 4, we assess whether there are differences in younger and older patients’ willingness 
to undergo adjuvant systemic therapy (i.e., adjuvant chemotherapy and adjuvant hormonal 
therapy) and their motivations for or against undergoing therapy. Chapter 5 presents a 
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comparison of both age groups’ preferred and perceived roles in making the decision about 
surgery and adjuvant systemic therapy. 
The final chapter of this thesis focuses on the perspectives of clinicians about treatment 
of older patients. Chapter 6 describes the treatment recommendations of breast cancer 
specialists concerning older patients. Via an anonymous, online questionnaire, we presented 
hypothetical cases of older patients (aged ≥70 years) to surgical, radiation and medical 
oncologists to identify how different patient-related characteristics affect their treatment 
recommendations, and whether the specialties differ in their recommendations.
In Chapter 7, the main findings, the implications for clinical practice and health care policy, 
and the future perspectives for research in this field are discussed. A summary in Dutch of this 
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Purpose | Treatment decisions in early breast cancer can revolve around type of surgery and 
whether or not to have adjuvant systemic therapy. This systematic review aims to give an 
overview of patient self-reported factors affecting preferences for breast-conserving surgery 
(BCS) versus mastectomy (MAST), the minimal benefit patients require from adjuvant 
chemotherapy (aCT) and/or adjuvant hormonal therapy (aHT) to consider it worthwhile, and 
factors influencing this minimally-required benefit.
Methods | PubMed and EMBASE were searched for relevant articles. Two reviewers 
independently selected articles and extracted data. 
Results | We identified 15 studies on surgical and six on adjuvant systemic treatment decision-
making. Factors affecting patient preference for BCS most frequently related to body image 
(44%), while factors influencing preference for MAST most often related to survival/recurrence 
(46%). To make adjuvant systemic therapy worthwhile, the median required absolute increase 
in survival rate was 0.1-10% and the median required additional life expectancy was 1 day to 
5 years. The range of individual preferences was wide within studies. Participants in the aHT 
studies required larger median benefits than those in the aCT studies. Factors associated 
with judging smaller benefits sufficient most often (44%) related to quality of life (e.g., less 
treatment toxicity).
Conclusion | Decisive factors in patients’ preferences for surgery type commonly relate to 
body image and survival/recurrence. Most participants judged small to moderate benefits 
sufficient to consider adjuvant systemic therapy worthwhile, but individual preferences 
varied widely. Clinicians should therefore consider the patient’s preferences to tailor their 
































































Breast cancer is the most common cancer in women worldwide and the leading cause of 
female cancer death. In 2008, an estimated 1.4 million women were diagnosed with breast 
cancer and more than 450,000 women died from the disease.1 The European age-adjusted 
five-year relative survival for all stages is estimated to be 81% (95% CI: 80.2-81.7).2 The 
estimated overall ten-year relative survival is 71% (95% CI: 69.9-72.1).2 A significant proportion 
of the patients are diagnosed with early-stage invasive breast cancer.3 
Different treatment options are available for early-stage invasive breast cancer. The majority 
of newly-diagnosed patients are eligible for two surgical options: breast-conserving surgery 
(BCS) with radiotherapy, or mastectomy (MAST). Randomized clinical trials with long follow-
up periods have demonstrated similar survival rates for women who underwent BCS followed 
by radiotherapy or MAST.4,5 Given that both treatment options are equally effective with 
respect to survival, patient preferences play a decisive role in determining the best treatment 
decision.   
Another treatment decision may relate to systemic therapy following surgery. Adjuvant 
systemic treatments include chemotherapy and/or hormonal therapy and have been shown 
to significantly improve disease-free and overall survival,6 but are associated with several 
adverse effects. These can negatively impact quality of life. The decision regarding adjuvant 
systemic therapy therefore involves a marked trade-off between the expected benefits and 
the potential risks. How patients value the benefits and risks will thus affect their preference 
for one treatment over the other.  
Over the past decade, patient preferences have become an increasingly important 
determinant of treatment choice due to a greater emphasis on shared decision-making and 
patient autonomy. Breast cancer patients’ involvement in treatment decisions has been 
shown to improve their satisfaction7 and short and long-term well-being8 and to increase 
their level of comfort with the decision made.9 More recently, integration of data on patients’ 
preferences into clinical treatment guidelines has been emphasized.10,11 
Given that BCS with radiotherapy and MAST are equivalent from a strictly medical point of 
view, insight into the factors that play a decisive role in patients’ preferences for surgery type 
is valuable for making treatment recommendations. Similarly, insight into patients’ strength 
of preference for adjuvant systemic therapy is important to understand patients’ willingness 
to accept such treatment. The aim of this systematic review is therefore twofold. First, to 
identify which patient self-reported factors influence their preferences for BCS versus 
MAST. Second, to give an overview of the benefit patients minimally require from adjuvant 
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chemotherapy (aCT) and/or adjuvant hormonal therapy (aHT) to consider it worthwhile, as 




We searched PubMed and EMBASE for articles published between January 1, 1990 and 
October 2, 2012. Appendix 1 lists the search strings. Also, the reference lists of included 
articles and relevant review articles12-16 were hand-searched for additional articles.
Selection criteria
Articles were selected if they (1) were published in English, (2) in a peer-reviewed journal, (3) 
included early-stage breast cancer patients, and assessed (4) patient self-reported factors 
affecting preferences for BCS versus MAST, or (5) patients’ preferences for aCT and/or aHT. 
Both quantitative and qualitative studies were eligible for inclusion.
We considered the disease as early-stage if it was stage I/II(A), T1-2,N0-1,M0 or invasive T1-2. If 
not specified, articles were included if the words ‘early’, ‘early stage’, or ‘early-stage invasive 
breast cancer’ appeared in the sample description and/or article title. Studies also involving 
other patient or non-patient populations were included if results had been reported specifi-
cally for the subgroup of early breast cancer. 
Articles regarding surgical treatment decision-making were selected if they (1) reported at 
least one patient self-reported factor (different than the surgeon’s role) that distinguished 
preferences for BCS (with or without radiotherapy) or MAST, and (2) included participants 
who had been surgically treated within two years prior to the study. 
Articles regarding adjuvant systemic treatment decision-making were included if a 
probability trade-off method17 or a similar method was used to determine the strength of 
patients’ preference for aCT and/or aHT. In short, the probability trade-off method requires 
respondents to consider potential benefits and risks of various treatment options, and the 
probabilities of obtaining those outcomes.17 Minimally-required benefit is then determined by 
systematically increasing or reducing benefit of treatment until participants judge the benefit 
sufficient to outweigh the risks. 
Data selection































































on titles and abstracts. Next, they screened the full-texts of potentially relevant articles. 
When multiple articles reported on the same study, the article with the largest sample was 
included. Agreement about eligibility was achieved during consensus meetings. 
Data extraction and analysis
The reviewers independently extracted data on study design (retrospective or prospective), 
participants, data collection method, time from treatment to study and response rates. If 
no subgroup details were reported, details regarding the total sample were extracted. 
Disagreements in data extraction and interpretation were resolved in consensus meetings. 
From articles on surgical treatment decision-making, we extracted patient self-reported 
factors that were significantly (p<0.05, in univariable or multivariable analyses) associated 
with preferences for BCS or MAST, and information about whether these factors were 
measured through open or closed-ended questions. When articles did not report outcomes 
quantitatively, or test for statistical significance, all factors that patients reported to influence 
their preferences for BCS or MAST were extracted, in order to provide a complete as possible 
overview. The reviewers defined six categories based on the patient self-reported factors 
retrieved: (1) body image (e.g., wanting to keep one’s breast, wanting to minimize scar 
size), (2) survival/recurrence (e.g., no difference in survival, concern about recurrence), (3) 
surgeon’s opinion (e.g., surgeon’s recommendation or preference for a particular type of 
surgery), (4) psychosocial (e.g., relevance of the breast to feelings of femininity, ‘to get it 
over with’), (5) treatment (e.g., avoiding radiotherapy, recovery), and (6) costs (e.g., concern 
about costs). Two other reviewers (GJL, AMS) independently assigned the extracted factors 
to one of the six categories. If they disagreed, a third party (EB) resolved the disagreement. 
Next, for both BCS and MAST, factors within each category were counted and reported as a 
percentage of all retrieved factors. Percentages were also reported by study design. 
From articles on adjuvant systemic treatment decision-making, details were extracted on the 
method for eliciting preferences, including how benefits and risks of adjuvant systemic therapy 
and their probabilities were presented; the minimally-required benefit; and the percentage of 
participants who would refuse treatment irrespective of treatment benefit. If not reported in 
the text, data were extracted based on figures or tables. If preferences had been examined at 
several time points, only the first measurement was extracted. We further extracted factors 
that patients reported to influence their preferences and determinants that were significantly 
(p<0.05, in univariable or multivariable analyses) related to patient preferences. VCH and EB 
defined four categories of determinants based on those retrieved: (1) treatment (e.g., having 
or not having received a particular treatment), (2) socio-demographic characteristics (e.g., 
age), (3) cognitive/affective factors (e.g., anxiety), and (4) quality of life (e.g., treatment 
toxicity). GJL and AMS independently assigned determinants to one of the four categories. 
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Again, EB resolved disagreements about categorization if necessary. Determinants within 
each category were counted and reported as a percentage of all retrieved determinants.
The quality of the studies examining patients’ preferences for adjuvant systemic therapy was 
assessed using the PREFS checklist.18 This checklist consists of five criteria: (1) Purpose of 
the study; (2) Respondent sampling; (3) Explanation of the preference assessment methods; 
(4) Findings reported for the total sample; and (5) Significance testing (Appendix 2). Studies 
were assessed against each of the five criteria. An item was scored as ‘yes’ if the information 
was present, as ‘no’ if the information was absent, or as ‘unclear’ if the information was not 
adequately reported. The total quality score for each study was calculated by adding the 
number of positive responses, resulting in a possible score from 0 to 5. In cases of discrepancy, 
two researchers (VCH and EB) discussed the study until consensus was achieved. As only three 
out of five criteria were applicable to the factors that influence patients’ surgical preferences, 
we did not use the checklist to assess the quality of those studies.   
RESULTS
Our search strategy yielded 3266 unique citations, of which 84 were selected for further 
review (Figure 1). Of these, 18 articles met the inclusion criteria. Another three articles were 
included after review of the reference lists of included articles. A total of 21 articles were 
included: 15 studies examined patient self-reported factors affecting preferences for surgery 
type and six studies examined patients’ preferences for adjuvant systemic treatment. 
Surgical treatment decision-making
Characteristics of the studies included 
Retrospective studies
Ten studies with a retrospective design were included (Table 1).19-28 Mean age of the 
participants ranged from 54 to 61 years19,20,22,23,28 and their median age ranged from 47 to 58 
years.24-27 Timing of data collection relative to diagnosis or surgery varied widely between 
the studies. In studies that reported this information, mean time between diagnosis or 
surgery and the study ranged from one week to five months21-23,27,28 and median time from 
diagnosis to study was 19 months.24 Other studies only reported that factors were assessed 
after surgery,26 during adjuvant radiotherapy or after completion of treatment25 or within 
two years after surgery.19
Prospective studies
Five prospective studies were identified (Table 1).29-33 Mean age of the participants ranged 































































factors before surgery. The remaining study32 collected their data before and after surgical 
treatment, but did not specify at what point in time factors were assessed. 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Assessment of patient self-reported factors
Retrospective studies
Three studies20,25,26 did not clearly report if they assessed patient self-reported factors through 
open or closed-ended questions. Two studies21,27 used open-ended questions to assess factors 
and five studies19,22-24,28 asked participants to rate the importance of predefined factors, 
varying from four to 17 items, on a Likert-type scale. These studies derived factors from the 
literature only,22,23,28 or also from reports on focus groups and interviews with patients and 
providers,24 or from consultations with a breast cancer self-help group.19 
Prospective studies
Two studies30,32 examined factors using open-ended questions. In the other three studies,29,31,33 
participants had to rate the importance of predefined factors on a Likert-type scale. The 
number of items varied from five to eight and they were based on a decision aid,29,33 or were 
self-designed.31 
Patient self-reported factors affecting their preference for BCS or MAST 
Overall, 77 factors that affected patients’ preferences for BCS (36 factors, Table 2) or MAST 
(41 factors, Table 3) were identified. The reviewers assigned 58 (75%) factors to the same 
category. They disagreed with the categorization of 19 factors (25%). Thus, the third party 
resolved the categorization of these factors. 
Overall, 44% of the factors relating to preferring BCS involved body image (Table 2). The 
remaining factors related to survival/recurrence (17%), treatment (17%), psychosocial factors 
(11%) and surgeon’s opinion (11%). In retrospective studies, body image-related factors were 
most frequently (40%) reported to affect patients’ preferences. In the prospective studies, 
this predominance was even more pronounced (67%).
Overall, factors influencing preference for MAST most often related to survival/recurrence 
(46%) and treatment (39%) (Table 3). Specifically, most treatment-related factors revolved 
around radiotherapy. The remaining factors involved psychosocial factors (7%), surgeon’s 
opinion (5%) and costs (2%). Body image was not reported to affect preference for MAST. 
Factors relating to survival/recurrence and treatment most strongly affected preferences, 




Table 2. Number of factors reported (N=36) to affect patients’ preferences for breast-conserving surgery (BCS)









Benedict20 a 1 1 1
Katz22 b,e 1 1
Mastaglia23 d 1 1
Schou28 d 1 1
Sepucha24 d 1
Ballinger19 d 3 1
Caldon27 a 3 1 1
Agrawal25 a 1 1 1
Zhang26 a 1 1 2 3
Total, n (%): 12 (40) 5 (17) 3 (10) 4 (13) 6 (20) 0 (0)
Prospective (n=6 factors)
Cotton30 a 1




Total, n (%): 4 (67) 1 (17) 1 (17) 0 (0) 0 (0) 0 (0)
Overall, N (%): 16 (44) 6 (17) 4 (11) 4 (11) 6 (17) 0 (0)
a The study did not statistically test for significant differences
b No significant differences in factors between participants with ductal carcinoma in situ and invasive breast cancer
c No significant differences in factors between participants who received the decision aid and those who did not
d All factors were tested in univariable analysis only































































Adjuvant systemic treatment decision-making
Characteristics of the studies investigating patient preferences for adjuvant chemotherapy
Three retrospective studies34-36 and one prospective study37 were included (Table 4). Mean 
age of the patients ranged from 42 to 54 years35,37 and the median age from 49 to 55 years.34,36 
Two studies34,36 reported they included patients who had been treated with aCT, but in one36 
it was unclear whether a proportion (<1%) of the participants did receive aCT. The remaining 
retrospective study included patients with and without aCT experience.35 The prospective 
study specifically aimed to compare preferences between patients who were about to start 
aCT (50%) versus those who would not undergo aCT (50%).37 The quality assessment of the 
studies is presented in Table 4. Three studies were considered to be of high quality34,35,37 
(scoring four out of five criteria) and one study36 was judged to be of low quality (two out of 
five).
Table 3. Number of factors reported (N=41) to affect patients’ preferences for mastectomy (MAST)










Guadagnoli et al.21 a 1 1
Benedict et al.20 a 2 2
Katz et al.22 b,e 2 2
Schou et al.28 d 1
Sepucha et al.24 d 1
Ballinger et al19 d 1 2
Caldon et al.27 a 2 2
Agrawal et al.25 a 1 1
Zhang et al.26 a 2 2 2 1
Total, n (%): 0 (0) 12 (43) 2 (7) 2 (7) 11 (39) 1 (4)
Prospective (n=13 factors)
Cotton et al.30 a 2 1 1
Kraus et al.32 a 2 1
Molenaar et al.33 c,d 1 1
Collins et al.29 e 1 1
Gollop et al.31 e 1 1
Total, n (%): 0 (0) 7 (54) 0 (0) 1 (8) 5 (38) 0 (0)
Overall, N (%): 0 (0) 19 (46) 2 (5) 3 (7) 16 (39) 1 (2)
a The study did not statistically test for significant differences
b No significant differences in factors between participants with ductal carcinoma in situ and invasive breast cancer
c No significant differences in factors between participants who received the decision aid and those who did not
d All factors were tested in univariable analysis only










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Assessment of patient preferences for adjuvant chemotherapy
All four studies presented participants with two treatment strategies: treatment with aCT 
versus treatment without aCT. Descriptions of potential risks of aCT varied between the 
studies. In two studies,34,36 patients were asked to state their preference based on their own 
experiences with aCT. The other studies35,37 gave patients information about the risks of aCT 
regardless of the patient’s experience or treatment plan. The studies differed in how much 
detail they gave about aCT schedules, e.g., describing aCT as a six-month therapy,34,36 or as 
an outpatient administration of one cycle of therapy per month for six months.35,37 In the 
studies, the benefit of aCT was expressed as an increased probability of cure35 or (disease-
free37) survival,34,36 or in terms of additional life expectancy.34-36 In all studies, the survival 
probabilities or life expectancies for both treatment options was made explicit. Three studies 
used probability of survival without aCT as starting point, and then asked participants what 
additional benefit of aCT they would require to make it worthwhile.34,36,37 In contrast, in 
Lindley et al.35 the starting point was probability of survival with aCT and likelihood of survival 
without aCT was systematically decreased. 
Median required increase in survival rate from adjuvant chemotherapy
Table 5 summarizes the minimum absolute increase in survival rate that participants 
considered sufficient to make aCT worthwhile. The median required benefit ranged from 
0.1% to 7%. Required benefit seemed to be independent of baseline survival probabilities.34-36 
Although most participants judged small benefits sufficient to make aCT worthwhile, 
individual preferences varied widely within each study. Additionally, 2-19% of the participants 
would refuse aCT irrespective of benefit. Jansen et al.37 observed that most patients who were 
scheduled for aCT would accept it for significantly less benefit than patients who were not 
scheduled for aCT (median required benefits: 1% versus 12%). Moreover, a higher proportion 
of patients would accept aCT for no (0%) benefit in those who were scheduled for aCT than 
in those who would not undergo aCT (39% versus 8%). Similarly, Lindley et al.35 showed that 
for each scenario, patients who had been treated with aCT were significantly more willing to 
accept aCT than patients who had not been treated with aCT.
Median required additional life expectancy from adjuvant chemotherapy
Three studies assessed patients’ preferences in terms of additional life expectancy (Table 
5).34-36 Most participants considered small increases, ranging from 1 additional day to 0.8 
additional years, sufficient to make aCT worthwhile. Simes et al.36 reported that participants 
required larger benefits on the longer (15 years) versus shorter (5 years) term. Variation in 
individual preferences was large within the studies and 1-10% would refuse aCT irrespective of 
benefit. Again, Lindley et al.35 observed that the proportion of patients who would accept aCT 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Characteristics of studies investigating patient preferences for adjuvant hormonal therapy
Table 4 describes the characteristics of two retrospective aHT studies.38,39 Both studies 
included only premenopausal patients. In Thewes et al.39, most participants were undergoing 
aHT during the study. In Duric et al.38 7% of the participants had not been treated with aHT, 
but were included in the analyses. The studies were considered to be of medium39 (scoring 
three out of five criteria) and high38 (four out of five) quality, respectively (Table 4).
Assessment of patient preferences for adjuvant hormonal therapy
The aHT studies used similar methods as those used in two aCT studies.34,36 In short, participants 
were asked to choose between treatment with aHT versus treatment without aHT based 
on their personal experience. In Duric et al.38, those participants without aHT experience 
received information about the potential side effects of aHT. The studies explored patients’ 
preferences for both survival rate and life expectancies scenarios (5 versus 15 years). 
Median required increase in survival rate from adjuvant hormonal therapy
In Thewes et al.39, most participants judged small (2%) benefits sufficient to make aHT 
worthwhile, while in Duric et al.38, the majority required moderate (10%) benefits (Table 5). 
In both studies, the range in individual preferences was wide. In Thewes et al.39, 5% of the 
participants would consider the treatment worthwhile for a benefit of 0%, while 2-7% would 
refuse aHT irrespective of benefit. 
Median required additional life expectancy from adjuvant hormonal therapy
Table 5 also shows the minimum absolute increase in life expectancy judged sufficient to 
consider aHT worthwhile. While Thewes et al.39 reported that most participants required an 
additional 3-6 months to consider aHT worthwhile, Duric et al.38 observed larger (an additional 
3-5 years) median required benefits. Both studies reported larger median required benefits 
in the 15-year versus the 5-year life expectancy scenario. Individual preferences varied greatly 
within the studies. Thewes et al.39 reported that few participants (4-5%) would accept aHT at 
no benefit, while 1% would refuse aHT irrespective of benefit. 
  
Factors affecting patient preferences for adjuvant systemic treatment
Determinants of patient preferences
All six studies examined associations between patient characteristics and treatment 
preference. The number of determinants examined varied from nine to 37. Altogether, the 
studies reported 27 significant determinants of patient preferences (24 for aCT and three for 
aHT, Table 5). The reviewers assigned 78% (21/27) of the determinants to the same category. 
The third party resolved the categorization of the other six determinants (22%). 
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Most significant determinants related to quality of life (12/27, 44%). The remaining determinants 
related to treatment (6/27, 22%), cognitive/affective factors (5/27, 19%) and socio-demographic 
characteristics (4/27, 15%). As shown in Table 5, significant determinants of preference varied 
between the studies. Additionally, some determinants were not consistently associated 
with treatment preference. For example, two34,36 out of five studies34,36-39 found that having 
dependents was significantly associated with judging smaller benefits worthwhile. Another 
socio-demographic factor with no consistent significant association included having (better36) 
social support.34 As described earlier, the prospective study37 ascertained a significant 
association between being versus not being scheduled for aCT and preferences for the 
therapy. This study found no other significant associations. 
Patient self-reported factors influencing their preferences
Thewes et al.39 qualitatively explored factors that patients reported had influenced their 
treatment preferences and found three main factors: (1) altruism (e.g., the belief that 
accepting treatment would increase knowledge and therefore benefit future patients), (2) a 
sense of control, or the idea of doing something to deal with the disease, and (3) the belief 
that accepting treatment could offer benefits that are not yet fully known. 
DISCUSSION
Our systematic review of patient preferences for breast-conserving surgery (BCS) versus 
mastectomy (MAST) and the benefit patients minimally require from adjuvant chemotherapy 
(aCT) and/or adjuvant hormonal therapy (aHT) to consider it worthwhile, show that patients 
who prefer one or the other type of surgery are driven by different motives and that patients’ 
preferences for adjuvant systemic therapy widely vary.
Surgical treatment decision-making
Patients who prefer BCS are predominantly driven by body image, while for patients who 
prefer MAST survival and/or recurrence is the most prominent factor. It is disturbing that 
survival was a driving factor in preferring MAST over BCS, because survival probabilities are 
the same, regardless of surgery type, in early breast cancer. Possible explanations are that 
women were not informed about the equivalent survival rates or that the information was 
unconvincing.  
As one may expect, factors determining preferences varied according to whether they were 
assessed prospectively or retrospectively. Prospective assessment of factors revealed that 
body image and survival/recurrence determined patient preferences for, respectively, BCS or 































































as well. In those who have undergone treatment, this experience may well outrank factors 
that determined preferences when the decision was made.  
Adjuvant systemic treatment decision-making
Most patients judged small to moderate benefits sufficient to consider adjuvant systemic 
therapy worthwhile. However, studies reported that some patients would accept treatment 
for little or no benefit, while others would refuse treatment no matter the benefit. 
Determinants most consistently associated with patient preferences, once patients had 
experienced the treatment, related to quality of life. Patients were more willing to accept 
therapy if they had experienced better well-being during the particular adjuvant systemic 
therapy. 
Our review revealed that clinical characteristics (e.g., nodal status) did not predict patients’ 
preferences, nor did socio-demographic factors. These findings imply that it is difficult 
to predict individual preferences based on disease or socio-demographic characteristics. 
One retrospective study39 qualitatively explored patients’ motives and found other factors 
(e.g., doing something to deal with their disease). It is possible that such motives better 
explain patients’ treatment preferences. Hence, future research should examine potential 
determinants beyond socio-demographic or disease characteristics, and preferably in a 
prospective manner in order to be able to generalize findings to new patients. 
Interestingly, one aHT study found higher median required benefits than those reported 
by the aCT studies. At first sight this is surprising, as it is commonly assumed that patients 
perceive the side effects of aHT to be milder compared to aCT. Yet, the results cannot be easily 
compared because the aHT studies involved premenopausal patients who were significantly 
younger than patients in the aCT studies. At the same time, the results are in line with recent 
studies showing that some breast cancer patients who had received aHT did not consider 
its efficacy to outweigh its side effects.40,41 Clearly, clinicians should not underestimate how 
impactful patients can perceive side effects of aHT. To examine how differently patients value 
the risks and benefits of these therapies, further research could examine preferences for aCT 
and aHT within the same patient population.
Limitations and future research
Some limitations of the included studies should be noted. Most studies were retrospective 
or carried out after a treatment decision had been made. As a result, findings most probably 
were influenced by patients’ need for so-called ‘cognitive dissonance reduction’. According 
to this theory, individuals have a tendency to reduce inconsistencies between previous 
decisions, in this case the treatment decision, and current beliefs or treatment preferences.42 
Thus, patients are expected to have adjusted their current beliefs about treatments in favor 
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of the treatment they received or would undergo. Therefore, generalization of the findings 
to patients who are facing a treatment decision should be done with caution. We recommend 
that future studies are carried out before the treatment decision is made to exclude this 
cognitive dissonance reduction and to be better able to generalize the findings to new 
patients. 
Regarding surgical treatment decision-making, it is important to note that in most studies, 
patients were asked to rate the importance of a predetermined list of items. A possible 
drawback of this method is that it does not invite participants to identify other factors. 
Nevertheless, studies that used open-ended questions to elicit factors reported factors that 
were very much comparable to those from the predetermined lists. 
Remarkably, none of the aHT studies included postmenopausal patients. Future research 
should focus on this patient group, as a majority have hormone receptor-positive disease 
and are eligible for aHT. Furthermore, it has been shown that aHTs in older patients have 
increased over time.43
Furthermore, only one study28 addressed preferences of patients aged 65 years and older; 
it found that fear of recurrence and the need for additional treatment (e.g., radiotherapy) 
most frequently affected older (≥70 years) patients’ preference for MAST. We identified a 
few studies44-49 that examined treatment decision-making in older breast cancer patients, but 
they did not meet our inclusion criteria. These studies showed that fear of recurrence,45 the 
surgeon’s recommendation,45 and wanting no additional therapy beyond surgery47 influenced 
older patients’ preference for MAST. Body image45,47 and equivalence of survival rates45 
affected preference for BCS. Others examined whether factors affecting surgical decision-
making differed by age44,48 and showed that older patients were less concerned about body 
image,44,48 recurrence,44,48 or work-related issues48 than younger patients. Interestingly, one 
study48 found that older versus younger patients were more concerned about transportation, 
while others44 reported that frequent trips for radiotherapy were of greater concern to 
younger patients. Considering the increasing number of older breast cancer patients,50 
preferences in this population should be further explored, especially since current disease 
management in older patients can involve aCT. To date, the evidence is inconclusive as to 
whether older patients would require greater survival gains from aCT than younger patients, 
to consider it worthwhile.46,49,51-53
Clinical implications
The large variation in patients’ preferences and factors influencing their preferences 
suggests that individual patient views and preferences should be sought and incorporated in 































































and discuss the benefits and risks with each patient. Body image and survival/recurrence are 
important issues that should be addressed during consultations between patients and their 
surgeon. Additionally, clinicians should explicitly ask the patient which potential benefits and 
risks she considers important, and correct possible misconceptions about breast cancer and 
treatment. By identifying patient preferences, clinicians will be better able to tailor treatment 
recommendations to the needs, values and priorities of individual patients.
Conclusion
Breast cancer patients’ preferences for surgery type most frequently relate to body image 
and survival/recurrence. Most patients considered small to moderate benefits sufficient to 
make adjuvant systemic therapy worthwhile, however patient’s preferences varied widely 
and some patients would accept adjuvant systemic therapy for no benefit. Additional studies 
are needed that focus on older and postmenopausal patients and that assess determinants 
and preferences before the treatment decision is made.   
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APPENDIX 1. Search strategy per database
Database Search strategy
PubMed (“Patient Preference”[MeSH] OR ”patient preference”[ti] OR (Patients’[ti] AND preferences[ti]) OR 
”patient preferences”[ti] OR (Patients’[ti] AND preference[ti]) OR ”prefer”[ti] OR ”preferred”[ti] OR 
”preference”[ti] OR “preferences”[ti] OR ”Choice”[ti] OR “choices”[ti] OR “choose”[ti] OR “decision”[ti] 
OR “decide”[ti] OR “Choice Behavior”[MeSH:NoExp] OR “Patient Education as Topic”[Majr] OR “Decision 
Making”[Mesh]  OR “Patient Satisfaction”[Majr]) AND (“Breast Neoplasms”[Mesh] OR ((breast*[tiab] 
OR mammary[tiab]) AND (neoplasm*[tiab] OR tumor[tiab] OR tumors[tiab] OR tumour*[tiab] OR 
cancer*[tiab] OR carcinoma*[tiab]))) AND (“therapy”[Subheading] OR “therapy”[All Fields] OR 
“therapeutics”[MeSH Terms] OR “therapeutics”[All Fields] OR “therapeutic”[All Fields] OR “treatment”[All 
Fields] OR “mastectomy, simple”[MeSH Terms] OR “mastectomy”[All Fields] OR “mastectomy”[MeSH 
Terms] OR “surgery”[Subheading] OR “surgery”[All Fields] OR “surgical procedures, operative”[MeSH 
Terms] OR “surgical”[All Fields] OR “general surgery”[MeSH Terms] OR “breast conserving”[All Fields] 
OR  “lumpectomy”[All Fields] OR “drug therapy”[Subheading] OR “chemotherapy”[All Fields] OR 
“drug therapy”[MeSH Terms] OR “radiotherapy”[Subheading] OR “radiotherapy”[All Fields] OR 
“radiotherapy”[MeSH Terms] OR “adjuvants, pharmaceutic”[MeSH Terms] OR “adjuvants”[All Fields] 
OR “adjuvant”[All Fields] OR “adjuvants, immunologic”[Pharmacological Action] OR “hormonal”[All 
Fields] OR “hormones”[MeSH Terms] OR “hormones”[All Fields] OR “hormone”[All Fields] OR 
“hormones”[Pharmacological Action] OR “reconstructive surgical procedures”[MeSH Terms] OR  
“reconstructive surgical procedures”[All Fields] OR “reconstruction”[All Fields])
EMBASE (patient* preference*.mp. OR exp patient preference/ OR ((patient*.ti.) AND (“prefer”.ti. OR “preferred”.
ti. OR preference*.ti. OR Choice*.ti. OR “choose”.ti. OR “decision*”.ti. OR “decide”.ti.)) OR exp *Decision 
Making/ OR exp *Patient Satisfaction/) AND (exp breast tumor/ OR ((breast*.ti,ab. OR mammary.ti,ab.) 
AND (neoplasm*.ti,ab. OR tumor*.ti,ab. OR tumour*.ti,ab. OR cancer*.ti,ab. OR carcinoma*.ti,ab.))) 
AND (exp “therapy”/ or therapy.mp. OR “therapeutic*”.mp. or “treatment”.mp. or exp mastectomy/ or 
“mastectomy”.mp. or exp surgery/ or “surgery”.mp. or exp surgical technique/ or “surgical”.mp. or “breast 
conserving”.mp. or “lumpectomy”.mp. or exp chemotherapy/ or “chemotherapy”.mp. or exp drug therapy/ 
or “drug therapy”.mp. or exp radiotherapy/ or “radiotherapy”.mp. OR adjuvant*.mp. or exp cancer 
adjuvant therapy/ or exp adjuvant therapy/ or exp adjuvant chemotherapy/ OR hormon*.mp. or exp 
hormone/ OR exp breast reconstruction/ or reconstructi*.mp.) 
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APPENDIX 2. PREFS checklist for assessing quality18
Question No/not clear Yes
(1) Purpose: Is the purpose of the 
study in relation to preferences 
clearly stated? 
The purpose/research question/
objectives/aim doesnot mention 
preference, but may mention 
satisfaction, quality of life, ratings, 
acceptance
Any reference in the research question/
objectives/aim to preference, utility/disutility, 
willingness to pay, importance, priorities, goals, 
revealed preference (e.g., choice to continue)
(2) Respondents: Are the 
responders similar to the non-
responders?
Evidence of significant differences OR 
No assessment of the difference 
between responders and non-
responders OR
Responders are compared only to a 
target population rather than non-
responders
Any evidence that the responders do not differ 
significantly from the non-responders
(3) Explanation: Are methods 
of assessing preferences clearly 
explained?
The question(s) or response options 
are not clear
The actual preference question is reported in 
the text or an appendix, or if it is referenced 
and available elsewhere, and if it is clear what 
response options were available to respondents, 
even if the mode of the question (e.g., written, 
oral, online) is not clear OR 
For studies with multiple questions relating to 
preferences such as conjoint/discrete choice 
studies, it is clear what was presented to 
respondents and what responses were available
(4) Findings: Were all respondents 
included in the reported findings 
and analysis of preference results?
Some responses are excluded from 
the analysis and the possibility of this 
introducing systematic bias has not 
been ruled out OR
It is not clear whether all respondents 
were included in the analysis
All respondents who completed the preference 
question were included in the analysis OR
For studies with multiple questions relating to 
preferences such as conjoint/discrete choice 
studies, all respondents who at least partially
completed the preference questions were 
included in the analysis OR
If some respondents who at least partially 
completed the preference questions were 
excluded from the analysis (e.g., non-traders,
lexicographic preferences, failed test question, 
irrational preferences, did not complete) AND 
there is any evidence that those excluded do not 
differ significantly from those included
(5) Significance: Were significance 
tests used to assess the preference
results?
The study reports only proportions, 
counts, graphs, etc.
The study reports p values, p value ranges 
(e.g., p<0.05), confidence intervals, means 
with standard deviations or standard errors in 
relation to the preference results (e.g., testing 
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Older women with breast cancer (BC) currently comprise about 40% of all new cases, and this 
percentage will increase in coming decades.1 Most early BC patients are eligible for either 
mastectomy (MAST) or breast conserving-surgery (BCS). These treatments are equivalent 
in terms of survival rates,2 but differ in cosmetic outcome, use of additional surgery or 
radiotherapy, and local recurrence. Patient age is not a contraindication for BCS,3 but older 
patients less frequently undergo BCS than younger patients.4 This variation by age remains 
after accounting for clinical and nonclinical factors (e.g., tumour stage, comorbidities).4 An 
explanation may be different patient preferences. Given older patients’ higher occurrence of 
medical and nonmedical challenges (e.g., limited transportation access),3 their preferences 
may differ from those of younger patients. They may also value the impact of treatment (on 
e.g., body image) differently. 
Older patients also less often undergo breast reconstruction following MAST.5 Although the 
procedure is suggested to be safe for older patients with comparable complication rates and 
quality of life improvements as in younger patients,5 older patients are thought to more often 
decline reconstruction.5 However, little is known about their preferences.
Age-differences in treatment decision-making have received little attention.6 Most studies 
identified which factors influenced patients’ choice for type of surgery. Other studies were 
restricted to older patients, thereby making it difficult to determine whether the decisive 
factors count only in older patients. A shortcoming of most studies is that they assessed 
preferences after surgery, or after the treatment decision had been made.6 Consequently, 
cognitive justification may account for patients’ strong preference in these studies for the 
treatment they received or were recommended.7 The findings may therefore not reflect the 
preferences of patients facing the decision. 
We prospectively compared younger versus older patients’ surgical treatment preferences, 
influencing factors and preferences for breast reconstruction. 
METHODS 
Participants
Eligible patients had a first primary ductal carcinoma in situ or T1-2 invasive disease and were 
candidates for both BCS with radiotherapy and MAST. Exclusion criteria were bilateral 
tumour, BRCA 1/2 mutation, malignancy within the past five years, poor proficiency in Dutch, 


















































































recruited in three (academic and non-academic) hospitals from January 2012-December 2013. 
The Medical Ethical Committee of the Leiden University Medical Center and the review boards 
of the participating hospitals approved the study. All patients provided informed consent. 
Patients were approached after having been informed about their diagnosis in the first 
surgical consultation. The surgeons were instructed to discuss the benefits and risks of each 
option in their usual fashion, but were asked to explicitly mention that the patient had a 
choice between BCS and MAST, and to not direct the patient towards one or the other option. 
At the end of the consultation, the surgeon handed out a questionnaire and asked the patient 
to complete it shortly after the consultation. During the second surgical consultation, the 
surgeon discusses the options again and gives a recommendation for either surgical option. 
To prevent the surgeon’s recommendation from influencing the participant’s preference, 
participants were asked to complete the questionnaire before the second consultation. 
Measures and analyses
The questionnaire included a one-page overview of the differences in the main features 
of BCS and MAST (Appendix A.1). Except that both options have equivalent survival rates, 
similarities were not presented (e.g., indication for systemic therapy), to limit the amount 
of information and because we expected that this information would not influence the 
participant’s choice. Participants were then asked: ‘Imagine that both BCS (with radiotherapy) 
and MAST were available options, which type of surgery would you prefer?’ The response scale 
ranged from (1) definitely prefer BCS with radiotherapy, to (3) no preference for either option, 
to (5) definitely prefer MAST. Subsequently, they rated a list of factors (e.g., the surgeon’s 
recommendation) based on literature.8 
After a short description of breast reconstruction (Appendix A.2), all participants were also 
asked: ‘Imagine that you would undergo a MAST, which option would you prefer (probably 
would choose reconstruction/probably would not choose reconstruction/do not know)?’. 
Participants were categorized into ‘younger’ (40-64 years) and ‘older’ (≥65 years) patients. 
Response categories were recoded into preference for BCS with radiotherapy; preference 
for MAST; and no/unknown preference (‘no preference for either option’ and the participants 
not answering the question). Mean scores were calculated for each factor and compared 
between the younger and older participants indicating a preference for either BCS or MAST. 
RESULTS
One hundred and seventeen patients agreed to participate (72%). Participants were excluded 
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if they completed the questionnaire after the second consultation (n=20) or if, for logistic 
reasons, the decision had been made in the first consultation (n=18). The median age of the 
remaining 79 participants was 61 years (range, 42-80); 34% (n=27) were aged ≥65 years (Table 
1). 
Table 1. Characteristics of the study population overall and by age category
  Total 40-64 years ≥65 years  
(n=79) (n=52, 66%) (n=27, 34%)
Variables n % n % n % p
Patient characteristics 
Median age in years (range) 61 (42-80) 56 (42-64) 70 (65-80) -
Marital status
married/living together 54 68 37 71 17 63 0.46
single/divorced/widowed 25 32 15 29 10 37
Educational levela
low 24 30 15 29 9 33 0.50
intermediate 34 43 21 40 13 48
high 21 27 16 31 5 19
Employment status
full/part-time 39 49 37 71 2 7 <0.001
housekeeper 10 13 3 6 7 26
unemployed/long-term sick leave 5 6 5 10 0 0
retired 25 32 7 13 18 67
Having children
no children 16 20 9 17 7 26 0.05
yes, children not living at home 45 57 27 52 18 67
yes, children living at home 18 23 16 31 2 7
Number of comorbid conditions
0 22 28 18 35 4 15 0.14
1 20 25 13 25 7 26
2 or more 37 47 21 40 16 59
Geriatric health conditionb
no 49 62 37 71 12 44 0.02
yes 30 38 15 29 15 56
Tumour characteristics
Morphology
DCIS 16 20 10 19 6 22 0.75
invasive T1-2 63 80 42 81 21 78
DCIS= Ductal carcinoma in situ; BCS= Breast-conserving surgery; MAST= Mastectomy; T1-2= Tumour size not larger than 5 cm
 
A p-value in bold means a significant difference between younger and older participants with respect to that variable
a Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary education/
vocational training; or high=completed pre-university education/high vocational training/university 
b  Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily activities, 



















































































BCS (with radiotherapy) was most frequently preferred; by 69% (36/52) of the younger and 
56% (15/27) of the older participants respectively. Nineteen percent (10/52) of the younger 
and 40% (11/27) of the older participants preferred MAST, and 12% (6/52) of the younger and 
4% (1/27) of the older participants expressed no preference, or the preference was unknown. 
These differences were not significant (p=0.11).
Both age groups assigned the highest importance to the surgeon’s treatment recommendation 
(Figure 1). Two factors significantly differed between the groups: younger participants rated 
the possibility of breast reconstruction as more important than older participants (2.6 versus 
1.9, p=0.01), whereas older participants were more concerned about possible additional 
surgery (3.2 versus 2.7, p=0.04). Further, older participants tended to be more concerned 
about the side effects of radiotherapy (2.8 versus 2.4, p=0.07) and the frequent hospital visits 
for radiotherapy (2.6 versus 2.0, p=0.06). 
Breast reconstruction 
Thirty-five percent (18/52) of the younger versus 26% (7/27) of the older participants did not 
know whether they would opt for post-MAST breast reconstruction or did not answer the 
question. Of those reporting a preference, significantly fewer older (40%; 8/20) than younger 
(77%; 26/34) participants would probably choose to have a reconstruction (p=0.01). 
DISCUSSION
The current study is the first to prospectively compare younger and older patients’ surgical 
treatment preferences. It is often assumed that MAST is the preferred choice among older 
women who are thought to be less interested in their physical appearance than younger 
women.4 Indeed, our study showed that treatment preferences differed between the age 
groups, but not significantly so. Like the younger women, older participants also frequently 
preferred BCS to MAST, and both groups did not differ in their views on loss of a breast. A 
retrospective study9 among patients aged ≥67 years found that body image was stated to 
be an important factor when deciding about treatment. These findings illustrate that older 
women require as much information as younger women about breast appearance after 
surgery when discussing each option.
Our findings suggest that treatment-related factors appear to play a larger role in decision-
making. Older patients may want to avoid the extra daily hospital visits for radiotherapy that 
are needed to complete breast-conserving therapy.9 Getting to radiotherapy appointments 
can be a larger burden at older age, as patients are more likely to experience mobility 
limitations and/or to rely on others. This may explain why older women may not choose 
















































































































































































































































































































well as radiotherapy side effects are contributing factors to older patients’ preference for 
MAST over BCS. Thus, the benefit of breast preservation may not outweigh the treatment 
inconvenience and the possible side effects. Another treatment-related factor that seemed 
relevant to older women is the wish to avoid the risk of having a second surgery.9 The risk 
of undergoing another surgery after MAST is generally smaller than after BCS. In our study, 
older participants were indeed more concerned about the possible need of having to undergo 
additional surgery than younger participants. 
Both age groups stated the surgeon’s treatment recommendation to be the most important 
factor. Since the clinician’s recommendation may possibly overrule other factors that patients 
also consider important,10 this stresses the imperative for clinicians to avoid providing a 
recommendation before having assessed patients’ concerns. Especially when deciding 
between BCS and MAST, patient preferences become increasingly relevant. 
Unfortunately, the sample of older participants was small. Some differences that can be seen 
as relevant were therefore not statistically significant. Nonetheless, our findings demonstrate 
the need to discuss both surgical options, not just with younger patients. Similarly, although 
not all older patients may want a reconstructive surgery, before making a decision patients 
should know about the option of post-MAST reconstruction. Whether they consider having 
reconstruction and when (during/after MAST) should be preferably elicited in the first 
surgical consultation, as it may influence the choice between MAST and BCS. A visit to a 
plastic surgeon can then be scheduled before a surgical decision is reached.
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APPENDIX A. Preferences for type of surgery and for breast reconstruction following mastectomy
A.1 Breast-conserving surgery versus mastectomy
The content in the overview was based on patient education brochures1 and on information 
provided on the website2 of the Dutch Breast Cancer Association. The information about 10-
year loco-regional recurrence risks after breast-conserving surgery with radiotherapy and 
mastectomy was based on data of the Early Breast Cancer Trialists’ Collaborative Group.3 
Drawings of the breast after breast-conserving surgery and mastectomy were reprinted by 
permission of the American Society of Clinical Oncology.4
The content was checked after discussion with two surgical oncologists, one radiation 
oncologist, three research nurses/nurse specialists and one plastic surgeon. A pilot test 
was carried out among three healthy women and seven breast cancer patients to check for 
problems in understanding. During this process, the researcher encouraged them to think 
aloud as they answered the question, and to vocalize any thoughts, including difficulties, 
distress and suggestions for improvement. Based on their feedback, we rephrased the 
question and clarified the instruction. 
In most situations there is a choice between:
- breast-conserving surgery 
- mastectomy
The choice depends, amongst others, on the size and location of the tumour in the breast. A breast-
conserving surgery is always followed by radiotherapy. 
The chances of surviving breast cancer are the same for both breast-conserving surgery with 
radiotherapy and mastectomy. 
On the next page you will find an overview with general information about both surgical options. The 
information is based on education material of the Dutch Cancer Society and Dutch Breast Cancer 
Association.
Please carefully read the overview and scan the differences between both surgical types. Then answer 
the question: Imagine that both breast-conserving surgery (followed by radiotherapy) and 
mastectomy were available treatment options, which type of surgery would you prefer?





















Length of time 
in hospital
Only the cancer lump is removed.
The remaining of the breast is 
preserved.
Most patients are home within 24 hours 
of surgery or the next day.
The whole breast is removed.







•	 Pain and discomfort





•	 Pain and discomfort
•	 Collection of fluid under the wound
A second 
surgery
(more than one 
operation)
If there are still cancer cells after the 
surgery, another operation on the 
breast may be needed. 
The second surgical procedure may 
be a breast-conserving surgery or a 
mastectomy. 
After a mastectomy, another operation 
is seldom to never required.
Radiotherapy A breast-conserving surgery is always 
followed by radiotherapy to the breast. 
A course of radiotherapy can take 3 
to 5 weeks. Most patients undergo 
radiotherapy 4 or 5 days a week.  
Radiotherapy usually begins within 
a few weeks after surgery and takes 
place at the hospital. You can go home 
after each session of radiotherapy. 
After a mastectomy, radiotherapy 
is usually not given. Whether or not 
radiotherapy is given depends on 
the results of the surgery; 1 out of 10 
women still need radiotherapy.
In case radiotherapy is needed after 
a mastectomy, the procedure is the 
same as with a breast-conserving 
surgery (see left).
Side effects of 
radiotherapy 
Possible side effects of radiation to the 
breast:
•	 Redness of the skin. This is a 
temporary reaction.
•	 Painful and/or tender breast. This is 
a temporary reaction.
•	 A slight discoloration of the skin. 
This is irreversible and occurs 
rarely.
•	 The breast tissue may feel 
permanently firmer.
•	 Most patients experience fatigue 
during radiotherapy and in the first 
weeks afterwards.
In case radiotherapy is given after 
mastectomy, side effects can occur 
similar as to those of radiotherapy after 
breast-conserving surgery (see left).






















































































About 14.4 out of 100 women will 
develop a recurrence in the breast and/
or armpit in the 10 years after a breast-
conserving surgery.
About 13.8 out of 100 women will 
develop a recurrence in the chest 




(what will my 
breast look like 
after surgery?)
The effect of the surgery on the 
appearance of the breast is minimal, 
but the breast can look different. 
The shape and size of the breast after 
surgery may differ somewhat from the 
other breast.
The whole breast is removed and a 
large scar remains. 
There are options to undergo breast 






After a breast-conserving surgery, a 
breast reconstruction is usually not 
performed.
After a mastectomy, there are options 
for a breast reconstruction. In some 
cases a breast reconstruction can 
be carried out at the same time as 
the mastectomy. In some cases, in 
another operation, sometime later. 




The information below was based on patient education brochures,1 information of the Dutch 
Breast Cancer Association,5 and expertise of two surgical oncologists and one plastic surgeon. 
A pilot study was conducted among three healthy women and seven breast cancer patients. 
Minor revisions were made based on their feedback. 
It is possible to undergo a breast reconstruction following a mastectomy. This is an operation to create 
a new breast that matches the shape and size of the other breast as closely as possible. For this 
procedure the surgeon will refer you to a plastic surgeon. 
The procedure differs from patient to patient. In some cases the reconstruction can be performed 
immediately after the mastectomy (during the same operation). In some cases the surgery is performed 
at a later time after the mastectomy. A breast reconstruction does not affect the chance of the cancer 
coming back or the ability to check for recurrence.  
Breast reconstructive surgery usually requires a hospital stay of a few days. It will take a few weeks to 
heal fully. 
As with any (breast) surgery, complications may occur after breast reconstruction. 
After a reconstruction the new breast looks natural. However, the reconstructed breast feels different 
and the shape and size may differ from the original breast. 
Imagine that you would undergo a mastectomy, which option would you prefer?
□ After a mastectomy, I would probably choose to have a breast reconstruction
□ After a mastectomy, I would probably not choose to have a breast reconstruction
□ I do not know
Reference list
1. Dutch Cancer Society. Breast cancer. Accessed on 9 May 2011. Available from: https://www.kwf.nl/
SiteCollectionDocuments/brochure-Borstkanker.pdf 
2. Dutch Breast Cancer Association. Surgery. Accessed on 6 June 2011. Available from: http://www.
borstkanker.nl/chirurgie
3. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the 
extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 2005;366:2087-2106.
4. Whelan T, Levine M, Gafni An et al. Mastectomy or lumpectomy? Helping women make informed 
choices. J Clin Oncol 1999;17:1727-1735.
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Purpose | It is unknown what minimal benefit in disease-free survival older breast cancer 
patients require from adjuvant systemic therapy, and if this differs from that required 
by younger patients. We prospectively examined patients’ preferences for adjuvant 
chemotherapy (aCT) and adjuvant hormonal therapy (aHT), factors related to minimally-
required benefit, and patients’ self-reported motivations. 
Methods | Fifty-two younger (40-64 years) and 29 older (≥65 years) women with a first primary, 
invasive tumor were interviewed post-surgery, prior to receiving aCT/aHT recommendation. 
Results | The proportions of younger versus older participants who would accept, refuse, 
or were undecided about therapy were 92% versus 62%, 4% versus 24%, and 4% versus 14% 
for aCT, and 92% versus 59%, 8% versus 17%, and 0% versus 24% for aHT. The proportion of 
older participants who would refuse rather than accept aCT was larger than that of younger 
participants (p=0.005). No significant difference was found for aHT (p=0.12). Younger and 
older participants’ minimally-required benefit, in terms of additional 10-year disease-free 
survival, to accept aCT (median, 5% versus 4%; p=0.13) or aHT (median, 10% versus 8%; p=0.15) 
did not differ. Being single/divorced/widowed (odds ratio [OR], 0.16; p=0.005), presence 
of geriatric condition (inability to perform daily activities, incontinence, severe sensory 
impairment, depression, polypharmacy, difficulties with walking; OR, 0.27; p=0.047), and 
having a preference to make the treatment decision either alone or after considering the 
clinician’s opinion (active role; OR, 0.15; p=0.012) were independently related to requiring 
larger benefits from aCT. The most frequent motivations for/against therapy included the 
wish to survive/avoid recurrence, clinician’s recommendation, side effects, and treatment 
duration (only aHT).
Conclusion | Whereas older participants were less willing to accept aCT than younger 
participants, no significant difference was found for aHT. However, a majority of older 
participants would still accept both therapies. Adjuvant systemic therapy should be discussed 




















































































Breast cancer (BC) is a disease affecting a large proportion of women over 65 years of age. 
In Western countries, approximately 40% of new cases occur in older women.1 As the risk of 
developing BC increases with age and the general population is ageing, the number of older 
patients is expected to rise significantly.1 
In most cases of early-stage (I-II) BC, adjuvant systemic therapy is recommended in addition 
to primary surgery with or without post-operative radiotherapy. The addition of adjuvant 
chemotherapy (aCT) or adjuvant hormonal therapy (aHT) can lower the risk of BC relapse 
and mortality.2 However, these therapies are associated with short- and long-term side 
effects which, in turn, can cause physical, psychological and social problems.3 Therefore, the 
expected benefits need to be carefully weighed against its side effects. With regard to older 
patients, making the decision for or against systemic therapy is generally difficult. Benefits of 
adjuvant systemic therapy in older patients, especially those of aCT, are uncertain because of 
small numbers of older women in trials.2,4 Moreover, high rates of comorbid conditions and 
polypharmacy in this patient group pose additional challenges.4 Consequently, treatment 
decisions in older patients should incorporate their valuation of potential benefits and side 
effects of treatment strategies.5
So far, data on older patients’ preferences for aCT and aHT are limited. We performed a 
systematic review of patients’ preferences,6 and found that most patients judged small to 
modest survival benefits sufficient to consider these therapies worthwhile, regardless of 
the consequences. A limitation of the reviewed studies was that the women surveyed had 
already been treated or had already received a treatment recommendation, which could have 
had a strong influence on their reported treatment preferences.7 Moreover, most patients 
were young or middle-aged (mean/median of 36-55 years),7-12 and none of the studies on aHT 
included patients aged ≥65 years.8,12 
A few studies have retrospectively explored factors that may affect the decisions about 
adjuvant systemic treatment of older patiens with BC.13-15 These studies involved only patients 
aged 65-70 years and over, making it difficult to determine whether older patients place 
different values on benefits versus side effects of adjuvant systemic therapy than younger 
patients. To our knowledge, solely one retrospective study examined age differences in 
factors influencing treatment decisions for aCT and aHT.16 Of the other existing studies 
involving patients of all ages, none specifically focused on differences in motivations between 
younger and older patients.17-19 
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Given the growing incidence of BC in older women, it will become increasingly relevant 
to establish a more complete picture of treatment preferences in this patient group, and 
to determine whether their preferences differ from those of younger women. A better 
understanding of older patients’ preferences and the factors that distinctively affect their 
preferences will assist clinicians in determining the set of treatment options relevant to older 
patients and in tailoring their information provision better. 
The objectives of this prospective study were threefold. First, to examine whether there 
are differences in the benefit that younger and older patients minimally require from aCT 
and aHT to consider it worthwhile. Second, to determine which factors are related to the 
minimally-required benefit. Lastly, to examine whether motivations for and against therapy 
differ between younger and older patients.  
METHODS
Participants 
This study took place at one academic and two non-academic teaching hospitals in the 
Netherlands. Between January 2012 and December 2013, women aged ≥40 years with a 
primary invasive tumor (clinical T1-2) scheduled to undergo surgery with curative intent, were 
included. Exclusion criteria were bilateral BC, BRCA 1/2 mutation, history of (non)invasive BC, 
history of other malignancies (other than non-melanoma skin cancer or cervical carcinoma 
in situ) within the past five years, insufficient knowledge of the Dutch language, cognitive/
mental problems, inability to participate in a telephone interview (e.g., hearing impairment), 
and a diagnosis of metastatic BC after resection. The Medical Ethical Committee of the Leiden 
University Medical Center and the institutional review boards of the participating hospitals 
approved the study. All participants provided informed consent. 
Procedure
In a telephone interview, we determined participants’ minimally-required benefit from aCT and 
aHT and their motivations for/against both therapies. Eligible participants were approached 
following their diagnosis, and they received an informed consent form and a self-administered 
questionnaire on socio-demographic background. After the pre-surgical consultation and 
before surgery, consenting patients were handed out a questionnaire about their preferred 
involvement in decision-making as well as information to prepare for a telephone interview 
scheduled after their surgery. Participants were asked to read the information right before 
the interview. Patients usually receive a recommendation for or against adjuvant systemic 
therapy based on pathological findings following surgery, during a post-surgical consultation. 



















































































preference, the interview was held before that post-surgical consultation. Three trained 
interviewers conducted the interviews, strictly adhering to a script.
Measures
Minimally-required benefit and motivations for/against adjuvant systemic therapy
The minimally-required absolute benefit, in terms of additional 10-year disease-free survival, 
from aCT and aHT was assessed using the probability trade-off method.20 As part of this 
method, we developed two hypothetical scenarios: no aCT versus aCT, and no aHT versus 
aHT (see Appendix A for details). The scenarios were provided to the participant and included 
information about the treatment strategies and the accompanying health consequences 
and recurrence risks. During the interview, we read aloud the information, and asked the 
participant to read along. Next, participants were asked to imagine that their clinician had 
offered them two treatment strategies. We presented a 10% difference in BC recurrence risk 
at 10 years between no aCT (25 out of 100 women with a recurrence) and aCT (15 out of 
100 with a recurrence), and asked the participants which treatment they preferred at this 
benefit of aCT of 10%. The participants were asked to indicate their preference each time 
in subsequent comparisons, in which the absolute benefit from aCT was systematically 
increased or decreased, depending on their answer. If their initial preference was aCT, we 
searched for their minimally-required benefit between the range of 0 (no benefit) and 10%. If 
their initial preference was no aCT, we searched for the minimally-required benefit between 
the ranges of 11 and 25% (maximum benefit). Participants could indicate to refuse aCT if they 
considered that, for a benefit of 25%, aCT was not worthwhile. After the aCT scenario, we 
similarly assessed participants’ preferred benefit from aHT, except that we presented a 15% 
difference in 10-year recurrence risk between no aHT and aHT in the initial question. At the 
end of each scenario, we asked participants about their motivations for their preference. 
Participants’ demographic and medical characteristics
The first self-report questionnaire contained questions about socio-demographic details. 
Information with regard to type of surgery, comorbid conditions, and geriatric health 
conditions (i.e., inability to carry out daily activities, incontinence, severe sensory impairment, 
depression, polypharmacy, difficulty with walking21) were extracted from medical records. 
Comorbid conditions at the time of diagnosis were registered according to the 10th revision of 
the International Classification of Diseases.22
Decisional role preference
We assessed participants’ preferred involvement in decision-making about aCT and aHT using 
an adapted version of the Control Preferences Scale.23 Participants were asked to choose 
one of five decisional roles, ranging from (1) the patient making the decision, (2) the patient 
making the decision after considering the clinician’s opinion, (3) the patient making the 
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decision jointly with the clinician, (4) the clinician making the decision after considering the 
patient’s opinion, to (5) the clinician making the decision.
Statistical analyses
Participants were categorized into ‘younger’ (40-64 years) and ‘older’ (≥65 years) based on 
their age at diagnosis. The response options for decisional role preference were merged into 
three categories: active (1-2), shared (3), and passive (4-5). Comorbidity was defined as the 
sum of any comorbid disease (0, 1, or 2 or more diseases). Differences in patient characteristics 
and decisional role preferences between the groups were examined using the χ² or Fisher 
exact tests, as appropriate. 
Participants’ minimally-required benefits to accept aCT and aHT were categorized into 0%, 
1-5%, 6-10%, 11-15%, 16-20%, and 21-25%. Participants who were undecided about the minimally-
required benefit were excluded from further analyses. Younger versus older participants’ 
minimally-required benefits and acceptance versus refusal of therapy were compared using 
the Fisher exact test. 
Univariable logistic regression analyses were conducted to examine the association between 
minimally-required benefit and patient characteristics and decisional role preference. The 
minimally-required benefit of both aCT and aHT was dichotomized into 0-10% required benefit 
(‘1’) and 11-25% required benefit or refusal of therapy (‘0’). A multivariable model was built 
with all significant factors (p<0.05) in univariable analysis. 
Two researchers independently coded participants’ motivations. Dissimilarities in coding 
were resolved through consensus. As this section was conducted for exploratory purposes, 
statistical differences in motivations between the age groups were not tested. 




Overall, 100 women with invasive BC were eligible for this study. Of them, 13 were not 
interviewed before the post-surgical consultation, and six withdrew before the interview. The 
reasons for withdrawal were no interest (n=3), being nervous about getting the pathology 
results within the next few days (n=2), and not being fully recovered from surgery (n=1). 



















































































the interview was six days (range, three to 12 days), and the telephone interview lasted on 
average 30 minutes (range, 10-50 minutes). 
The participants’ median age was 61 years (range, 42-86 years). Fifty-two (64%) participants 
were aged 40-64 years, and 29 (36%) were aged ≥65 years (Table 1). Overall, most women 
were married/lived together (51/81; 63%), had completed an intermediate-level education 
(35/81; 43%), were employed (38/81; 47%), and had children (not living at home) (49/81; 61%). 
Seventy-two (58/81) percent had ≥1 comorbid conditions, and 38% (31/81) suffered from ≥1 
geriatric health conditions at diagnosis. Eighty percent (65/81) were treated with breast-
conserving surgery. Most participants preferred to share the decision about aCT (42/73; 58%) 
and aHT (39/73; 53%) with the clinician. 
Minimally-required benefit in 10-year disease-free survival from aCT 
Some younger (2/52; 4%) and older (4/29; 14%) participants could not decide which benefit they 
would minimally require to consider the therapy worthwhile. In the remaining participants, 
92% (48/52) of the younger and 62% (18/29) of the older participants, respectively, would 
accept aCT, and 4% (2/52) of the younger and 24% (7/29) of the older participants would refuse 
aCT at the maximum absolute benefit of 25% (Figure 1A). Older participants refused aCT 
significantly more often than younger participants (p=0.005). Of those who would accept 
therapy, the younger participants considered aCT worthwhile at an absolute median benefit 
of 5% (range, 1-25%) and the older participants at an absolute median benefit of 4% (range, 
0-25%). These minimally-required benefits did not significantly differ (p=0.13). 
Minimally-required benefit in 10-year disease-free survival from aHT 
None of the younger and 24% (7/29) of the older participants were undecided about their 
minimally-required benefit. In the remaining group, the majority of younger (48/52; 92%) 
and older (17/29; 59%) participants would accept aHT (Figure 1B). Eight percent (4/52) of the 
younger and 17% (5/29) of the older participants would refuse aHT at an absolute benefit of 
25%. Overall, acceptance versus refusal rates did not significantly differ between younger and 
older participants (p=0.12). Of the group accepting therapy, younger and older participants 
considered it worthwhile at a median of 10% (range, 1-25%) and 8% (range, 0-25%) absolute 
benefit, respectively. These minimally-required benefits did not significantly differ (p=0.15). 
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Table 1. Characteristics of the study population overall (N=81) and by age category
  Total (n=81) 40-64 y (n=52, 64%) ≥65 y (n=29, 36%)  
Variables n % n % n % p
Marital status
married/living together 51 63 33 63 18 62 0.90
single/divorced/widowed 30 37 19 37 11 38
Educational levela
low   20 25 13 25 7 24 0.19
intermediate 35 43 19 37 16 55
high 26 32 20 39 6 21
Employment status
full/part-time 38 47 36 69 2 7 <0.001
housekeeper 9 11 3 6 6 21
unemployed/long-term sick leave 8 10 8 15 0 0
retired 26 32 5 10 21 72
Having children
no children 18 22 11 21 7 24 0.044
yes, children not living at home 49 61 28 54 21 72
yes, children living at home 14 17 13 25 1 3
Number of comorbid conditions
0 23 28 19 37 4 14 0.08
1 21 26 13 25 8 28
2 or more 37 46 20 39 17 59
Geriatric health conditionb
no 50 62 35 67 15 52 0.17
yes 31 38 17 33 14 48
Type of surgery
BCS 65 80 43 83 22 76 0.46
MAST 16 20 9 17 7 24
Decisional role preferencec
Adjuvant chemotherapyd
active 19 26 12 26 7 26 0.71
shared 42 58 25 54 17 63
passive 12 16 9 20 3 11
Adjuvant hormonal therapyd
active 21 29 14 30 7 26 0.42
shared 39 53 22 48 17 63
passive 13 18 10 22 3 11  
A p-value in bold means a significant difference between younger and older participants with respect to that variable
BCS = Breast-conserving surgery; MAST = Mastectomy
a Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary edu-
cation/vocational training; or high=completed pre-university education/high vocational training/university
b Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily 
activities, incontinence, severe sensory impairment, depression, polypharmacy; difficulties with walking   
c Decisional role preferences were merged into three categories: active (the patient makes the decision alone, the patient makes the 
decision after considering the clinician’s opinion); shared (patient makes the decision together with the clinician); and passive (the 
clinician makes the decision after considering the patient’s opinion, the clinician makes the decision alone)



















































































Figure 1. Minimum absolute increase in 10-year disease-free survival that younger (N=52) and older (N=29) participants 
would require to consider adjuvant chemotherapy (A) or hormonal therapy (B) worthwhile
In both scenarios, the 10-year disease-free survival without adjuvant systemic therapy was 75%, and the minimally-required benefit 
to accept therapy could range from 0 (no benefit) to 25% (maximum benefit)
Note: pdistr=p-value for distribution; refuse=women who would not accept therapy at any benefit; do not know=women who were 
undecided about the minimal benefit they would require to consider the therapy worthwhile
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Factors related to minimally-required benefit 
Univariable logistic regression analyses showed that participants who were single/divorced/
widowed were significantly less likely to accept aCT (odds ratio [OR] 0.21; 95% confidence 
interval [CI] 0.08-0.59; p=0.003) or aHT (OR 0.34; 95% CI 0.13-0.92; p=0.033) for 10% benefit 
or less, compared to participants who were married/lived together (Table 2). For aHT, there 
were no other significant factors besides marital status. For aCT, participants with a geriatric 
health condition had lower odds of accepting therapy at a 0-10% benefit (OR 0.18; 95% CI 0.06-
0.50; p=0.001). Furthermore, participants who preferred an active decisional role were less 
likely to accept aCT at a 0-10% benefit than participants who preferred a shared decisional role 
(OR 0.25; 95% CI 0.08-0.81; p=0.021). 
Factors included in the multivariable model for aCT were marital status, geriatric health 
condition, and decisional role preference. The participants who were single/divorced/
widowed had an odds of 0.16 (95% CI 0.04-0.57; p=0.005) for accepting aCT at a 0-10% benefit, 
compared to participants who were married/living together. Having a geriatric condition was 
related to requiring larger benefits to accept aCT (OR 0.27; 95% CI 0.07-0.98; p=0.047). Having 
an active decisional role preference was related with requiring larger benefits compared to 
having a shared decisional role preference (OR 0.15; 95% CI 0.04-0.67; p=0.012). 
Table 2. Univariable logistic regression analysis between patient characteristics, type of surgery, and decisional role 






at a 0-10% 
benefit (%)




at a 0-10% 
benefit (%)
ORb 95% CI p
Patient characteristics 
Age in years 
40-49 78 1 (ref) 78 1 (ref)
50-59 88 2.00 (0.28-14.53) 0.49 44 0.22 (0.04-1.30) 0.10
60-69 59 0.42 (0.07-2.39) 0.33 63 0.49 (0.08-2.81) 0.42
≥70 40 0.19 (0.03-1.25) 0.08 46 0.25 (0.04-1.66) 0.15
Marital status
married/living together 79 1 (ref) 65 1 (ref)
single/divorced/widowed 44 0.21 (0.08-0.59) 0.003 39 0.34 (0.13-0.92) 0.033
Educational levelc
low 79 1 (ref) 50 1 (ref)
intermediate 64 0.47 (0.13-1.73) 0.26 59 1.46 (0.46-4.67) 0.52




















































































full/part-time 75 1 (ref) 55 1 (ref)
housekeeper 75 1.00 (0.17-5.87) 1.00 50 0.81 (0.18-3.73) 0.79
unemployed/long-term sick leave 50 0.33 (0.07-1.62) 0.17 50 0.81 (0.18-3.73) 0.79
retired 57 0.43 (0.14-1.33) 0.14 60 1.21 (0.40-3.65) 0.73
Having children
no 63 1 (ref) 43 1 (ref)
yes, children not living at home 65 1.13 (0.35-3.66) 0.85 57 1.73 (0.52-5.80) 0.37
yes, children living at home 77 2.00 (0.39-10.31) 0.41 64 2.40 (0.52-10.99) 0.26
Number of comorbid conditions
0 81 1 (ref) 64 1 (ref)
1 65 0.44 (0.11-1.82) 0.26 58 0.79 (0.22-2.77) 0.71
2 or more 59 0.34 (0.09-1.22) 0.10 49 0.54 (0.18-1.62) 0.27
Geriatric health conditiond
no 81 1 (ref) 64 1 (ref)
yes 43 0.18 (0.06-0.50) 0.001 41 0.39 (0.15-1.03) 0.06
Treatment characteristics
Type of surgery
BCS 68 1 (ref) 51 1 (ref)
MAST 60 0.70 (0.22-2.23) 0.54 73 2.66 (0.76-9.31) 0.13
Decisional role preferencee,f
shared 72 1 (ref) 56 1 (ref)
active 39 0.25 (0.08-0.81) 0.021 40 0.53 (0.18-1.62) 0.27
passive 80 1.57 (0.29-8.60) 0.60 67 1.60 (0.41-6.29) 0.50
A p-value in bold means a significant difference beween that group and the reference group 
aCT = Adjuvant chemotherapy; aHT = Adjuvant hormonal therapy; BCS = Breast-conserving surgery; MAST = Mastectomy; OR = Odds ratio; ref= 
reference; CI = Confidence interval
a  Participants who could not decide upon their minimally-required benefit were excluded (aCT, n=6; aHT, n=7)
b An OR over 1 indicates a greater likelihood to accept therapy at a 0-10% benefit, an OR below 1 indicates a lower likelihood to accept therapy at a 
0-10% benefit (and a greater likelihood to require a >10% benefit)
c Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary education/vocational 
training; or high=completed pre-university education/high vocational training/university
d Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily activities, incon-
tinence, severe sensory impairment, depression, polypharmacy; difficulties with walking
e Decisional role preferences were merged into three categories: active (the patient makes the decision alone, the patient makes the decision after 
considering the clinician’s opinion); shared (patient makes the decision together with the clinician); and passive (the clinician makes the decision after 
considering the patient’s opinion, the clinician makes the decision alone)
f Eight respondents did not fill out the questions about aCT and aHT before the post-operative consultation and were excluded from this analysis
Motivations in favor of or against adjuvant systemic therapy
Both younger and older participants frequently reported that the wish to survive/avoid 
recurrence and the treatment recommendation of their clinician were motivations in favor 
of aCT (Table 3). In the case of aHT, younger participants frequently cited the clinician’s 
recommendation and wanting to survive/avoid recurrence as arguments for the therapy. For 
older participants, the clinician’s recommendation was the predominant argument. 
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For both younger and older participants, the most often reported argument against aCT 
was concern about potential side effects. Older participants also commonly reported that 
the wish to maintain their current quality of life and independence, the negative treatment 
experience of others, the benefits not outweighing side effects, and their old age were 
arguments against aCT. Regarding aHT, both age groups frequently noted that side effects 
and the long duration of treatment were arguments against the therapy. 
Table 3. Arguments in favor of and against adjuvant chemotherapy (N=75)a and adjuvant hormonal therapy (N=74)a 
according to age categoryb
aCT aHT
40-64 y ≥65 y 40-64 y ≥65 y
(n=50) (n=25) (n=52) (n=22)
% % % %
Arguments in favor of systemic therapy
Wish to survive/avoid recurrence/ Do everything possible to fight the cancer 40 28 25 14
Clinician’s recommendation for treatment 24 36 25 36
Downplays side effects/ not everybody will have side effects 14 16 13 18
Positive treatment experience of others 12 4 6 0
Age (“I am too young”) 12 4 6 0
Potential benefits outweigh potential side effects 12 8 8 18
Someone (e.g., partner, (grand)children) to live for 6 4 6 5
Reduce possible (future) regret 6 4 4 5
Trust in (effectiveness) of treatment 2 4 2 5
Preference based on feeling (not further specified) 2 0 4 0
Trust in the capability of my body to deal with the drug 0 4 0 0
Specific for aCT:
Short duration of treatment 2 0 - -
Specific for aHT:
Able to discontinue therapy in case of many/severe side effects - - 8 5
Is experiencing/has experienced little/no menopausal complaints - - 6 18
Not having to go to hospital to undergo treatment - - 2 0
Medication/life style changes possible to lessen the severity of side effects - - 2 0
Taking a daily pill is not a burden - - 2 9
Arguments against systemic therapy
Concerns about short- and/or long-term side effects 50 40 42 36
Maintain quality of life/independence/ Continue work 12 24 10 18



















































































Health status/condition 12 12 8 14
Potential benefits do not outweigh potential side effects 8 24 0 5
Undergoing adjuvant systemic therapy does not guarantee no recurrence 6 8 0 5
Relies on regular check-ups/ option of new therapy in case of recurrence 4 0 2 0
Hopes to be cured without adjuvant systemic therapy 2 0 2 0
Age (“I am too old”) 2 24 2 9
Lack of social support 2 8 2 5
Long duration of treatment 2 0 40 23
No or little trust in (effectiveness) of treatment 0 0 0 5
Specific for aCT:
Frequent hospital visits for chemotherapy are a burden 2 4 - -
Fear of needles 2 0 - -
Specific for aHT:
Is experiencing/has experienced many/severe menopausal complaints - - 6 0
Taking a daily pill is a burden - - 2 0
Negative experience with hormones - - 2 0
‘’—‘’ indicates that the argument is not applicable to the therapy
aCT = Adjuvant chemotherapy; aHT = Adjuvant hormonal therapy 
a Participants who could not decide upon their minimally-required benefit, were excluded (aCT: n=6; aHT: n=7)
b Participants could indicate more than one argument
DISCUSSION 
This prospective study compared the minimal benefit in 10-year disease-free survival that 
younger and older patients with early BC would require to consider aCT and aHT worthwhile. 
Additionally, we assessed which factors were related to minimally-required benefit, and 
explored younger and older patients’ motivations for and against these therapies. To 
our knowledge, this is the first study that examined preferences for aCT and aHT in older 
patients24 and before patients received a recommendation for or against adjuvant systemic 
therapy, thereby minimizing the biasing influence of cognitive dissonance reduction. This 
cognitive mechanism of adaptation leads individuals to reduce inconsistencies between 
previous decisions (such as treatment decisions) and current beliefs. Thus, patients will tend 
to justify earlier decisions about how they will be treated in such ways that their current 
preferences are in accordance with that decision.7 In this sample, participants did not know 
which treatment was indicated, and no treatment decision was yet made. We are aware that 
participants may already have had a treatment preference, based on clinical information they 
received after diagnosis (e.g., having a very large tumor), experiences from significant others, 
or on information found on the Internet or elsewhere. This is true also in daily practice. 
78
 4
Our results reveal that older participants would more often refuse aCT than younger 
participants, but no significant difference was found regarding aHT. However, the proportion 
of older participants willing to accept systemic therapy was large (three out of five women, 
for both aCT and aHT), and for these older women, the minimally-required benefit did not 
differ from that of younger women. The latter finding is in line with other studies on aCT 
that found no association between age and minimally-required benefit, in terms of overall9-11 
or disease-free survival,7 but not with other studies demonstrating in contrast that higher 
age was related to higher minimally-required benefit from aCT25,26 or aHT.26 However, our 
study as well as earlier studies7,9-11 showing no such association differ from the latter two25,26 
regarding design and population in the following way. Firstly, in the two latter studies it was 
unclear whether participants could refuse therapy. Secondly, the latter studies also involved 
more advanced BC stages, which could lead to different treatment preferences. Based on our 
results, it appears that for early-stage BC, age is not a factor in determining the minimally-
required benefit, and that the majority of patients are willing to consider adjuvant systemic 
therapy. It is important for clinicians to be aware of these preferences. 
Another finding was that some participants, predominantly older participants, were 
undecided about the minimal benefit they would require to consider adjuvant systemic 
therapy worthwhile. Participants primarily reported they would rely on the treatment advice 
of their clinician. It is important that clinicians themselves are aware of this finding, and 
they should try to ensure that information provision is clear and tailored to the needs of the 
patient. Additionally, patients should be made aware that they should voice their preferences 
and concerns.   
Another finding was that being single, divorced, or widowed, having a geriatric health 
condition, and having a preference for an active decisional role predicted patients’ preference 
for aCT. Women who were single/divorced/widowed had a five times higher odds of requiring 
a large benefit than women who were married/living together. This may be explained by 
either not having a partner for whom to consider a treatment worthwhile (“to live for”), 
or by lack of support from a partner during treatment. If a patient has one or more geriatric 
health conditions, she might be more likely to think that she might not cope with the side 
effects of adjuvant systemic therapy, and thus her minimally-required benefit should be 
higher to make it worthwhile. The association with role preference may be explained by two 
mechanisms with a different causal direction. On the one hand, patients who do not want aCT 
may want to be actively involved to ensure that no overtreatment occurs. That is, patients’ 
existing treatment preference may determine their role preference. On the other hand, it has 
been found that patients who are more active, following the use of a decision aid, tend to 




















































































As expected, the predominant motivation in favor of aCT was to survive/avoid recurrence, 
irrespective of age. Nevertheless, older participants seemed to value the clinician’s 
recommendation more compared to younger participants. These two factors have often 
been noted in previous studies concerning older patients’ decision-making about aCT13,14 and 
about treatment for BC in general.15,28 Further, our study indicated that motivations against 
aCT largely differed between younger and older participants. Both groups frequently reported 
concern about side effects as a motivation. Additionally, older participants reported the wish 
to maintain their current quality of life and independence and the belief that benefits do not 
outweigh side effects as concerns about aCT. As these concerns are specific to older patients, 
more focus should be placed on quality of life and independence when discussing treatment 
consequences, and sufficient information should be provided to help develop realistic 
expectations on side effects of aCT. This will better support older patients in developing an 
informed treatment preference. Interestingly, although age was not a factor in determining 
the minimally-required benefit to accept therapy, it was an important argument for women 
in deciding for or against adjuvant systemic therapy. The most striking observation was that 
older participants more frequently stated that their old age was an argument against aCT. 
The motivations for aHT were similar to those found for aCT, except that the wish to survive/
avoid recurrence was less frequently reported. An explanation may be that participants 
generally know less about this treatment compared with aCT, and thus possibly doubt or 
underestimate the effectiveness of aHT. The wish to survive/avoid recurrence and the 
clinician’s recommendation were valued equally in younger participants. This was not found 
for older participants who considered the clinician’s recommendation most important. 
With regard to arguments against aHT, no overt differences were found in the predominant 
motivations between the age groups. 
Some limitations of this study need to be noted. Participants were approached before they 
actually faced a decision. Although they probably would be confronted with this decision, the 
preference they reported here might still differ from their preference once they had received 
a recommendation. Further, fewer older participants than anticipated could be included in 
the study. This was owing to the fact that primarily older participants were excluded based 
on the exclusion criterion of having a previous malignancy (11 older compared with 2 younger 
women). Nevertheless, comparison of our older participants with older patients with early-
stage invasive BC enrolled in a population-based cohort study in the Netherlands29 showed 
that our sample was compared favorably with the average older woman with BC with regard 
to median age and presence of comorbid and geriatric conditions. Finally, because our sample 
was small, further investigation about younger and older participants’ preferences for aHT in 




This prospective study revealed that whereas older participants were less willing to undergo 
aCT than younger participants, no significant difference was found for aHT. Still, a majority of 
older participants would accept both therapies, and these women required similar benefits 
in 10-year disease-free survival as younger women. The option of adjuvant systemic therapy 
should therefore be discussed with eligible patients regardless of age. Younger and older 
participants’ motivations for and against therapy generally did not differ, except that, contrary 
to younger participants, older participants reported multiple motivations against aCT, which 
included fear of treatment-related toxicity, the wish to maintain current quality of life and 
independence, the negative treatment experience of others, benefits not outweighing side 
effects, and old age. Clinicians should explore what matters most to the patient, elicit their 
preference, and incorporate these evaluations in their treatment recommendation.  
CLINICAL PRACTICE POINTS
•	 To date, little is known about older patients’ preferences for aCT and aHT. Previous 
studies have mainly focused on young or middle-aged patients. The scarcity of 
evidence on older patients’ treatment preferences indicates that clinicians have 
no clear guidance about what older patients generally desire. Several studies 
demonstrated that patient age often influences clinicians’ advice about adjuvant 
systemic therapy.30,31 This ageism may partially explain why older patients more often 
receive suboptimal therapy than younger patients, which might then be associated 
with lower survival rates.32
•	 Our prospective study has generated new knowledge that can be of help when making 
adjuvant treatment decisions with older patients. We found that the proportion of 
older women that would accept adjuvant systemic therapy was large, and for these 
women the minimally-required benefit for aCT and aHT did not differ from that of 
younger women. Also, we found a large variation in preferences within the older 
group, suggesting that each individual older patient may value the benefits and side 
effects of treatment strategies differently. 
•	 It is necessary to involve older patients in the decision-making process. This requires 
patients to be made aware that adjuvant systemic therapy is an option. Next, the 
benefits and side effects involved, including the associated uncertainty given the 
individual’s biological age, should be discussed. It is essential to explicitly explore the 
patient’s consideration as to whether the expected benefit is worth the side effects.33 
Acknowledgements
The authors would like to thank all patients who were willing to participate, and all health care 
professionals of the Leiden University Medical Center (Leiden), Haga Hospital (The Hague) 



















































































Ranke, Elly Krol Warmerdam (Leiden), Karen Fennema-Bensink, Monique Bouwman, Jolanda 
Fris (The Hague), Angelique Smulders-Prince, Anja Verhamme-Jongenelen and Susanne van 
den Broek (Tilburg) for their efforts in approaching eligible patients. We would also like to 
thank Mariette Bergmans (Dutch Breast Cancer Association), Judith Kroep, Astrid Scholten 
and Yvette van der Linden (Leiden) for recruiting women for the pilot study; Monique Baas-
Thijssen (Leiden) for her feedback on the hypothetical scenarios and her assistance in the 
pilot study; Annemarie Voet-van den Brink and Graziella Kallenberg-Lantrua (Leiden) for their 
contribution in interviewing participants, Nanny van Duijn-Bakker (Leiden) for her assistance 
in data analysis, Johan Polderdijk (The Hague), Dilsher Singh and Kenneth Chin for assisting 
in data collection from medical records, and Richard Zwaan (Leiden) for constructing the 
ProMISe database. This study is part of the FOCUS study (Female breast cancer in the 
elderly; optimizing clinical guidelines using clinico-pathological and molecular data), which is 
supported by the Dutch Cancer Society (grant number 2007-3968).  
Role of the funding source
This study was supported by a grant from Pink Ribbon, the Netherlands (grant number 2011.
WO06.C107). The sponsor had no role in the study design, methods, subject recruitment, the 




1. DeSantis C, Ma J, Bryan L et al. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52-62.
2. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for 
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 
2005;365:1687-1717.
3. Grimison PS and Stockler MR. Quality of life and adjuvant systemic therapy for early-stage breast cancer. 
Expert Rev Anticancer Ther 2007;7:1123-1134.
4. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated 
recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of 
Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012;13:e148-e160.
5. Politi MC, Lewis CL, Frosch DL. Supporting shared decisions when clinical evidence is low. Med Care Res 
Rev 2013;70:113S-128S.
6. Hamelinck VC, Bastiaannet E, Pieterse AH et al. Patients’ preferences for surgical and adjuvant systemic 
treatment in early breast cancer: A systematic review. Cancer Treat Rev 2014;40:1005-1018.
7. Jansen SJ, Kievit J, Nooij MA et al. Patients’ preferences for adjuvant chemotherapy in early-stage 
breast cancer: is treatment worthwhile? Br J Cancer 2001;84:1577-1585.
8. Duric VM, Fallowfield LJ, Saunders C et al. Patients’ preferences for adjuvant endocrine therapy in early 
breast cancer: what makes it worthwhile? Br J Cancer 2005;93:1319-1323.
9. Duric VM, Stockler MR, Heritier S et al. Patients’ preferences for adjuvant chemotherapy in early breast 
cancer: what makes AC and CMF worthwhile now? Ann Oncol 2005;16:1786-1794.
10. Lindley C, Vasa S, Sawyer WT et al. Quality of life and preferences for treatment following systemic 
adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.
11. Simes RJ and Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how 
much benefit is needed? J Natl Cancer Inst Monogr 2001;146-152.
12. Thewes B, Meiser B, Duric VM et al. What survival benefits do premenopausal patients with early breast 
cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005;6:581-588.
13. Harder H, Ballinger R, Langridge C et al. Adjuvant chemotherapy in elderly women with breast cancer: 
patients’ perspectives on information giving and decision making. Psychooncology 2013;22:2729-2735.
14. Kreling B, Figueiredo MI, Sheppard VL et al. A qualitative study of factors affecting chemotherapy use in 
older women with breast cancer: barriers, promoters, and implications for intervention. Psychooncology 
2006;15:1065-1076.
15. Schonberg MA, Birdwell RL, Bychkovsky BL et al. Older women’s experience with breast cancer 
treatment decisions. Breast Cancer Res Treat 2014;145:211-223.
16. Shelton RC, Clarke HG, Hershman DL et al. Interpersonal influences and attitudes about adjuvant 
therapy treatment decisions among non-metastatic breast cancer patients: an examination of 
differences by age and race/ethnicity in the BQUAL study. Breast Cancer Res Treat 2013;137:817-828.
17. Duric VM, Butow PN, Sharpe L et al. Psychosocial factors and patients’ preferences for adjuvant 
chemotherapy in early breast cancer. Psychooncology 2007;16:48-59.
18. Harrow A, Dryden R, McCowan C et al. A hard pill to swallow: a qualitative study of women’s 
experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 2014;4:e005285.
19. Tusquets I, Espinosa AE, Mendez M et al. Epidemiologic study to assess patient involvement in choice of 
adjuvant chemotherapy for breast cancer (PROSA Study). Clin Transl Oncol 2009;11:221-227.
20. Llewellyn-Thomas HA. Investigating patients’ preferences for different treatment options. Can J Nurs Res 
1997;29:45-64.
21. Wildiers H, Heeren P, Puts M et al. International Society of Geriatric Oncology consensus on geriatric 
assessment in older patients with cancer. J Clin Oncol 2014;32:2595-2603.
22. World Health Organization. International Statistical Classification of Diseases and Related Health 
Problems 10th Revision. Accessed on 6 November 2014. Available from: http://apps.who.int/
classifications/icd10/browse/2010/en 



















































































24. Puts MT, Tapscott B, Fitch M et al. A systematic review of factors influencing older adults’ hypothetical 
treatment decisions. Oncology & Hematology Reviews 2015;11:19-33.
25. Acevedo F, Sanchez C, Jans J et al. How much survival benefit is necessary for breast cancer patients to 
opt for adjuvant chemotherapy? Results from a Chilean survey. Ecancermedicalscience 2014;8:391.
26. Thiel FC, Schrauder MG, Fasching PA et al. Shared decision-making in breast cancer: discrepancy 
between the treatment efficacy required by patients and by physicians. Breast Cancer Res Treat 
2012;135:811-820.
27. Stacey D, Legare F, Col NF et al. Decision aids for people facing health treatment or screening decisions. 
Cochrane Database Syst Rev 2014;1:CD001431.
28. Petrisek AC, Laliberte LL, Allen SM et al. The treatment decision-making process: age differences in 
a sample of women recently diagnosed with nonrecurrent, early-stage breast cancer. Gerontologist 
1997;37:598-608.
29. Kiderlen M, van de Water W, Bastiaannet E et al. Survival and relapse free period of 2926 unselected 
older breast cancer patients: a FOCUS cohort study. Cancer Epidemiol 2015;39:42-47. 
30. Foster JA, Salinas GD, Mansell D et al. How does older age influence oncologists’ cancer management? 
Oncologist 2010;15:584-592.
31. Hurria A, Wong FL, Villaluna D et al. Role of age and health in treatment recommendations for older 
adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 
2008;26:5386-5392.
32. Bouchardy C, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in 
elderly women. J Clin Oncol 2003;21:3580-3587.
33. Stiggelbout AM, van der Weijden T, De Wit MP et al. Shared decision making: really putting patients at 
the centre of healthcare. BMJ 2012;344:e256.
34. Dutch Cancer Society. Chemotherapy. Accessed on 1 June 2011. Available from: http://www.kwf.nl/Site-
CollectionDocuments/brochure-Chemotherapie.pdf 
35. Dutch Cancer Society. Hormonal therapy. Accessed on 1 June 2011. Available from: http://www.kwf.nl/
SiteCollectionDocuments/brochure-Hormonale-therapie-bij-kanker.pdf 
36. Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and 
other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 
Lancet 2011;378:771-784.
37. Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy 
regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 
randomised trials. Lancet 2012;379:432-444.
38. Nationaal Borstkanker Overleg Nederland. Breast Cancer Guideline, version 2.0. Accessed on 6 




APPENDIX A. Hypothetical scenario A.1: no adjuvant chemotherapy versus adjuvant chemotherapy; and hypothetical 
scenario A.2: no adjuvant hormonal therapy versus adjuvant hormonal therapy 
The numbers represent the order in which the information about the treatment strategies 
was read aloud. Health consequences and side effects were based on a previous study about 
patient preferences (in the case of adjuvant chemotherapy only),7 patient education bro-
chures of the Dutch Cancer Society,34,35 and expertise of two medical oncologists. Recurrence 
probabilities with and without adjuvant systemic therapy at 10 years were based on Early 
Breast Cancer Trialists’ Collaborative Group data36,37 and the Dutch treatment guidelines for 
BC.38 The time period of 10 years differs from earlier studies,7-9,11,12 but reflects current clinical 
practice. The treatment strategies were listed next to each other to ease comparability, and a 
combination of frequency formats and bar graphs was used to present the recurrence proba-
bilities. This format was pilot-tested (face-to-face and by phone) among two healthy women 
and 23 patients, to assess readability, ease of understanding, and the level of distress the 
information might provoke. Based on the feedback, the wording of the interview questions 

























































































2. HEALTH CONSEQUENCES AND SIDE EFFECTS 
3. PROBABILITY OF RECURRENCE AT 10 YEARS 
Chemotherapy No chemotherapy 
The treatment consists of surgery (and 
possibly irradiation), followed by 
chemotherapy. 
 
In most cases, chemotherapy is given once 
every three weeks for up to 6 months. It is 
administered by intravenous drip in the arm 
at the hospital, and each session lasts a few 
hours.  
 
After chemotherapy check-ups with the 
treating specialist take place.  
 
Both the disease and surgery (and 
irradiation) can cause physical, 
psychological and/or social problems.  
 
Additionally chemotherapy can cause side 
effects, such as: 
Hair loss, tiredness, feeling sick and 
vomiting, muscle and joint pain, 
diarrhea or constipation, decrease in 
the number of red blood cells, 
increased chance of infections, sores 
in the mouth, feeling of numbness or 
pins and needles, loss of appetite, skin 
rashes, itching, sore eyes, menopausal 
symptoms, infertility and (rarely) heart 
problems 
 
The intensity of these side effects is 
impossible to predict; this varies from 
person to person. 










After surgery check-ups with the treating 
specialist take place.  
 
Both the disease and surgery (and 
irradiation) can cause physical, 
psychological and/or social problems.  
 
Of the 100 women who do not undergo chemotherapy: 
 
75 will have no recurrence of the disease  
25 will have a recurrence of the disease 
 
Of the 100 women who do undergo chemotherapy: 
 
75 will have no recurrence of the disease  
10 will benefit from chemotherapy 












out of 100 women out of 100 women 
out of 100 women 
out of 100 women 










2. HEALTH CONSEQUENCES AND SIDE EFFECTS 
3. PROBABILITY OF RECURRENCE AT 10 YEARS 
Hormonal therapy No hormonal therapy 
The treatment consists of surgery (and 
possibly irradiation), followed by hormonal 
therapy. 
 
Hormonal therapy is given for 5 years and 
consists of a tablet taken daily.  
 
During hormonal therapy check-ups with the 
treating specialist take place.  
 
Both the disease and surgery (and 
irradiation) can cause physical, 
psychological and/or social problems.  
 
Additionally hormonal therapy can cause 
side effects, such as: 
Menopausal symptoms (hot flushes, 
feeling sick, muscle and joint pain, 
tiredness, breast pain or discomfort, hair 
thinning, mood changes, feeling sleepy, 
weight changes, vaginal bleeding and/or 
dryness) and (rarely) an increased risk of 
womb cancer, thrombosis –blood clots in 
veins- and bone loss 
 
The intensity of these side effects is 
impossible to predict; this varies from 
person to person. 







After surgery check-ups with the treating 
specialist take place.  
 
Both the disease and surgery (and 
irradiation) can cause physical, 
psychological and/or social problems.  
 
Of the 100 women who do not undergo hormonal therapy: 
 
75 will have no recurrence of the disease  
25 will have a recurrence of the disease 
 
Of the 100 women who do undergo hormonal therapy: 
 
75 will have no recurrence of the disease  
15 will benefit from hormonal therapy 












out of 100 women out of 100 women 
out of 100 women 
out of 100 women 
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Purpose | Older patients are believed to prefer a more passive role in treatment decision-
making, but studies reporting this relation were conducted over a decade ago or were 
retrospective. We prospectively compared younger (40-64 years) versus older (≥65 years) 
breast cancer patients’ preferences for decision-making roles and their perceived actual roles.
Methods | A prospective multicenter study was conducted in Leiden, The Hague and 
Tilburg over a two-year period. Early-stage breast cancer patients were surveyed about 
their preferred and perceived decision-making roles (active, shared, or passive) concerning 
surgery type (breast-conserving versus mastectomy) (n=74); adjuvant chemotherapy (aCT, 
n=43); and adjuvant hormonal therapy (aHT, n=39). 
Results | For all decisions, both age groups most frequently preferred a shared role before 
consultation, except for decisions about aHT, for which younger patients more commonly 
preferred an active role. The proportion of patients favouring an active or passive role in 
each decision was lower for the older than the younger patients, but none of the differences 
was significant. Regarding perceived actual roles, both groups most frequently reported an 
active role in the surgical decision after consultation. In deciding about both aCT and aHT, a 
larger proportion of older patients perceived having had a passive role compared to younger 
patients, and a greater proportion of younger patients perceived to have been active. Again, 
differences were not statistically significant.
 
Conclusion | Most older patients preferred to decide together with their clinician, but 
preferences varied widely. Older patients more often than younger patients perceived they 
had not been involved in decisions about systemic therapy. Clinicians should invite all patients 












































































Over the last years, patient decisional role preferences in treatment decisions and shared 
decision-making (SDM) have been of central interest.1 SDM entails clinicians helping patients 
to understand the potential benefits and risks of different treatment options, based on the 
best available medical evidence, and encouraging them to consider what matters most to 
them and to communicate their preferences. These preferences are then integrated with 
the clinical evidence to select the treatment option that best fits the patient.2,3 SDM is 
strongly advocated in situations in which more than one option is medically appropriate and 
the choice strongly depends on patient preferences.4 This is particularly true in early-stage 
breast cancer (BC). Primary treatment often involves a choice between breast-conserving 
surgery (BCS) and mastectomy (MAST). Both surgical options are equally effective in terms 
of survival,5 but they have different consequences that may be valued differently by individual 
patients.6,7 The importance of SDM has also been emphasized in the decisions about adjuvant 
systemic therapy in early-stage BC.8 Adjuvant chemotherapy (aCT) or hormonal therapy 
(aHT) can improve disease-free survival,9 but the benefits sometimes are only marginal and 
must be balanced against the large probability of side effects and inconveniences associated 
with treatment. Research has shown that large differences exist in preferences for adjuvant 
systemic therapy between individuals.6 In these decisions, treatment choice therefore relies 
on a subjective weighing of the considerations. 
Decision-making about treatment is complex for all patients, but it may be even more 
challenging when it comes to older patients. There is more uncertainty about the most 
appropriate treatment in this patient group, as clinical trials have frequently excluded older 
patients because of age or comorbid conditions,10 and as shorter life expectancy decreases 
the benefit from treatment. Additionally, older patients often use multiple medications 
which may interact with treatment.11 Further, a large heterogeneity exists among older 
patients in terms of general health status, physical and cognitive functioning, and tolerance 
to treatment toxicity.12 Finally, non-clinical challenges (e.g., less social support) may affect 
treatment preferences of older patients differently compared to younger patients.13 These 
reasons underscore the need to involve older patients in the decision-making process.14,15
A commonly reported argument against SDM with older patients is that they do not want a 
role in which they share the responsibility for the decision with the clinician, and that they 
would rather just receive information about their disease and treatment.16-19 Studies that 
examined the preferred role of older patients in deciding about BC treatment have yielded 
inconsistent findings. Some found that a majority of older patients preferred a passive role like 
younger patients,20 while others reported that a majority of the elderly wished a shared role21-
23 like younger patients.24-27 It is noteworthy that most studies reporting a relation between 
older age and a passive decisional role preference were conducted over a decade ago.20,28-31 
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In the current era, in which patients are encouraged to be involved in treatment decision-
making, it is conceivable that older patients have different decisional role preferences than 
older patients from previous generations.32 It therefore remains unclear if and to what 
extent older patients prefer to be involved in decision-making, and how their preferences 
compare to that of younger patients. Furthermore, most studies assessed preferences 
following decision-making, whereby the patients’ perceived role in the consultation could 
have strongly influenced their preferences, and whereby older patients in particular most 
likely had experienced passive roles.16,33 Little is known about patients’ decision-making 
preferences as assessed prospectively.
This prospective study aimed to compare the preferences of younger versus older patients 
for decision-making roles concerning three decisions (type of surgery, aCT, and aHT) in early 
BC. We also explored, for each decision, whether younger versus older patients differed in 
their perceived roles, and the concordance between preferred and perceived roles. 
METHODS 
Participants
This study was conducted at one academic and two non-academic teaching hospitals in the 
Netherlands, from January 2012 to December 2013. Eligible patients were aged ≥40 years, had 
a primary ductal carcinoma in situ or an invasive tumour (clinical T1-2), and were candidates 
for both BCS (with radiotherapy) and MAST. Exclusion criteria were bilateral BC, BRCA 1/2 
mutation, previous diagnosis of (non)invasive BC, other malignancies within the past five 
years (except non-melanoma skin cancer or cervical carcinoma in situ), poor comprehension 
of the Dutch language, mental/cognitive problems, intention to undergo neo-adjuvant 
therapy, any concurrent malignancy, and evidence of metastatic disease. Approval of the 
study protocol was obtained from the Medical Ethical Committee of the Leiden University 
Medical Center and the review boards of the other participating hospitals. Written informed 
consent was obtained from all participants. 
Additional criteria were applied to each treatment decision. For surgery, patients who 
underwent a re-operation due to tumour positive surgical margins were excluded. For 
adjuvant systemic therapy, only patients eligible to receive aCT, aHT, or both were included. 
We first selected the patients who were referred to a medical oncologist. Subsequently, 
patients with hormone receptor (HR)-negative tumours were excluded from the aHT-related 
analysis, as they are ineligible to be treated with aHT. Finally, based on the national treatment 
guidelines,34 patients aged ≥70 years were only included in the aCT analysis if they presented 
with highly unfavourable prognostic features (i.e., positive nodes and/or HR-negative 












































































Eligible patients were informed about the study during the first surgical consultation, after 
having been informed about the diagnosis and their eligibility for both BCS and MAST. 
Those who were interested received a questionnaire that contained a short comparative 
overview of the surgical options (see Hamelinck et al.35 for more details), and one question 
to determine the participant’s role preference in decision-making. They were instructed to 
complete the questionnaire before the second surgical consultation, in which the surgical 
options are usually discussed more in detail, a treatment recommendation is given, and a 
decision is made. 
Before surgery, only the participants with invasive disease received another questionnaire. 
This questionnaire contained information on aCT and aHT (see Hamelinck et al.13 for more 
details) and two questions to determine their preferred role in decision-making about these 
treatments. They had to complete the questionnaire after surgery but before the post-
surgical consultation. During that consultation, patients are informed whether adjuvant 
systemic therapy is recommended based on pathology results, and that in case of eligibility, 
a consultation with the medical oncologist follows to discuss the systemic therapy options. 
We purposively asked participants to complete the questionnaire about surgery before the 
second surgical consultation, and the questionnaire about adjuvant systemic therapy before 
the post-surgical consultation, to prevent the surgeon’s recommendation for type of surgery 
and for referral to the medical oncologist, respectively, from influencing the participant’s 
decisional role preference. Six weeks after surgery, all participants received a mailed follow-
up questionnaire containing questions regarding participants’ perceptions of their role 
during decision-making about surgery, and if applicable, about aCT and/or aHT. By then, it was 
expected that patients with an indication for adjuvant systemic therapy had been referred to 
the medical oncologist and that a treatment plan had been determined. 
Measures
Preferred and perceived role in decision-making
A modified version of the Control Preferences Scale36 was used to assess decisional role 
preferences. For each treatment decision, participants were asked to indicate their preferred 
role for involvement in decision-making from the following five roles: (1) the patient decides, 
(2) the patient decides after considering the clinician’s opinion, (3) the patient decides jointly 
with the clinician, (4) the clinician decides after considering the patient’s opinion, and (5) 
the clinician decides. Perceived role in decision-making was assessed by asking participants 
to indicate the role they had played in each decision, by choosing from the same five roles 
(presented in the past tense).  
Participants’ characteristics 
Self-report data on socio-demographic details were collected in the pre-surgery questionnaire. 
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Medical charts were reviewed for information on tumour and treatment characteristics, date 
of first medical oncology visit (in which a decision about systemic therapy is usually made), 
and geriatric conditions.37 Comorbid conditions were also registered using the 10th revision of 
the International Classification of Diseases.38
 
Statistical analyses
Participants were divided into younger (aged 40-64 years) and older (aged ≥65 years) pa-
tients. For each decision, only participants who filled in both their preferred and perceived 
role were included. Responses regarding preferred and perceived roles were categorized as 
active (responses of 1-2), shared (3), and passive (4-5). Each participant’s preferred role was 
compared to her perceived role, resulting into two categories: concordance (preferred and 
perceived role were similar) and discordance (preferred role differed from perceived role). 
In case of discordance, we noted whether more (from passive to shared/active; from shared 
to active) or less (from active to shared/passive; from shared to passive) involvement was 
perceived than preferred. Descriptive statistics were used to present participants’ character-
istics, preferred and perceived roles, and concordance. Differences in characteristics, roles, 
and concordance among the age groups were assessed by the χ² or Fisher Exact tests. Data 




Overall, 132 eligible patients agreed to participate (75% response). Of them, 92 answered 
the question about preferred role in surgical decision-making before the second surgical 
consultation. No significant differences were found between characteristics of participants 
who did versus who did not return the questionnaire before the consultation (data not 
shown). As three patients subsequently withdrew from the study, 89 were sent the follow-
up questionnaire and 83 of these returned it. Nine of them were excluded for the following 
reasons: underwent a reoperation (n=7), had a concurrent malignancy discovered after surgery 
(n=1), or did not answer the question about perceived role (n=1). In total, 74 participants 
completed the questionnaire at a median of 60 days after the consultation (range, 45-115; 
Table 1 and Figure 1). A majority had invasive disease (85%) and underwent BCS (72%). The 
sample included 49 younger (66%) and 25 older (34%) patients. Younger and older patients did 
not differ on most variables, with the exception that older versus younger participants were 
less often employed (p<0.001) and had less often children living at home (p=0.05). Further, 
older patients more often experienced one specific geriatric health condition: severe sensory 
impairment (p=0.02). Although a greater proportion of the older patients had one or more 
comorbid conditions than younger patients, there were no significant differences between 











































































Figure 1. Flow chart of selection of patients included in analysis for decision-making about type of surgery 
Figure 2. Flow chart of selection of patients included in analysis for decision-making about adjuvant chemotherapy 




In total, 104 participants received the questionnaire about preferred roles in aCT and aHT 
decision-making, and 78 completed the questions before the post-surgical consultation. No 
significant differences were found for patients’ age between those who did versus did not 
return the questionnaire before the consultation. One participant dropped out after filling 
out the questionnaire, and 77 received the follow-up questionnaire. Of the 75 who returned 
it, 52 had visited a medical oncologist. Participants were excluded if they had a concurrent 
malignancy (n=1), if the perceived role question was answered before their medical oncology 
visit (n=2), or if the question was not answered (n=1). Of the remaining 48 patients, 34 had 
an indication for both aCT and aHT, 9 had an indication for only aCT and 5 for only aHT. 
Thus, 43 participants were included in the aCT analysis and 39 in the aHT analysis (Figure 2). 
Participants completed the aCT questionnaire on average 29 days after consultation (range, 
9-89, Table 1) and the aHT questionnaire on average 31 days (range, 8-58) after consultation. 
In the aCT analysis, 11 patients (26%) were aged ≥65 years, and in the aHT analysis, 12 patients 
(31%) were aged ≥65 years.
Table 1. Patient characteristics by age group and decision type
  Total 40-64 y ≥65 y
Variables n % n % n %
Surgerya (n=74) (n=49, 66%) (n=25, 34%)
Patient characteristics
Age (y) 60 (42-80) 55 (42-64) 70 (65-80)
Time from second surgical consultation to filling in the 
follow-up questionnaire (d) 60 (45-115)b 60 (46-105)b 61 (45-115)
Marital status
married/living together 50 68 33 67 17 68
single/divorced/widowed 24 32 16 33 8 32
Educational levelc
low 19 26 11 22 8 32
intermediate 34 46 20 41 14 56
high 21 28 18 37 3 12
Employment status
full/part-time 36 49 34 69 2 8
housekeeper 9 12 2 4 7 28
unemployed/long-term sick leave 7 10 7 14 0 0
retired 22 30 6 12 16 64
Having children
no children 16 22 10 20 6 24
yes, children not living at home 40 54 23 47 17 68
yes, children living at home 18 24 16 33 2 8
Number of comorbid conditions
0 25 34 21 43 4 16
1 16 22 9 18 7 28
2 or more 33 45 19 39 14 56
Type of comorbid conditions











































































endocrine diseases (ICD10-4; yes) 18 24 10 20 8 32
musculoskeletal diseases (ICD10-13; yes) 15 20 8 16 7 28
other diseases (yes)d 30 41 19 39 11 44
Geriatric health conditione
no  49 66 36 73 13 52
yes 25 34 13 27 12 48
Specific geriatric health conditionf
incontinence (yes) 3 12 1 8 2 17
severe sensory impairment (yes) 10 40 2 15 8 67
depression (yes) 4 16 3 23 1 8
polypharmacy (yes) 17 68 11 85 6 50
difficulties with walking (yes) 6 24 2 15 4 33
Preoperative tumor morphology
DCIS 11 15 7 14 4 16
invasive 63 85 42 86 21 84
Type of surgery performed
BCS 53 72 38 78 15 60
MAST 21 28 11 22 10 40
Adjuvant chemotherapya (n=43) (n=32, 74%) (n=11, 26%)
Patient characteristics
Age (y) 60 (42-76) 55 (42-63) 70 (65-76)
Time from medical oncologist consultation to filling in 
the follow-up questionnaire (d) 29 (9-89)g 30 (9-58)g 24 (18-89)
Received chemotherapy
no 19 44 11 34 8 73
yes 24 56 21 66 3 27
Had initiated therapy at time of filling in the follow-up  
questionnaire
no 12 50 10 48 2 67
yes 12 50 11 52 1 33
Adjuvant hormonal therapya (n=39) (n=27, 69%) (n=12, 31%)
Patient characteristics
Age (y) 60 (42-86) 55 (42-63) 73 (65-86)
Time from medical oncologist consultation to filling in 
the follow-up questionnaire (d) 31 (8-58)g 31 (9-58)g 28 (8-53)
Received hormonal therapy
no 4 10 2 7 2 17
yes 35 90 25 93 10 83
Had initiated therapy at time of filling in the follow-up  
questionnaire
no 18 51 18 72 0 0
yes 17 49 7 28 10 100
Data are presented as n (n%) or median (ranges)
DCIS= Ductal carcinoma in situ; BCS= Breast-conserving surgery; MAST= Mastectomy; ICD= International Classification of Disease; y = years; d=days
a Three patient groups because of three different inclusion criteria
b Two participants did not fill in date of completion
c Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary education/vocational 
training; or high=completed pre-university education/high vocational training/university
d Other comorbid diseases included respiratory diseases (ICD10-10), neurologic diseases (ICD10-6), psychiatric diseases (ICD10-5), digestive diseases 
(ICD10-11), genitourinary diseases (ICD10-14) and blood diseases (ICD10-3)
e Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily activities, 
incontinence, severe sensory impairment, depression, polypharmacy; difficulty walking
f No participant had difficulties carrying out daily activities
g One participant did not fill in date of completion
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Preferred and perceived roles in decision-making
Type of surgery
Differences in both preferred and perceived roles between the age groups were found, but 
the differences were not significant (p=0.62 and p=0.94, respectively). Both younger and 
older participants most often preferred a shared role (49% and 60%, respectively) before 
consultation (Table 2A). Fewer members of both groups wished an active role (35% and 32%, 
respectively), and only 16% of younger and 8% of older participants preferred a passive role. 
After consultation, both younger and older participants most frequently reported to have 
perceived they had had an active role (49% and 56%, respectively), followed by shared (37% 
and 32%) and passive (14% and 12%) roles. Comparison of preferred and perceived roles showed 
that 32% of the younger and 36% of the older participants had participated to their preferred 
extent, 43% of the younger and 40% of the older participants had played a greater role in the 
decision than initially preferred, and 25% of the younger and 24% of the older participants had 
been less involved than preferred. The differences in concordance between the groups did 
not significantly differ (p=0.77). 
Adjuvant chemotherapy
Again, both preferred and perceived roles varied between the age groups, but the differences 
were not significant (p=0.41 and p=0.82, respectively). Younger and older participants most 
frequently indicated a preference for a shared role (47% and 73%, respectively), followed 
by a preference for an active (34% and 18%) or a passive (19% and 9%) role (Table 2B). After 
consultation, younger participants more often perceived to have had an active role than older 
participants (41% versus 36%), and older participants more often indicated to have perceived 
a passive role (36% versus 25%). In 50% of the younger and 54% of the older participants, 
their perceived role matched their preferred role (p=0.80). The remainder of the younger 
participants were most often more involved than initially desired (28%), whereas older 
participants were most often less involved (27%). 
Adjuvant hormonal therapy
As earlier, differences in preferred and perceived roles between the age groups were not 
significant (p=0.43 and p=0.52, respectively). Younger participants often preferred an active 
role (44%), whereas older participants more often had a preference for a shared role (58%) 
(Table 2C). Younger participants most often perceived to have had an active role (44%) and 
older participants most often a passive role (42%). Fifty percent of the older participants had 
their preferred role match their perceived role, compared to 37% of the younger participants, 
but this difference was not significant (p=0.45). Also in this decision, younger participants 
were most often more involved than initially desired (33%) and older participants most often 











































































Table 2. Preferred (pre-consultation) and perceived (post-consultation) roles and concordance between the roles by 
decision type
A. Type of surgery (breast-conserving surgery vs. mastectomy)
  40-64 y (n=49) ≥65 y (n=25)
  Perceived role Perceived role
 Preferred role active shared passive total active shared passive total
active 8 (16) 5 (10) 4 (8) 17 (35) 5 (20) 3 (12) 0 (0) 8 (32)
shared 13 (27) 8 (16) 3 (6) 24 (49) 8 (32) 4 (16) 3 (12) 15 (60)
passive 3 (6) 5 (10) 0 (0) 8 (16) 1 (4) 1 (4) 0 (0) 2 (8)
total 24 (49) 18 (37) 7 (14) 49 (100) 14 (56) 8 (32) 3 (12) 25 (100)
B. Adjuvant chemotherapy (yes/no)
 
 
40-64 y (n=32) ≥65 y (n=11)
Perceived role Perceived role
 Preferred role active shared passive total active shared passive total 
active 6 (19) 2 (6) 3 (9) 11 (34) 2 (18) 0 (0) 0 (0) 2 (18)
shared 6 (19) 7 (22) 2 (6) 15 (47) 2 (18) 3 (27) 3 (27) 8 (73)
passive 1 (3) 2 (6) 3 (9) 6 (19) 0 (0) 0 (0) 1 (9) 1 (9)
total 13 (41) 11 (34) 8 (25) 32 (100) 4 (36) 3 (27) 4 (36) 11 (100)
C. Adjuvant hormonal therapy (yes/no)
 
 
40-64 y (n=27) ≥65 y (n=12)
Perceived role Perceived role
 Preferred role active shared passive total active shared passive total
active 5 (19) 2 (7) 5 (19) 12 (44) 2 (17) 1 (8) 0 (0) 3 (25)
shared 6 (22) 3 (11) 1 (4) 10 (37) 0 (0) 3 (25) 4 (33) 7 (58)
passive 1 (4) 2 (7) 2 (7) 5 (19) 1 (8) 0 (0) 1 (8) 2 (17)
total 12 (44) 7 (26) 8 (30) 27 (100) 3 (25) 4 (33) 5 (42) 12 (100)
Data are presented as n (%)
Numbers and proportions in bold add up to numbers and proportions of concordance between preferred and perceived role; Numbers and proportions 
below the diagonal bold line add up to  numbers and proportion of participants who experienced a greater role than initially preferred; Numbers and 
proportions above the diagonal bold line add up to numbers and proportions of participants who experienced a lesser role than initially preferred
DISCUSSION
In this prospective study of patients with early BC, we compared the preferred and perceived 
roles of younger and older patients in decisions about type of surgery, aCT and aHT, as well as 
the concordance between their preferred versus perceived decision-making roles. 
Our findings challenge the belief that older patients often prefer to leave treatment decisions 
to their clinician. Only few older patients wished a passive role, and most preferred to make 
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the decision themselves or together with their oncologist, in line with another recent study39 
showing that most older patients preferred a shared or active role over a passive role. In our 
study, about three in five older patients preferred to make the decision together with their 
clinician. Our finding that both younger and older patients most often preferred to be involved 
in making the decision about type of surgery is in line with one of the few other prospective 
studies among newly-diagnosed patients with early-stage disease eligible for BCS and MAST.25 
In contrast, a retrospective study found that preferring a passive role was related to being 
older.40 Patients’ experiences of the decision-making process may possibly have influenced 
their reported preferences in the latter study. Our results suggest that patients of all ages 
prefer to be involved in decision-making and thus that one should not automatically assume 
that older patients wish to defer the decision to the clinician. This is particularly important 
because clinicians often underestimate patients’ decisional role preferences41 and rarely ask 
patients for their preferences.42
Although decisional role preferences did not significantly differ between age groups, 
preferred roles in deciding whether to undergo aHT stand out, with relatively more younger 
than older patients preferring to make the decision themselves. Premenopausal patients may 
perceive aHT as having a greater impact on their daily lives than older patients, given that aHT 
can cause menopausal symptoms. We found in our previous study13 that both age groups, 
but more so in younger patients, frequently reported that concern about the short- and long-
term side-effects was an important factor in their preferences for aHT (of 74 patients in our 
previous study, 35 participated in the present study). 
We also found that older patients’ perceived roles varied from those of younger patients and 
varied across the different decisions. Because BCS and MAST are equivalent options in terms 
of survival, and are presented as such in national guidelines,34 we may expect that clinicians 
offer patients a choice between these two surgical options. It is, not surprising then, that 
both older and younger patients frequently perceived to have had an active role in making 
the decision. In contrast, older patients more often than younger patients felt that they had 
not been involved in making the decision concerning aCT. The treatment guidelines indeed 
state that aCT may not be a reasonable treatment option for patients over 70 years of age.34 
Similarly, older patients more often perceived to have had a passive role in deciding about 
aHT. In clinical practice, patients with HR-positive tumours, irrespective of their age, are rarely 
offered a choice about aHT.43 Younger patients may ask more questions after being informed 
about aHT, which could result in more communication about treatment characteristics. As a 
result, younger patients may have felt more involved in decision-making,44 thereby explaining 












































































For each decision, we found an overall difference between patients’ preferred versus 
perceived decisional roles in 40% of the younger patients and 47% of the older patients. For 
both age groups, the largest difference was observed with respect to the decision about 
surgery. Differences in these gaps between the age groups were minimal, except for the 
decision about aHT. Discordance can negatively impact patients’ treatment outcomes and 
experiences of care45,46 and it is therefore important that future studies examine how the 
occurrence of discordant roles can be minimized. 
To our knowledge, our study is the first to prospectively explore patients’ preferences 
regarding decisional roles for three common breast cancer treatment decisions with a 
specific focus on age-differences. A strength is that data were prospectively collected from 
patients. A potential limitation is that the decisional role preferences were regarded as if 
these remained stable; however, a patient’s preference can change during or between 
consultations (e.g., a more active decisional role preference after receiving information 
about treatment options than before the consultation47). Also, recall bias could have affected 
participants’ perception of their role during the consultation. Another limitation is the small 
number of older participants. We did not find significant differences between the age groups, 
as the sample size may not have been large enough to detect these. We believe it to be 
worthwhile to examine whether our findings also hold with a larger sample of older patients. 
Regardless of this limitation, this study provides valuable insights into the decision-making 
roles of this growing patient group.
It is important for clinicians to know that most older patients are willing to be involved 
in decision-making. However, we also want to stress the variation in role preferences 
among older patients and across the different decisions. As clinicians set the agenda for 
the consultation, it is reasonable to expect that the responsibility for inviting patients to 
participate in decision-making lies with clinicians. They should explicitly inform patients 
that a decision needs to be made and explain why patient involvement is relevant.2,48 Older 
patients who feel they are not (yet) ready or able to engage in deliberation about different 
treatment options should be offered more time and support (e.g., an appointment with a 
nurse specialist, patient decision aids49,50 or other support tools if available). This approach 
could improve their participation in decision-making. In the end, of course, at the patient’s 
wish, the clinician can make the final decision, as long as he/she has elicited the patient’s 
concerns and goals.2 In addition, health care as a whole should empower older patients to 
become more involved in the decision-making process. The use of interventions that guide 
older patients through topics that are important to ask can help them better prepare for 
the consultation and may give them encouragement to be involved,51 such as campaigns like 




Older patients, like younger patients, often favoured participation in decision-making about 
treatments for early BC. Also, both age groups mostly perceived more involvement than they 
preferred in the decision about surgery. Some older patients perceived less involvement 
than they preferred in aCT and aHT decision-making, and these patients may therefore need 
more encouragement to participate. Our results underscore the need for clinicians to invite 
all patients to participate in decision-making for each decision, and to retrieve to what extent 
patients want to be involved in making the final decision.
CLINICAL PRACTICE POINTS
•	 Older patients are believed to prefer a more passive role in treatment decision-making 
than younger patients. However, studies showing this relation were conducted over 
a decade ago, or were retrospective. In this era of increased attention to shared 
decision-making, it is conceivable that older patients have different decisional role 
preferences than older patients from previous generations. 
•	 This prospective study found that older patients, like younger patients, often favoured 
to participate in decision-making. However, older patients more often than younger 
patients perceived they had not been involved in decisions about systemic therapy.
•	 Clinicians need to know that most older patients are willing to be involved in making 
treatment decisions, although role preferences varied within older – as in younger – 
patients and across decisions. It is therefore important that clinicians invite all patients 
to participate in decision-making, regardless of their age. Aside from the clinician’s 
role, it is also important to stimulate older patients themselves to become more 
involved in decisions about their treatment, for example by directing patients to key 
questions to help them prepare better for the consultation.
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Purpose | As older women with breast cancer (BC) are underrepresented in trials, it is often 
unclear what represents the best treatment option for this patient group. To understand how 
oncologists approach the management of BC in older patients, we assessed their treatment 
recommendations. 
Methods | In an online survey, 106 surgical, 37 radiation and 31 medical oncologists provided 
a treatment recommendation for hypothetical patients aged >70 years. Scenarios included 
loco-regional therapy with patient age varying at 76 and 84 years; systemic therapy with 
Karnofsky performance score varying at 90% and 50%; neo-adjuvant therapy; and adjuvant 
chemotherapy in triple-negative BC. 
Results | Participants would less often recommend breast-conserving surgery plus 
radiotherapy for an 84 versus a 76-year-old patient (56% versus 73%, p=0.001). They would 
more often accept omission of radiotherapy after breast-conserving surgery in older than 
in younger patients, if the patient wished to avoid this therapy (26% versus 4%, p<0.001). All 
participants would propose systemic therapy for a high-recurrence risk patient with a good 
performance score, and 92% would still recommend therapy if the patient had a poor score 
(p<0.001). Neo-adjuvant hormonal therapy followed by breast-conserving surgery for a 
large tumour was recommended by 27% of the participants. Adjuvant chemotherapy for an 
otherwise healthy woman with triple-negative BC was considered by 83% of the participants. 
Conclusion | Patient age and performance status influenced specialists’ treatment 
recommendations. The observed recommendations for the treatment scenarios under 
investigation differ from older women’s actual treatment. This discrepancy highlights the 














































































With over 14,000 new cases in 2013, breast cancer (BC) is the most common malignancy 
among women in the Netherlands.1 Approximately 30% of the cases are in women over 70 
years of age.1 Although BC in older women is a common health problem, optimal treatment of 
this patient group remains unclear, since older patients are often excluded from clinical trials.2 
Besides, those enrolled in trials are usually in better than average health, and therefore may 
not be representative for all older BC patients.3 Elderly patients comprise a heterogeneous 
group due to differences in comorbid conditions, functional capacity, and social support.4 
The large variety in characteristics within this population, together with the lack of evidence 
on treatment approach and the limited data on older patients’ preferences5 make treatment 
decision-making for these patients generally difficult. 
The Dutch treatment guidelines for BC make little or no age-specific recommendations.6 This 
provides room for variation in the treatment of older patients. Studies have demonstrated 
that older patients are less likely than younger patients to undergo breast-conserving surgery 
and radiotherapy after breast-conserving surgery. They also less often receive adjuvant 
chemotherapy compared to younger patients with similar disease severity.7,8 The reasons 
for these age-differences in treatment are unclear and could result from either patients’ or 
clinicians’ preferences. It has been shown that individual patient’s treatment preferences 
vary greatly,5 whilst others have suggested that clinicians play a notable role in treatment 
decision-making, particularly among older patients.9,10 
Currently, it is unknown how clinicians weigh treatment options for patients aged ≥70 years. 
Previous surveys using hypothetical scenarios explored how patient age or health status 
influenced clinicians’ treatment recommendations,11-19 but most only focused on adjuvant 
systemic therapy.11-15,18 Furthermore, their recommendations were seldom compared for 
scenarios only involving patients aged over 70.12-15,19 Of these latter studies, none compared 
the recommendations of oncologists of different specialties, despite multidisciplinary team 
decision-making becoming the norm in BC. Surgical, radiation and medical oncologists are 
ought to decide together what could be the best treatment for the patient. With the increasing 
incidence of BC in older women,2 a better understanding of clinicians’ recommendations and 
influencing factors become increasingly relevant.
This study aimed to examine the treatment recommendations of BC specialists for loco-
regional and (neo-)adjuvant systemic therapy in older patients, and to explore whether the 






Eligible participants were surgical, radiation, and medical oncologists (including doctors 
in training) involved in BC treatment. Between October 2013-February 2014, members of 
the Dutch Society of Surgical Oncology (n=~550), the Dutch Society of Radiotherapy and 
Oncology (n=525) and the Dutch Society of Medical Oncology (n=418) received an emailed 
newsletter of their society which contained an invitation to participate. As it was not possible 
to select BC specialists only, the emailed newsletter was sent to all members, irrespective of 
their cancer type specialism. The invitation was addressed to BC specialists only, and briefly 
described the study and provided a link to the anonymous online questionnaire. Four weeks 
after, all members were once again informed via a newsletter. Between July-November 2014, 
collaborating partners (Comprehensive Cancer Centre Leiden Region, the Netherlands, and 
three medical oncologists) forwarded our invitation directly to medical oncologists within 
their network to increase their response. Consequently, 37 oncologists of the regional medical 
oncology working party, and a random sample of 40 medical oncologists were approached. 
As this study did not involve patients, no ethical approval was required for this study. 
Questionnaire
The two-part questionnaire consisted of participants’ socio-demographic and work-related 
characteristics and of hypothetical scenarios, which resembled situations for which there 
is currently little or no consensus about the best treatment for patients aged ≥70 years 
(Appendix 1). The scenarios were based on the Dutch treatment guidelines for BC6 and 
previous work.2,8  We pilot-tested the scenarios for clarity among seven health professionals 
and five BC researchers. Minor modifications to the phrasing of the questions and lay-out of 
the questionnaire were made. We used NetQ software to create the questionnaire.
Participants were presented the scenarios and asked to choose a treatment recommendation 
from a list of options. Each scenario included a description of patient (e.g., age and Karnofsky 
Performance Status [KPS]) and clinical characteristics (e.g., hormone receptor status) that 
would usually be available at decision-making. Scenario 1 explored whether a patient’s 
chronological age influenced the recommendation for loco-regional therapy. Two identical 
sub-scenarios (1A and 1B) were developed, except the age of the patient differed (76 versus 
84 years). Scenario 2 examined whether a patient’s performance status influenced the 
recommendation for adjuvant systemic therapy, by decreasing the KPS score from 90% (2A) 
to 50% (2B), keeping all other characteristics identical. Scenario 3 focused on neo-adjuvant 
hormonal therapy. The guidelines state that this therapy should only be prescribed to old and 
frail patients who are unsuitable for neo-adjuvant chemotherapy or surgery.6 In recent years, 













































































conserving surgery in patients who would otherwise undergo a mastectomy. This therapy 
could be appropriate for older patients, as most have hormone receptor-positive BC.2 Scenario 
4 concerned adjuvant chemotherapy for hormone receptor-negative and HER2-negative BC. 
Triple-negative BC in older patients is particularly challenging, because chemotherapy is the 
only systemic option, but most (e.g., who are unfit) are ineligible for this therapy.2
Analyses
Participants were included in the analyses if the first question of the scenarios was completed. 
Regarding scenarios 1 and 2, we excluded participants who did not complete questions about 
both sub-scenarios (1A and 1B, or 2A and 2B). Free-text responses (i.e., ‘other, namely:’) 
were independently reviewed by three investigators and were recoded appropriately if it 
corresponded to an already available answering option; otherwise they were considered 
as ‘other’ and excluded from further analyses. Descriptive statistics were used to describe 
participants’ characteristics, and responses to the scenarios. Differences in the proportions 
of the recommendations between sub-scenarios, and between speciality groups (in scenarios 
3 and 4) were assessed using χ² or Fisher Exact test. A p-value below 0.05 was considered 
statistically significant. Analyses were conducted using SPSS version 22. 
RESULTS 
Participants 
Overall, 243 oncologists opened the link to the questionnaire and 190 eligible participants 
began the survey. Of them, 16 dropped out after the socio-demographic questions. In 
total, 164/174 participants completed all questions. Socio-demographic and work-related 
characteristics did not significantly differ between participants who had fully/partly completed 
the questions (data not shown). The median age of the participants was 47 years (range, 
27-68), and most were male (55%, Table 1). The participants comprised of 106 (61%) surgical, 
37 (21%) radiation, and 31 (18%) medical oncologists. Nearly half (49%) practiced in general 
teaching hospitals, and 58% had been specialized in BC treatment for more than ten years. All, 
except one, reported to see at least one newly-diagnosed woman aged ≥70 years per month. 
Hypothetical scenarios
Overall, 167 (96%) participants responded to scenarios 1A and 1B, and 164 (94%) to all scenarios 
(1A, 1B, 2A, 2B, 3, and 4). 
Influence of age on recommendation for loco-regional therapy (scenario 1) 
The scenario portrayed a woman, aged either 76 (1A) or 84 (1B) years, who was otherwise in 
good health, and had a clinically small, node-negative, hormone receptor-positive tumour. 
She was eligible for both surgical options. 
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(n=174) (n=106, 61%) (n=37, 21%) (n=31, 18%)
 Variables n (%) n (%) n (%) n (%)
Median age in years (range) 47 (27-68) 46 (32-64) 48 (27-64) 48 (30-68)
Gender
male 95 (55) 65 (61) 17 (46) 13 (42)
female 79 (45) 41 (39) 20 (54) 18 (58)
Practice setting
general non-teaching hospital 42 (24) 37 (35) 0 (0) 5 (16)
general teaching hospital 86 (49) 55 (52) 8 (22) 23 (74)
university medical center/specialized oncology center 46 (26) 14 (13) 29 (78) 3 (10)
Regiona
North (i.e. Groningen, Friesland, Drenthe) 19 (11) 12 (11) 4 (11) 3 (10)
East (i.e. Gelderland, Overijssel, Flevoland) 30 (17) 18 (17) 7 (19) 5 (16)
West (i.e. Noord-Holland, Zuid-Holland, Utrecht) 83 (48) 52 (49) 18 (49) 13 (42)
South (i.e. Zeeland, Brabant, Limburg) 39 (22) 22 (21) 7 (19) 10 (32)
I prefer not to disclose this 3 (2) 2 (2) 1 (3) 0 (0)
No. of years of experience treating breast cancer patients
<2 years 6 (3) 2 (2) 3 (8) 1 (3)
2-5 years 32 (18) 22 (21) 2 (5) 8 (26)
6-10 years 36 (21) 24 (23) 9 (24) 3 (10)
>10 years 100 (58) 58 (55) 23 (62) 19 (61)
No. of new breast cancer patients seen per month 
1-2 patients 5 (3) 2 (2) 1 (3) 2 (6)
3-5 patients 43 (25) 21 (20) 10 (27) 12 (39)
6-10 patients 69 (40) 44 (42) 11 (30) 14 (45)
11-15 patients 32 (18) 18 (17) 11 (30) 3 (10)
>15 patients 25 (14) 21 (20) 4 (11) 0 (0)
No. of new breast cancer patients aged ≥70 years seen per month
none 1 (1) 0 (0) 0 (0) 1 (3)
1-2 patients 64 (37) 31 (29) 15 (41) 18 (58)
3-5 patients 82 (47) 54 (51) 18 (49) 10 (32)
6-10 patients 23 (13) 17 (16) 4 (11) 2 (7)
11-15 patients 3 (2) 3 (3) 0 (0) 0 (0)
>15 patients 1 (1) 1 (1) 0 (0) 0 (0)















































































Participants’ treatment recommendation regarding surgical resection differed significantly 
by patient age (p=0.001, Table 2; Question 1). For a 76-year-old patient, 73% of the participants 
reported to recommend breast-conserving surgery plus radiotherapy. If this patient 
was 84-years-old, only 56% would give this recommendation. Conversely, the proportion 
recommending a mastectomy (7% vs 1%), or leaving the choice to the patient (37% vs 26%) was 
greater if this patient was 84-years-old. 
Consistent with the overall results, the influence of patient age was observed among surgical 
oncologists (p=0.003), and to a lesser extent among medical oncologists (p=0.07). The 
recommendations of radiation oncologists did not differ by age (p=0.81). 
Radiotherapy omission after breast-conserving surgery:
Next, participants were asked whether they would accept the omission of radiotherapy if 
the patient indicated to prefer a breast-conserving surgery but wished to avoid radiotherapy. 
Responses varied significantly by patient age (p<0.001, Table 2; Question 2). If the patient was 
84-years-old, 26% would accept this without question. Only 4% would accept this if the same 
patient was 76. On the contrary, the proportion who would accept it, but would still try to 
convince the patient of the benefit of radiotherapy was greater if she was 76-years-old rather 
than 84-years-old (62% vs 57%). The proportion simply not accepting radiotherapy omission 
(16% vs 13%), or recommending a mastectomy with breast reconstruction instead (19% vs 4%) 
was greater for the younger patient. 
The recommendations of surgical (p<0.001) and medical oncologists (p=0.004) differed 
significantly by age, those of radiation oncologists did not (p=0.26). 
Influence of performance status on recommendation regarding adjuvant systemic therapy 
(scenario 2)
This scenario described a 77-year-old woman who underwent a mastectomy, and whose 
pathology results revealed positive lymph nodes, and a T2, high grade, hormone receptor-
positive tumour. Participants significantly differed in their recommendation for a woman 
with a good (KPS 90%; 2A) versus a poor (KPS 50%; 2B) performance status (p<0.001, Table 
3). If the patient had a good performance score, all participants would advise some form of 
systemic therapy: 86% would recommend hormonal therapy alone and 14% a combination of 
chemotherapy and hormonal therapy. If the same patient had a poor performance score, 92% 
would advise adjuvant systemic therapy, with all of them recommending hormonal therapy 
alone. 
Both surgical (p<0.001) and radiation oncologists’ (p=0.020) treatment recommendation 
significantly varied based on performance status. Similar differences in the recommendation 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Neo-adjuvant hormonal therapy (scenario 3)
For an otherwise healthy 75-year-old woman who was not initially a candidate for breast-
conserving surgery because of a large hormone receptor-positive tumour in relation 
to her breast size, 27% would recommend neo-adjuvant hormonal therapy followed by 
breast-conserving surgery (Table 4). Fifty percent of the participants would recommend a 
mastectomy, and the remaining 23% would not give a treatment recommendation, but would 
leave the choice to the patient. No relevant differences in the recommendation between the 
specialities were observed (p=0.12). 
Adjuvant chemotherapy for triple-negative BC (scenario 4)
The scenario described a 75-year-old woman, in otherwise good health, who underwent a 
mastectomy and was diagnosed with a T2, high grade, node-positive, triple-negative BC. Most 
(83%) would consider adjuvant chemotherapy, of which 56% (72/129) would only consider it if 
the patient indicated to have a strong preference to be treated with chemotherapy (Table 5). 
There were no significant differences among the specialities (p=0.30). 
Table 4. Specialists’ treatment recommendation for neo-adjuvant hormonal therapy (scenario 3)
A 75-year-old female, KPS score of 90% (able to carry on normal activity; minor signs or symptoms of disease), right-sided breast 
cancer, one lesion of 3.5 cm in the upper outer quadrant, cup size 36A, invasive ductal adenocarcinoma, cT2, cN0, ER+, PR+, 
Her2neu−, no comorbidities
What would be your treatment recommendation?
 
I would not give any 




therapy, followed by 
breast-conserving surgery
 
  n (%) n (%) n (%) p 
Total (n=164)a 36 (23) 80 (50) 43 (27) -
Surgical oncologists (n=101)b 21 (21) 51 (52) 26 (27) 0.12
Radiation oncologists (n=34)c 12 (37) 14 (44) 6 (19)  
Medical oncologists (n=29) 3 (10) 15 (52) 11 (38)  
KPS = Karnofsky Performance Status
a Five participants who filled in ‘other’ were excluded from the analyses
b Three participants who filled in ‘other’ were excluded from the analyses













































































Table 5. Specialists’ treatment recommendation for adjuvant chemotherapy in case of triple-negative BC (scenario 4)
A 75-year-old female, KPS score of 90% (able to carry on normal activity; minor signs or symptoms of disease), right-sided breast 
cancer, one lesion of 3.0 cm in the upper outer quadrant, invasive ductal adenocarcinoma, a modified radical mastectomy was 
performed, pT2, pN1, grade 3, ER−, PR−, Her2neu−, no comorbidities
Would you consider adjuvant chemotherapy?
 
No, I would not consider 
adjuvant chemotherapy Yes
Yes, but only if the patient 
has a strong preference for 
chemotherapy treatment  
  n (%) n (%)  n (%) p
Total (n=164)a 27 (17) 57 (37) 72 (46) -
Surgical oncologists (n=101)b 13 (14) 39 (41) 43 (45) 0.30
Radiation oncologists (n=34)c 8 (25) 7 (22) 17 (53)  
Medical oncologists (n=29) 6 (21) 11 (38) 12 (41)  
KPS = Karnofsky performance status
a Eight participants who filled in ‘other’ were excluded from the analyses
b Six participants who filled in ‘other’ were excluded from the analyses
c Two participants who filled in ‘other’ were excluded from the analyses
DISCUSSION
This study explored the treatment recommendations of different BC specialists for 
hypothetical patients aged >70 years. We found that patients’ chronological age influenced 
specialists’ recommendations for loco-regional therapy. This is in line with other comparable 
work. Warner et al.19 also found that radiation oncologists would be more comfortable with 
the option of omitting radiotherapy after breast-conserving surgery if a patient who chose 
to not undergo radiotherapy was 80-years-old rather than 70-years-old. Further, we found 
that patients’ performance status influenced participants’ recommendations for adjuvant 
systemic therapy: participants proposed hormonal therapy with or without chemotherapy 
for an older patient at high recurrence risk with a good performance score, and hormonal 
therapy without chemotherapy if she had a poor score. Previous studies among medical 
oncologists also reported that participants were less likely to recommend systemic therapy 
for hypothetical older women in poor health with node-positive, hormone receptor-positive 
tumours, compared to those in good health.12,13,15
Interestingly, a large proportion of the specialists would accept radiotherapy omission after 
breast-conserving surgery. Data from trials in older patients with small, node-negative, 
hormone receptor-positive tumours, who underwent breast-conserving surgery and were 
receiving hormonal therapy showed that the addition of radiotherapy had a small absolute 
benefit in terms of loco-regional control, but no impact on distant disease-free or overall 
survival.20,21 Since the absolute recurrence risk was low, these results suggested that 
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radiotherapy omission can be considered for selected groups of older, hormone receptor-
positive patients. Consistent with the evidence, a majority stated they would be willing to omit 
radiotherapy (66% for the 76-year-old and 83% for the 84-year-old woman, Table 2), despite 
the guidelines which recommend radiotherapy after breast-conserving surgery regardless of 
patient age.6 However, participants’ recommendations do not correspond with the low rates 
of radiotherapy omission in older patients, as observed in population-based data from the 
Netherlands Cancer Registry. In 2013, only 9% of the patients aged ≥70 years who underwent 
breast-conserving surgery for small (T1-2), node-negative, hormone receptor-positive tumours, 
were not treated with adjuvant radiotherapy.22 An explanation for this discrepancy is that, in 
practice, clinicians may find it difficult to omit treatments that are considered standard of 
care because of fear that the patient may develop a recurrence.23 As radiotherapy is generally 
well-tolerated by most older women,24 the threshold is low to recommend this treatment. 
Further, the introduction of equally effective and more convenient alternatives of standard 
radiotherapy, including hypofractionated and intraoperative radiotherapy, may explain why 
clinicians prefer to opt for radiotherapy rather than to omit the therapy for older patients 
with low-risk recurrence.23 
Differences were also observed between specialists’ recommendations for use of adjuvant 
chemotherapy (followed by hormonal therapy) in node-positive, high grade, hormone 
receptor-positive tumours (14% versus 5%22), and use of neo-adjuvant hormonal therapy for 
a clinically large hormone receptor-positive tumour (27% versus 6%22) and actual treatment 
of older patients. The proportion of participants recommending adjuvant chemotherapy 
and neo-adjuvant hormonal therapy was higher than anticipated, since the guidelines advise 
to consider this recommendation and do not mention this recommendation, respectively.6 
Another difference was found between the recommendation of use of adjuvant chemotherapy 
for triple-negative BC and actual practice (83% versus 27%22). The proportion considering 
adjuvant chemotherapy in this scenario is in accordance to the guidelines.6 
The currently available evidence might explain the differences between specialists’ 
recommendations and actual practice. In case of the radiotherapy scenario, there has been 
growing evidence since 2004 that the benefits of radiotherapy are limited in selected groups 
of older patients. Most participants seemed to be aware of this evidence, but seem to be 
reluctant to omit radiotherapy in clinical practice as this is not in line with the guidelines. In 
case of the other scenarios, the specialists we questioned might either not be convinced by 
currently available evidence, or feel that the evidence is insufficient or inadequate to determine 
which treatment options are appropriate. Another explanation to the differences is social 
desirability bias. The participants may have had a tendency to report a recommendation that 













































































Our findings raise the question whether adherence to the current treatment guideline is 
desirable concerning the treatment of older patients. Studies on adherence to BC guidelines in 
older patients demonstrated that large variation in loco-regional and systemic treatments did 
not result in differences in survival.25,26 The large heterogeneity of this patient group in terms 
of functional capacity, comorbid conditions, and social support implies that a one-size-fits-all 
approach may not be justified, but that emphasis needs to be placed on an individualized 
treatment approach, taking into account the older patient’s individual characteristics, 
including the patient’s treatment preference. 
A difference between the three specialities emerged when we analysed the influence of age 
on the recommendations regarding loco-regional therapy. Contrary to the other specialities, 
the recommendations of radiation oncologists were similar irrespective of patient age. They 
would more often offer a choice of surgery type to both the 76 and 84-year-old woman than 
surgical and medical oncologists, and if they did consider a treatment recommendation, all 
proposed breast-conserving surgery plus radiotherapy. Also, although they were somewhat 
more willing to accept without question the omission of radiotherapy for the older patient, 
they still had a greater tendency than the other specialities to convince a patient to undergo 
radiotherapy. These differences in recommendations are in line with previous work27 that 
show that specialists tend to favour the treatments they themselves provide. 
Strengths of this study include the comparison of the three main specialities involved in 
BC treatment, and an insight into their perspectives of multiple treatment modalities. Its 
innovative aspect is the exploration of other current challenges in the treatment of older 
patients, namely neo-adjuvant hormonal therapy and triple-negative BC. A limitation is 
the lower response of radiation and medical oncologists as compared to that of surgical 
oncologists. Unfortunately, we had no information about the total number of potentially 
eligible participants for this study and their characteristics. Therefore, we were unable to 
calculate an overall response rate and analyse to what extent our sample is representative 
for the general population of oncologists specialized in BC. Another limitation, as previously 
mentioned, is that participants’ responses may have been influenced by social desirability 
bias. 
Our results have important implications for future research. The difference between the 
reported recommendations and actual treatment of older women leads us to believe 
that more studies among older patients are needed to better define which subgroups are 
appropriate to receive further treatment. Although the need to improve the evidence on 
the treatment for older patients has often been addressed, a review demonstrated that only 
2% of all currently running trials on BC treatment specifically target older patients (i.e., aged 
≥60 years).28 Additionally, trials in older patients do not often incorporate patient-related 
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endpoints (e.g., preservation of functional capacity). This implies that current trials will result 
in little improvement in our knowledge regarding the treatment of older patients. More 
randomized and prospective observational studies (as an alternative to trials provided that 
methodology is adequate) examining relevant end points in the older patient population may 
trigger a change in or help fine-tune treatment guidelines, and aid clinicians in providing their 
older patients an evidence-based treatment recommendation.
In conclusion, this study showed that patient chronological age and performance status are 
factors that influence clinicians’ recommendations regarding loco-regional and adjuvant 
systemic therapy in older patients. Differences in recommendations between the three 
specialities were minimal, except for the influence of patient age on the recommendation 
for loco-regional therapy. The observed treatment recommendations for the scenarios under 
investigation do not match the actual treatment of older patients. This discrepancy could 
imply that specialists need more outcome data on the elderly, before they feel comfortable 
making recommendations in practice. Our results imply the need for trials and observational 
studies targeted at older patients to better inform and support decision-making and to 
develop evidence-based treatment guidelines for this growing group.
Acknowledgements
We would like to thank all participating clinicians for their effort and time investment. We are 
also grateful to the Dutch Society of Surgical Oncology, the Dutch Society of Radiotherapy 
and Oncology, the Dutch Society of Medical Oncology, the Comprehensive Cancer Center the 
Netherlands (Leiden region), Dr. Portielje, Dr. Van Warmerdam, and Dr. Van den Berkmortel 
for their help in disseminating the questionnaire. We are also thankful for the Comprehensive 














































































1. Netherlands Cancer Registry. Cijfers over kanker 2013. Accessed on 1 March 2015. Available from: http://
www.cijfersoverkanker.nl/selecties/dataset_1/img557eaaafc082b 
2. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated 
recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of 
Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012;13(4):e148-e160.
3. Van de Water W, Kiderlen M, Bastiaannet E et al. External validity of a trial comprised of elderly patients 
with hormone receptor-positive breast cancer. J Natl Cancer Inst 2014;106(4):dju051.
4. Braithwaite D, Satariano WA, Sternfeld B et al. Long-term prognostic role of functional limitations 
among women with breast cancer. J Natl Cancer Inst 2010;102(19):1468-1477.
5. Hamelinck VC, Bastiaannet E, Pieterse AH et al. Patients’ preferences for surgical and adjuvant systemic 
treatment in early breast cancer: A systematic review. Cancer Treat Rev 2014;40(8):1005-1018.
6. Nationaal Borstkanker Overleg Nederland. Breast Cancer Guideline 2012. Accessed on 1 November 2014. 
Available from: http://www.oncoline.nl/uploaded/docs/mammacarcinoom/Dutch%20Breast%20Can-
cer%20Guideline%202012.pdf
7. Bastiaannet E, Liefers GJ, de Craen AJ et al. Breast cancer in elderly compared to younger patients in the 
Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res 
Treat 2010;124(3):801-807.
8. Van de Water W, Markopoulos C, van de Velde CJ et al. Association between age at diagnosis and 
disease-specific mortality among postmenopausal women with hormone receptor-positive breast 
cancer. JAMA 2012; 307(6): 590-597.
9. Puts MT, Tapscott B, Fitch M et al. A systematic review of factors influencing older adults’ decision to 
accept or decline cancer treatment. Cancer Treat Rev 2015;41(2):197-215.
10. Brom L, Hopmans W, Pasman HR et al. Congruence between patients’ preferred and perceived 
participation in medical decision-making: a review of the literature. BMC Med Inform Decis Mak 2014;14 
25.
11. Foster JA, Salinas GD, Mansell D et al. How does older age influence oncologists’ cancer management? 
Oncologist 2010;15(6):584-592.
12. Hurria A, Naeim A, Elkin E et al. Adjuvant treatment recommendations in older women with breast 
cancer: a survey of oncologists. Crit Rev Oncol Hematol 2007;61(3):255-260.
13. Hurria A, Wong FL, Villaluna D et al. Role of age and health in treatment recommendations for older 
adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 
2008;26(33):5386-5392.
14. Hurria A, Wong FL, Pal S et al. Perspectives and attitudes on the use of adjuvant chemotherapy 
and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists. Oncologist 
2009;14(9):883-890.
15. Naeim A, Wong FL, Pal SK et al. Oncologists’ recommendations for adjuvant therapy in hormone 
receptor-positive breast cancer patients of varying age and health status. Clin Breast Cancer 
2010;10(2):136-143.
16. Pang A, Ho S, Lee SC. Cancer physicians’ attitude towards treatment of the elderly cancer patient in a 
developed Asian country. BMC Geriatr 2013;13:35.
17. Protière C, Viens P, Rousseau F et al. Prescribers’ attitudes toward elderly breast cancer patients. 
Discrimination or empathy? Crit Rev Oncol Hematol 2010;75(2):138-150.
18. Ring A. The influences of age and co-morbidities on treatment decisions for patients with HER2-positive 
early breast cancer. Crit Rev Oncol Hematol 2010;76(2):127-132.
19. Warner E, Chow E, Fairchild A et al. Attitudes of Canadian radiation oncologists towards post-
lumpectomy radiotherapy for elderly women with stage I hormone-responsive breast cancer. Clin Oncol 
(R Coll Radiol) 2010;22(2):97-106.
20. Kunkler IH, Williams LJ, Jack WJ et al. Breast-conserving surgery with or without irradiation in women 
aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 
2015;16(3):266-273.
21. Van de Water W, Bastiaannet E, Scholten AN et al. Breast-conserving surgery with or without 
radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-
122
 6
analysis. Ann Surg Oncol 2014;21(3):786-794.
22. Comprehensive Cancer Center The Netherlands. Treatment of older women with breast cancer in 2013. 
Unpublished data, cited with permission. Received 9 July 2015.
23. Palta M, Palta P, Bhavsar NA et al. The use of adjuvant radiotherapy in elderly patients with early-stage 
breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
Cancer 2015;121(2):188-193.
24. Williams LJ, Kunkler IH, King CC et al. A randomised controlled trial of post-operative radiotherapy 
following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME 
trial. Health Technol Assess 2011;15(12):i-57.
25. Van de Water W, Bastiaannet E, Dekkers OM et al. Adherence to treatment guidelines and survival in 
patients with early-stage breast cancer by age at diagnosis. Br J Surg 2012;99(6):813-820.
26. Kiderlen M, Bastiaannet E, Walsh PM et al. Surgical treatment of early stage breast cancer in elderly: an 
international comparison. Breast Cancer Res Treat 2012; 132(2): 675-682.
27. Jagsi R, Abrahamse P, Morrow M et al. Coordination of breast cancer care between radiation 
oncologists and surgeons: a survey study. Int J Radiat Oncol Biol Phys 2012;82(5):2072-2078.
28. De Glas NA, Hamaker ME, Kiderlen M et al. Choosing relevant endpoints for older breast cancer patients 















































































Your answers will be analysed anonymously. For this study, it is important to have insight into the char-
acteristics of the participants. Therefore, we ask you to fill in the questions below. 
Fill in date:   …...... / …...... / …...... (day/month/year)
1. What is your specialism? (please choose one answer)
□ Surgical oncologist 
□ Medical oncologist 
□ Radiation oncologist 
□ Surgical oncologist in training 
□ Medical oncologist in training 
□ Radiation oncologist in training 
□ Other, namely: …………………………………………………………………………..
2. In which region do you practice? (please choose one answer)
□ Regio North (i.e. Groningen, Friesland, Drenthe) 
□ Regio East (i.e. Gelderland, Overijssel, Flevoland) 
□ Regio West (i.e. Noord-Holland, Zuid-Holland, Utrecht) 
□ Regio South (i.e. Zeeland, Brabant, Limburg) 
□ I prefer not to disclose this
3. In what type of hospital do you work? (please choose one answer)
□ General hospital (non-teaching) 
□ General hospital (teaching) 
□ University medical center, or specialized oncology center 
□ Other, namely: …………………………………………………………………………..
4. What is your gender? (please choose one answer)
□ Male 
□ Female 
5. What is your age?    ………… years old 
6. Do you have experience treating breast cancer patients? 
□ Yes  (Go to question 7)




7. How many years of experience do you have treating breast cancer patients? (please choose one 
answer)
□ < 2 years 
□ 2-5 years 
□ 6-10 years 
□ >10 years
8. Approximately how many new breast cancer patients do you see per month, where initially the treat-
ment intent is curative? (please choose one answer)
□ 0 
□ 1-2 patients 
□ 3-5 patients 
□ 6-10 patients 
□ 11-15 patients 
□ >15 patients
9. Approximately how many new breast cancer patients of 70 years of age or older do you see per 
month, where initially the treatment intent is curative? (please choose one answer)
□ 0 
□ 1-2 patients 
□ 3-5 patients 
□ 6-10 patients 
□ 11-15 patients 
□ >15 patients
On the following pages you will be presented with a clinical case scenario and asked to indicate 
your treatment recommendation. At the beginning of each case scenario the patient and tumour 
characteristics will be described. We kindly request you to carefully read each scenario and all 
possible responses, and then to answer the questions. We are interested in your treatment rec-













































































CASE SCENARIO 1 A – Type of surgery and adjuvant radiotherapy
Below you find the patient and tumour characteristics. Please read these carefully and then answer the 
questions.
•	 A 76-year-old female
•	 Karnofsky score: 90% (able to carry on normal activity; minor signs or symptoms of disease)
•	 Right-sided breast cancer 
•	 One lesion of 1.7 cm in the upper outer quadrant
•	 Invasive ductal adenocarcinoma
•	 cT1c, cN0
•	 ER+, PR+, Her2neu−
•	 No contraindications to breast-conserving therapy
•	 No comorbidities 
1. What would be your treatment recommendation regarding resection of the tumour? (please choose 
one answer
□ I would not give any recommendation, I leave the choice to the patient   
□ Breast-conserving surgery, followed by radiotherapy 
□ Mastectomy
2. Suppose the patient indicates that she would like to undergo breast-conserving surgery, but no radio-
therapy. Would you accept this? (please choose one answer)
□ Yes, without question 
□ Yes, but I would still try to convince her of the benefit of radiotherapy 
□ No, I would recommend her a mastectomy with reconstruction 
□ No
CASE SCENARIO 1 B – Type of surgery and adjuvant radiotherapy
Suppose that the same patient is 84-years-old. 
•	 An 84-year-old female
•	 Karnofsky score: 90% (able to carry on normal activity; minor signs or symptoms of disease)
•	 Right-sided breast cancer
•	 One lesion of 1.7 cm in the upper outer quadrant
•	 Invasive ductal adenocarcinoma
•	 cT1c, cN0
•	 ER+, PR+, Her2neu−
•	 No contraindications to breast-conserving therapy
•	 No comorbidities
1. What would be your treatment recommendation regarding resection of the tumour? (please choose 
one answer
□ I would not give any recommendation, I leave the choice to the patient   
□ Breast-conserving surgery, followed by radiotherapy 
□ Mastectomy
2. Suppose the patient indicates that she would like to undergo breast-conserving surgery, but no radio-
therapy. Would you accept this? (please choose one answer)
□ Yes, without question 
□ Yes, but I would still try to convince her of the benefit of radiotherapy 




CASE SCENARIO 2 A – Adjuvant systemic treatment 
•	 A 77-year-old female
•	 Karnofsky score: 90% (able to carry on normal activity; minor signs or symptoms of disease)
•	 Right-sided breast cancer
•	 One lesion of 3.0 cm in the upper outer quadrant
•	 Invasive ductal adenocarcinoma
•	 A modified radical mastectomy was performed
•	 pT2, pN1
•	 Grade 3
•	 ER+, PR+, Her2neu−
•	 No comorbidities
1. What would be your treatment recommendation? (please choose one answer)
□ No adjuvant systemic treatment
□ Adjuvant hormonal therapy 
□ Adjuvant chemotherapy, followed by adjuvant hormonal therapy




CASE SCENARIO 2 B – Adjuvant systemic therapy 
Suppose that the same patient has a Karnofsky score of 50%.
•	 A 77-year-old female
•	 Karnofsky score: 50% (requires considerable assistance and frequent medical care)
•	 Right-sided breast cancer
•	 One lesion of 3.0 cm in the upper outer quadrant
•	 Invasive ductal adenocarcinoma
•	 A modified radical mastectomy was performed
•	 pT2, pN1
•	 Grade 3
•	 ER+, PR+, Her2neu−
1. What would be your treatment recommendation? (please choose one answer)
□ No adjuvant systemic treatment 
□ Adjuvant hormonal therapy 
□ Adjuvant chemotherapy, followed by adjuvant hormonal therapy
















































































CASE SCENARIO 3 – Neo-adjuvant therapy
•	 A 75-year-old female
•	 Karnofsky score: 90% (able to carry on normal activity; minor signs or symptoms of disease)
•	 Right-sided breast cancer
•	 One lesion of 3.5 cm in the upper outer quadrant, size 36A
•	 Invasive ductal adenocarcinoma
•	 cT2, cN0
•	 ER+, PR+, Her2neu−
•	 No comorbidities
1. What would be your treatment recommendation? (please choose one answer)
□ I would not give any recommendation, I leave the choice to the patient  
□ Mastectomy                
□ Neo-adjuvant hormonal therapy, followed by breast-conserving surgery          




CASE SCENARIO 4 – Adjuvant systemic therapy
•	 A 75-year-old female
•	 Karnofsky score: 90% (able to carry on normal activity; minor signs or symptoms of disease)
•	 Right-sided breast cancer
•	 One lesion of 3.0 cm in the upper outer quadrant
•	 Invasive ductal adenocarcinoma
•	 A modified radical mastectomy was performed
•	 pT2, pN1
•	 Grade 3
•	 ER−, PR−, Her2neu−
•	 No comorbidities
1. Would you consider adjuvant chemotherapy? (please choose one answer)
□ No, I would not consider adjuvant chemotherapy 
□ Yes 
□ Yes, but only if the patient has a strong preference for chemotherapy treatment  











Older patients with breast cancer and their clinicians often face difficult treatment decisions, 
including a decision between a mastectomy (MAST) or a breast-conserving surgery (BCS), 
and whether to add systemic therapy (i.e., chemotherapy or hormonal therapy). Treatment 
decision-making for older patients generally presents a challenge, as scientific evidence for 
the best treatment option is often limited,1 older patients differ in a number of important 
aspects from younger patients, and as the older patient population itself is characterized 
by a wide diversity in health and functional status.2 Consequently, a shared decision-making 
process has been advocated as the preferred way to individualize breast cancer treatment 
for older patients.1,3,4 
Studies have shown that older patients are less likely to receive the same treatments as 
younger patients5,6: they less often undergo BCS, radiotherapy (following BCS) and adjuvant 
chemotherapy (aCT). It is unclear whether age-related differences in treatment reflect older 
patients’ preferences or clinicians’ preferences, or a combination of these. To optimize care 
for older breast cancer patients, knowledge about the treatment decision-making process 
with older women is urgently needed. 
The research in this thesis aimed to gain insight into the preferences of older patients 
and breast cancer specialists, with a focus on the first group. We started by reviewing the 
literature on patient preferences for surgical and adjuvant systemic therapy. We then carried 
out a prospective study in which we included older patients with newly-diagnosed early-stage 
breast cancer and compared their preferences for treatment and participation in decision-
making with those of younger patients. Finally, we explored the treatment recommendations 
of clinicians for older breast cancer patients, including how their recommendations were 
influenced by patient age and performance status, and by clinician specialty. In this chapter, 
the main findings are discussed and put into perspective. Subsequently, recommendations 
for practice, policy and future research are provided.
Main findings 
The systematic review (chapter 2) showed that factors related to body image and survival/
recurrence determined the preferences of early-stage breast cancer patients for, respectively, 
BCS or MAST. A majority of patients considered small/moderate benefits in survival rate/life 
extension sufficient to make both aCT and aHT worthwhile, although individual preferences 
varied widely. Determinants of patient preference were most often significantly related to 
quality of life: a better perceived well-being during treatment was related to more willingness 
to accept systemic therapy. Socio-demographic (e.g., patient age) and disease characteristics 














Results from the prospective study showed that both younger and older patients most 
frequently preferred BCS plus radiotherapy (69% and 56%, respectively) (chapter 3). Both 
age groups considered the clinicians’ recommendation to be the most important influencing 
factor. However, older patients were more concerned than younger patients about the 
possible need for additional surgery and they attached less importance to the possibility 
of breast reconstruction. The latter was also reflected in their lower preference for breast 
reconstruction following MAST. 
 
Further, older patients were less willing to undergo aCT (62% versus 92%, respectively) and 
aHT (59% versus 92%) than younger patients, although this was not statistically significant for 
aHT (chapter 4). The older patients willing to undergo aCT required similar benefits in 10-year 
disease-free survival as younger patients from aCT (median: 5% versus 4%) and aHT (median: 
10% versus 8%). Main motivations for undergoing therapy included the wish to survive/
avoid a disease recurrence and the clinician’s advice (more often affecting older patients). 
Motivations against therapy were concerns about the treatment duration (mainly referring 
to aHT) and side effects. Older patients cited additional motivations against aCT including the 
wish to maintain quality of life/independence. Overall, patients who were single/divorced/
widowed, who had a geriatric condition, or who preferred an active role were less likely to 
prefer aCT. 
Finally, our results showed that older patients more frequently preferred to share the 
decision about type of surgery, aCT and aHT with the clinician (chapter 5). In contrast, 
younger patients more often preferred to make these decisions themselves or to defer these 
decisions. Regarding perceived actual roles, both age groups most frequently reported an 
active role in the decision between BCS versus MAST. Contrary to younger patients, older 
patients more often reported to have had a passive role in the decisions about adjuvant 
systemic therapy.  The differences in preferred and perceived roles between the groups were 
not statistically significant. 
 
The online survey among breast cancer specialists showed that treatment recommendations 
about radiation, surgical and medical oncology treatments did not differ much among the 
different specialties (chapter 6). In the hypothetical scenarios representing only patients >70 
years of age, clinicians were more likely to recommend MAST for an older than for a younger 
patient with a small tumour, and more willing to omit radiotherapy after BCS in the older 
patient if this was the patient’s preference. Also, all clinicians would recommend either aHT 
with or without chemotherapy for a patient at high risk of recurrence in good health, whereas 
they would less often propose therapy (and if so, their recommendation always involved only 
aHT) for the same patient in poor health. In other scenarios, neo-adjuvant hormonal therapy 
followed by BCS for a patient with a large tumour was recommended by one-third of the 
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clinicians, and aCT in case of triple-negative breast cancer would be considered by four in five 
clinicians (either with or without a strong treatment preference of the patient).  
Discussion of the main findings 
Patient preferences for early-stage breast cancer treatments 
The elicitation of patient preferences for treatment and values regarding the benefits and risks 
of different treatment options is an essential component of shared decision-making between 
clinicians and patients. In decisions where there is no obvious best option, the patient’s own 
values become more important.7 Our systematic review of the literature identified numerous 
factors that breast cancer patients reported to influence their preferences for type of 
surgery (chapter 2). A main finding was that different decisive factors were found, namely 
patients who preferred BCS mostly valued body image-related factors, whereas patients 
who preferred MAST were mostly driven by concerns about survival or disease recurrence. 
The fact that early-stage breast cancer patients reported preferring MAST over BCS because 
they believe MAST will offer a better chance of survival is disconcerting as this may indicate 
that patients received inadequate information or, alternatively, that they were unconvinced 
about the equivalence of the options, despite being fully informed. It is therefore important 
that patients who are in a position to choose between BCS and MAST receive complete and 
balanced information about both surgical options and that their understanding of what they 
were told is checked to correct possible misconceptions. The results of the review showed 
that patient concerns about body image and disease recurrence are important topics that 
should be discussed between the patient and her clinician. Treatment-related factors, 
including the follow-up with radiotherapy, also appeared to be influential factors. However, 
most studies in the review included patients who had already made a treatment decision or 
who had already undergone surgery and radiotherapy. Factors that determined preferences 
may therefore not be extrapolated to patients who have yet to face the decision. Findings 
of the prospective study involving newly-diagnosed patients (chapter 3) support that fear 
of disease recurrence and concern about the loss of a breast are predominant concerns, but 
also show that patient preferences are strongly influenced by an aversion to more surgery, 
and to a smaller extent, by concerns about radiotherapy.
 
Patients with early-stage invasive breast cancer also often face the dilemma of whether to 
undergo a treatment that could potentially improve disease-free survival but is associated 
with unpleasant side effects. Chapter 2 described the finding that a majority of patients 
who were treated or had already made a treatment decision, were willing to undergo a 
systemic therapy for small or moderate chances of benefit, regardless of the side effects 
and inconvenience of the treatment. This is in line with findings of the prospective study 
(chapter 4), where we found that overall, most newly-diagnosed patients would accept 













prospective study showed that some patients would even choose therapy if there was no 
additional benefit, a finding also found in many other cancer contexts.8-12 Patients often 
reported to do everything possible to fight the cancer in order to live as long as possible and/
or to minimize their risk of local recurrence (chapter 4). Still, willingness to accept treatment 
for no or small extra chances of survival seems illogical or irrational, and clinicians should 
carefully question whether treatment should be given in these cases. Clinicians should know 
about their patient’s reasons for wanting or not wanting a burdensome treatment.  
 
Another important finding was the large variation in patient preferences for surgical and 
adjuvant systemic therapy and the different factors that shape their preferences (chapters 
2-4). Together, these findings suggest that clinicians should be aware of the different 
preferences between individual patients. However, evidence shows that patients rarely have 
individualized discussions with their clinicians and that exploration of patients’ treatment 
preferences is often done implicitly.13-17 Clinicians seldom inform patients of different 
treatment options or that a treatment decision needs to be made and seldom ask about their 
preferences. Other studies show that treatment plans often appear to have been already 
made at the multidisciplinary team meetings without knowing the patient’s preference.18 
It is known that patients and clinicians think about different determinants when making 
treatment decisions,11,19,20 with clinicians mainly focusing on the medical aspects of treatment. 
Consequently, there is a high probability that the recommended treatment plan will be 
unworkable in case the plan needs a revision if a patient becomes involved in a later stage.18 
The failure to incorporate patient preferences in clinical decision-making is disconcerting, 
given the preference-sensitive nature of the decisions in early breast cancer,21,22 but also in 
light of growing consensus that patients should be actively involved in their healthcare.23 
We also found that the input of the clinician was a highly influential factor for patients’ 
preference (chapter 3 and 4). Patients often tend to ask for guidance from their clinician 
as they believe that their clinician would know best. However, clinicians need to be aware 
that the preferences of patients might be different from theirs19,24 and that the preferences 
of (new) patients are not easily predicted based on their socio-demographic characteristics 
(e.g., patient age) or on actual health status (chapter 2-4). It is therefore crucial for clinicians to 
explicitly explore the values and preferences of their patients. Even though a strong influence 
of clinicians on patient’s preference does not automatically imply that patients’ values are 
left out in the treatment plan, we recommend that clinicians carefully plan communicating a 
treatment recommendation. Providing treatment advice early in the consultation may lead 
to patients believing that their own preferences and values no longer matter in the decision 
process, that the doctor knows what is best. It is also important that treatment information is 
provided without implicit persuasion. A recent oncology study14 regarding the decision about 
adjuvant systemic therapy demonstrated that clinicians often steered patients towards a 
particular treatment choice by the way they presented the information about the treatment 
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during the consultation. Even though clinicians are most likely unaware of this behaviour, 
patients may have the impression that they are pushed towards an option, possibly leading 
to an undesired decision. Therefore, only after balanced presentation about the treatment 
options, and patients’ preferences have been adequately discussed, clinicians could explicitly 
recommend a treatment that reflects the concerns of the patient.
The influence of age on patients’ preferences for treatment 
Although the need to gain insight into the treatment preferences of older patients is evident, 
only one study in our systematic review provided information on older patients and none of 
the included studies specifically explored age-related differences (chapter 2). Understanding 
which factors drive older patients’ preferences is important to tailor information provision 
and to assist clinicians in helping older patients in making treatment choices that fits their 
preferences. In daily practice, it is often assumed that older patients more frequently 
prefer MAST than younger patients. Potential explanations assumed are that older patients 
are less concerned about body image, are less willing to attend the subsequent visits for 
radiotherapy they would receive after BCS (due to limiting mobility or reliance on others for 
transportation), and that they do not desire more surgery.25 According to the results of our 
prospective study (chapter 3), older patients most frequently preferred BCS, although to 
a lesser extent compared to younger patients. Perhaps more importantly, the proportion 
of older participants preferring BCS was larger than those preferring MAST. We also found 
that both age groups attached high importance to the same influencing factors, including 
body image. In line with other studies,26-29 breast conservation appears to be relevant to 
older patients during the last decades of life as well. Its importance should therefore not be 
underestimated and body image and the option of breast reconstruction should be a part 
of the conversation with older patients. Our findings do confirm the assumption that older 
patients may have a stronger aversion to possibly requiring further surgical procedures. 
In addition, older patients seemed to be more concerned about the possible side effects 
from radiotherapy and the frequent hospital visits, although they were not overly put 
off by these factors. These factors should also receive attention in discussions with older 
patients. The opinions of older patients about the omission of radiotherapy (after breast-
conserving surgery) is a topic that is currently explored in the Tailored Treatment in Older 
patients study (TOP30), a research project initiated at the Leiden University Medical Center 
and in collaboration with the Dutch Breast Cancer Association. Based on our findings, BCS 
is something that older patients are interested in discussing and considering in a similar way 
as younger patients and when indicated, BCS should therefore be offered to eligible patients 
alongside the option of MAST. 
Another prevailing presumption among clinicians is that older patients have a lower 













more important than a small, possible gain in disease-free survival.31,32 Our study seems to 
confirm the finding that older patients are less willing to add a systemic therapy than younger 
patients (chapter 4), but the difference in willingness was only statistically significant for aCT, 
and not for aHT. On the other hand, we also found that the older patients who would accept 
therapy, desired it as strongly as younger patients, and some even considering therapy for 
a 1% benefit. This finding may be considered somewhat surprising, but corresponds with the 
finding that many older patients would be willing to accept burdensome treatment. Like 
younger patients, older patients placed much importance on the possibility to reduce their 
risk of disease recurrence as well as on avoiding possible side effects. Based on our findings, 
the option of adjuvant systemic therapy should be discussed with them, and information 
on benefits and risks concerning a treatment with or without systemic therapy should be 
fully and neutrally delivered, so that patients can make an informed treatment preference. 
Both age groups considered the same main motivations for and against systemic therapy, but 
regarding aCT, older patients had reported that they wanted to keep their current quality of 
life and to continue their daily life activities. They also feared losing their independence after 
undergoing aCT. When communicating the risks and benefits of adjuvant systemic therapy 
with older patients, the impact of treatment on these aspects should deserve specific 
attention. 
There were no overt differences regarding aHT between the age groups, and it was notable 
that older – like younger - patients also reported to be concerned about the side effects and 
treatment duration. Adjuvant hormonal therapy is often regarded as a treatment that is 
milder and easier to use than aCT, although treatment lasts for a considerably longer time. 
It is often the only available systemic treatment option for older patients, in particular for 
those with comorbid conditions. However, higher discontinuation and nonadherence rates 
have been observed in older patients,33-36 with up to 49% discontinuation rate reported.37 
Research has shown that patients find the side effects to be burdensome,38 and that the side 
effects were the most common reason for discontinuing treatment before completion of the 
recommended five years.39 As aHT is an important option for older patients, more attention 
should be given to the impact of treatment before they start treatment in order for them to 
better cope with the possible side effects and to improve therapy adherence/persistence.40
An essential question arising from these findings is whether treatment decision-making 
with older patients requires a different approach than that with of younger patients. It is 
important to acknowledge that reasons unique to this age group were found, but also that 
many influencing factors were the same for both younger and older patients. Older patients 
may have a lower willingness to undergo BCS or adjuvant systemic therapy than younger 
patients, but the variation in preferences and the weight put on different factors within the 
older – as within the younger – patient population illustrate the importance of eliciting and 
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taking into account older patients’ preferences, not just those of younger patients. That 
such an approach is needed is strengthened by the finding that patient preferences were 
influenced more by social support, health status and decisional role preference than by their 
age (chapter 4). Older patients were more likely to indicate the clinician’s advice as the most 
significant influence on treatment preference. Because the treatment recommendation of 
the clinician is more highly valued by older patients (also slightly seen in chapter 3) and by 
those who were undecisive about their preference (who were in particular older patients), 
clinicians should be aware of the factors that older patients consider important (and that are 
different than those of younger patients). For example, older patients differed most in their 
preferences from younger patients with regard to aCT, which indicates the need for age-
specific information provision about aCT. Our findings fits the current shift seen in oncology 
from a ‘one-size-fits-all’ approach towards personalized medicine.
The influence of clinician’s preference on treatment of older patients 
Understanding the variation in treatment between younger and older patients also requires 
insight into the ideas that clinicians have regarding the management of breast cancer in 
older patients. Using hypothetical scenarios, we found that most clinicians of the different 
breast cancer specialties seemed to take a similar approach to our treatment scenarios 
under investigation. However, the discrepancy between the overall selected treatment 
recommendations and the actual treatment of older breast cancer patients (chapter 6) 
raised the question which factors may lead clinicians in deciding whether or not to treat 
older patients. In the scenario about locoregional therapy, a majority of the clinicians would 
be willing to omit radiotherapy for a patient over the age of 70 years, but in practice older 
patients, like younger patients, almost always receive radiotherapy.41 The TOP study will 
assess whether radiotherapy after BCS can be omitted in specific older breast cancer patients 
without negatively affecting their disease recurrence or survival, and possibly resulting in 
reduced costs. To that end, comparative effectiveness research will be performed, as well 
as surveys among older breast cancer patients and specialists about their opinions regarding 
omission of treatment.30 Results of this study will provide more clarity regarding this topic. 
It is possible that clinicians find it difficult to advice omission of a treatment that is well-
established in clinical guidelines, despite the fact that there is strong scientific proof from 
trials that the option of radiotherapy may be questioned in certain selected older patients.42 
Our findings imply that although clinicians seemed to acknowledge this evidence, they have 
a strong tendency to adhere to the guidelines. Possibly, we might have to consider to change 
current guidelines by incorporating age- or subgroup-specific sections.
Another finding was that some clinicians would recommend or consider aCT for an older 
patient in otherwise good health at high-risk for recurrence, however, the actual uptake 













guidelines advocate the consideration of chemotherapy for ‘fit’ older patients without 
specifying this definition. Consequently, this lack of information may hinder the application 
of this recommendation.43 Clinicians may also be particularly reluctant to recommend current 
recommendation in older patients because they are uncertain about the benefits. Although 
clinicians selected treatment in accordance with current evidence, their uncertainty to 
recommend aCT seems to be a reflection of the guidelines. Possibly, more trials are needed 
to guide decisions about extensive treatment and to fine-tune current guidelines for 
chemotherapy at older age. 
While abovementioned factors may contribute to the age-based variation in treatment, 
recent attention has been directed to the strong influence of a patient’s chronological age 
on treatment options presented to patients by clinicians.44-46 A study showed that although 
performance status was cited the most important factor affecting their treatment decisions, 
96% of the clinicians would choose an intensive treatment for a 60-year-old breast cancer 
patient, compared to only 13% for an 85-year-old patient who had the same characteristics as 
the younger patient.47 Other vignette studies also found that patient’s age was considered 
the most influential factor when making treatment decisions for older patients.48 Similarly, 
clinicians in our study made different recommendations for locoregional therapy based on 
patient age. Although it was quite obvious for them to notice that we were interested in 
the age factor, they still provided different treatment recommendations, which raises the 
possibility of a different approach towards older adults based on their chronological age. 
Although it is inarguable that ageing is associated with an increase in medical and social 
problems, and that older patients may generally not benefit as much as younger patients 
from certain treatment, ageism can lead to misconceptions as to what is best for the patient. 
A number of potential explanations have been offered for a different approach.44 It is often 
expected by society that older adults are mentally and physically weak, and are dependent 
on others.18 These negative perceptions are further strengthened by the portrayal of older 
patients in the media. Further, breast cancer in older patients is often portrayed to be less 
agressive and less deadly compared to younger patients, although some studies show 
otherwise.49,50 Also, perceptions about older patients not wanting certain treatments or 
not wanting to share decision-making51 may lead to clinicians behaving – consciously or 
unconsciously – differently towards older patients. It may result in elderspeak (speaking 
slower/louder when talking to an older individual44), less consultation time spent with older 
patients,52 and being directer about their own preferences.3,53-55 Despite best intentions 
(e.g., protecting older patients from unacceptably harmful treatments), making unilateral 
decisions or witholding treatment options based on unsounded beliefs about an entire group 
of patients may jeopardize clinicians in fullfilling their obligations to inform eligible patients 
about available options, and also denies older patients becoming involved in decision-making. 
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It is important to be aware of this, because most older adults are different from how they 
are stereotyped, and most are still independent and fully capable of cognitive and physical 
activities. In addition, there are indications that older patients are becoming more assertive 
during consultations, desire more information and want to be above all kept informed about 
their disease and treatment options.56,57 Also, they use the Internet more to seek health 
information.58,59 As discussed earlier, results of the prospective study (chapters 3-5) run 
counter to the prevailing presumptions about the preferences of older breast cancer patients. 
Altogether, this raises interesting questions on how to approach older patients in clinical care 
and how to change the current views about older patients. Suggestions to improve clinical 
practice and health care policy are discussed in the following paragraphs. 
Methodological considerations
In the previous chapters, we described the various strengths and limitations of the studies in 
this thesis. In the following paragraphs, some general strengths and limitations are discussed 
in detail. 
An important strength of this thesis is that we captured the perspectives of older patients and 
clinicians. A strength of the studies performed among patients was its prospective design. 
The innovative aspect was that preferences were assessed even before patients received 
a treatment recommendation from the surgical oncologist or information about a possible 
referral to a medical oncologist. In retrospective studies, the patients may have had a strong 
preference for the treatment they underwent, which may be caused by a psychological 
mechanism (i.e., cognitive dissonance reduction or post-hoc justification60). Even in previous 
prospective studies, in which preferences were assessed before the start of treatment, but 
after a treatment decision had been made, patients may already have had a more positive 
attitude towards their recommended treatment.60 As a result of our study design, we could 
minimize the possible influence of cognitive dissonance reduction or justification. 
Nonetheless, several limitations should be considered. A main shortcoming of the studies 
among patients is the smaller number of older patients who participated in the study 
compared to that of younger patients. In two studies, one third of the sample were aged ≥65 
years and in one study, the percentage of older patients was around 30%. These percentages 
are smaller than the estimated 40% of the new breast cancer cases in older women. As earlier 
addressed, we were unable to include more older patients, as many of the older patients who 
were approached and participated in the study, were identified with a previous malignancy 
later on, after review of their medical records. This previous experience could have influenced 
their opinion about the treatment under investigation. We acknowledge that comparisons 
between younger and older patients could have been more properly explored using a larger 













characteristics of our older patients with those older patients in a population-based cohort 
study in the Netherlands61 and this showed that the samples were comparable with regard to 
median age and presence of comorbid and geriatric conditions.
Second, in the study among clinicians, the number of radiation and medical oncologists was 
lower than the number of surgical oncologists. Consequently, results may greater imply the 
views of the latter group. Further, we did not directly assess agreements between what 
clinicians report to recommend versus what they actually recommend. Therefore, it is not 
clear from our work which factors may lead clinicians in deciding whether or not to treat 
older patients. 
Next steps to further improve decision-making in older women with breast cancer
In the Netherlands, approximately 60,000 (60%) of all newly-diagnosed cancers currently 
occur in older adults.62,63 This number will rise due to the ageing of the Dutch population. 
Consequently, a trend will be seen in which all subspecialties of oncology will primarily deal 
with the care of older patients. Paradoxically, there is limited knowledge about the treatment 
and psychosocial needs of older cancer patients.64,65 Fortunately, it has become well-
recognized that the focus needs to be on this patient group. Between 2011 and 2014, the Dutch 
Cancer Society prioritized its agenda onto geriatric oncology and funded projects involving 
older individuals with cancer.58 Similarly, the Dutch Breast Cancer Association focused 
their policy on older patients between 2012 and 2014 and conducted a project to explore 
their information needs.66 Further, national (e.g., Geriatric Oncology Netherlands67) and 
international (e.g., SIOG1) societies and organizations committed to geriatric oncology have 
made great efforts to raise awareness in the medical community and to exchange information 
about best care between clinicians, patient associations and researchers with an interest in 
geriatric oncology. However, it is clear that still much work is to be done, especially in the 
field of breast cancer. If current demographic trends continue, older patients will comprise 
52% of the new breast cancer cases by 2030, compared to 40% in 2012.68 Consequently, more 
data are required to guide treatment decision-making; however, still only 2% of the ongoing 
clinical trials specifically focus on older patients.64 
In the following sections, implications for health policy and clinical practice are discussed 
based on the findings of this thesis. Also, recommendations for future research are given. 
Implications for practice and policy
Our findings prove the need for clinicians to explicitly explore older patients’ preferences, as 
their preferences varied widely. Even more so important, older patients reported preferences 
that deviated from previous assumptions (e.g., older patients would be willing to undergo 
breast-conserving surgery or adjuvant chemotherapy). If clinicians assume that they know 
their older patients’ preferences based on the patient’s age without explicitly asking them, 
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they may erroneously believe that older patients do not want certain treatments and propose 
a treatment plan that is not consistent with their preferences. Therefore, it is important that 
clinicians discuss all available treatment options and explicitly explore the older patient’s 
wishes, regardless of whether or not the patient defers the final decision.69 They need to be 
asked about their wishes as early as possible in the decision process, so that their preferences 
can be taken into account in multidisciplinary team meetings as much as possible. 
What can be done to help clinicians to further optimize elicitation of older patients’ 
preferences? A practical step could include the development and use of patient decision aids 
tailored to the needs of older patients. Decision aids are tools that help make the decision 
explicit by outlining the available treatment options and associated benefits and risks, and 
have been overall successful in clarifying patients’ values and preferences.70 These tools may 
well be effective in supporting older patients’ decision-making and improving patient-clinician 
communication.71-73 Our results on the unique concerns of older patients could inform on the 
benefits and risks to be included in new71,74 or existing75 patient decision aids (chapters 3 and 
4).  
It may also be useful to add a separate module dedicated to older patients to the current breast 
cancer treatment guidelines. Such an addition would likely create more awareness among 
clinicians about the severity of the disease in this patient group. Throughout the module the 
emphasis should be on the older patient’s preference, especially in decisions for which there 
is limited scientific evidence about the best treatment option. It would be helpful to mention 
the specific treatment decision points for which there is a high need to explicitly explore the 
older patient’s preference. The current breast cancer guidelines briefly remark that patient 
preference should be taken into account for the decision between breast-conserving surgery 
versus mastectomy, but do not elaborate on the reason to inform patients about treatment 
options and to discuss their values, nor acknowledge that an individualized approach may lead 
to different treatment advices. Additionally, a comment that older patients’ expectations, 
preferences and motivations can be different from those of previous generations of elderly 
could be helpful, supported by a description of research data about current older patients’ 
preferences. Our results have highlighted which topics clinicians should clearly consider 
bringing into their conversations with older patients (chapters 3 and 4). 
As described above, we argued that clinicians should more intensively ask the older patient 
about her preferences. However, this may not be sufficient to improve shared decision-
making between the clinician and older patient. Most importantly, the mindset of clinicians 
needs to be changed with regard to older patients. It is important for them to acknowledge 
that views of older patients about their desired role in decision-making may have changed 













expected. This change in the current group of older patients means that, consequently, a 
change in the perceptions among clinicians about older patients is required to reflect this 
reality. If clinicians fail to recognize this, then all abovementioned recommendations will most 
likely not be followed or considered. Implementation strategies must therefore rather focus 
on making clinicians aware of the possible impact of their attitude towards older patients, 
and on educating them about communication methods with older patients through training 
sessions. These sessions could be done by using role playing to practice communication skills. 
Previous research has shown that such interventions may result in increased knowledge 
about and a more positive attitude towards older patients.40,78 More general, clinicians can 
be trained more thoroughly in shared decision-making to create awareness about their 
important role therein.79 Current national campaigns stimulating the implementation of 
shared decision-making in hospitals (Beslist Samen! and Betere zorg begint met een goed 
gesprek80) are great initiatives to better equip clinicians with the tools to facilitate a shared 
decision-making conversation.
 
Aside from the clinician’s role, it is also important to stimulate older patients themselves to 
become more involved in decision-making. Older women are especially in need of support 
since they seem more likely to experience lower levels of patient involvement than younger 
patients (chapter 5) and also more likely encounter specific barriers (e.g., not really allowed 
to decide, lower health literacy81) next to general and well-known barriers (e.g., time 
constraints). Further, older patients may be exposed to negative stereotypes, but they 
themselves may also be biased (e.g., breast reconstruction is not appropriate at older age43), 
which may prevent them from bringing up important topics. As shared decision-making starts 
with the clinician inviting the patient to make the decision together, the clinician is according 
to our belief the most important person to empower older patients and to guide them in the 
decision-making process. It has been shown that clinicians serve as a useful first resource of 
information58,82,83 and that clinicians create a trustful environment in which the patient feels 
comfortable to express her values and concerns.69,84 Additionally, there are general initiatives 
to help older patients prepare better for their consultation, such as the ask-three-questions 
(‘what are my options?’; ‘what are the possible benefits and harms of those options?’; ‘how 
likely are each of those benefits and harms to happen to me?’85). Encouraging patients to ask 
a few key questions can already lead to higher quality information about treatment options 
from their clinician and thus greater patient involvement.86 Also, decision support tools may 
be helpful in supporting the participation of the older patient in decision-making. Therein 
also lies in part a responsibility of the Dutch Breast Cancer Association to stimulate them in 
taking an active role in their healthcare. Based on their information needs project, they have 
undertaken several actions to provide older patients with tailored patient education, one of 
which included the addition of segments about breast cancer at older age on their webpage 
and to their magazine.87 Further, they developed a checklist of relevant questions for older 
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patients during the consultation (i.e., B-bewust checklist88). 
Implications for research
An important area for future research would be to assess the preferences within the older 
patient population itself. Due to the low number of patients above the age of 75 years, we 
were unable to compare preferences between different age groups within the older patient 
sample. Since the heterogeneity of older patients drastically increases with increasing age, 
it would be important to know which factors may be more relevant for the older-old (often 
referred to as adults aged over 75) compared to the young-old (those aged 65-74 years). 
Further, it could be argued that with the changing demographic population, another cut-
off for older patients (e.g., 75 years and above) would provide greater meaning. It would 
be important for future research to recruit sufficient older-old patients to take into account 
their larger possibility of being excluded from the study, as in our case based on a previous 
malignancy. Possible solutions could be to recruit at more hospital sites (within the limits of 
financial resources and time available), or to recruit more older-old compared to young-old 
patients (for example, according to a 2:1 ratio). The findings of such studies can be compared 
with the findings of the patients in our studies, and could provide insight into whether our 
observed (dis)similarities hold in a larger sample. Aside from comparing age categories, it 
would be particularly relevant to assess whether treatment preferences are related to 
different levels of comorbid conditions, activities of daily living, social environment and 
quality of life in an older patient population. 
  
More research is needed on the factors that frequently affect older patients’ decision 
about whether to have breast reconstruction following a mastectomy. We noticed that 
the proportion of older patients who would prefer breast reconstruction was much lower 
than that of younger patients, but we had no information on the reasons for their different 
preferences. Based on our findings regarding their surgical treatment preference, older 
patients were less willing to deal with multiple surgeries, and this factor could be carefully 
extrapolated to breast reconstruction, as this procedure often entails multiple surgeries and 
is also a more extensive surgery. Other reasons of breast cancer patients, including being 
content with a prosthesis, could particularly apply to older patients,89 but it is also possible 
that older patients may believe that a breast reconstruction at old age is inappropriate.90 It 
is therefore necessary to enhance our study with results of other studies, to gain insight in 
reasons unique to older patients, and to (better) educate older patients about the possibility 
of breast reconstruction. 
 
Another important recommendation for future research is to more fully assess the decision-
making process by clinicians. If we want to stimulate the occurence of shared decision-













but also how clinicians make these. We would therefore argue for a combination of clinical 
encounters studies and self-reported data from clinicians to gain more insight into the 
decision-making process with older patients. Such findings could provide valuable insights for 
the development of interventions to optimize treatment decision-making with this patient 
group. 
Another key priority of future research is the development a decision tool, which not only 
predicts (disease-free) survival with or without therapy for an older patient, but also provides 
information on other outcomes, such as the quality of life or functional decline after specific 
breast cancer treatments. Such patient-centred outcomes are likely to be equally or more 
important to older patients and can be important considerations in decision-making. Current 
prediction models that are frequently used to communicate prognosis to patients, such as 
Adjuvant! Online, are based on basic patient and tumour characteristics and do not include 
outcomes such as functional decline. A prediction tool that not only includes traditional 
outcomes, but also focuses on other highly relevant outcomes for older patients could be 
particularly useful for both clinician and older patient in evaluating treatment options and in 
making more individualized treatment decisions.  
Finally, a general recommendation is to conduct more randomized clinical trials and 
prospective observational studies in older breast cancer patients to increase the evidence 
base. Fortunately, several (observational) studies have recently been initiated, such as the 
Climb Every Mountain study (functional, psychological, social and cognitive decline after 
treatment in older breast cancer patients91) and the TOP study.92 The studies described in this 
thesis were part of one of the largest studies among older patients, namely the FOCUS study 
(Female breast cancer in the elderly: Optimizing Clinical guidelines USing clinico-pathological 
and molecular data93), which combined information from various sources (e.g., population-
based national cancer registries, clinical trials and tumor tissues). The FOCUS study has 
recently been granted funding by the Dutch Cancer Society for a research project to develop a 
prediction tool, as earlier described, that should include both traditional and patient-centred 
endpoints.94 Findings of these and future studies in older patients will hopefully advance our 
knowledge and better guide clinicians and older patients in deciding which treatment option 
is best.
CONCLUDING REMARKS
The findings that this thesis brought to light will help in providing more understanding to the 
preferences of older patients and will assist clinicians in tailoring their information provision 
for this growing patient group. It showed that younger and older patients had many similar 
– but also some dissimilar – preferences. Although age-related differences need to be kept in 
mind, it is even more crucially important that an individualized approach is followed in older – 
144
  7
as in younger – patients. We consider it necessary that older patients are invited in treatment 
decision-making too, are informed about the risks and benefits of available treatment options, 
and are asked about their individual preferences and concerns. Our findings indicate that 
older patients may have certain preferences that run counter to the assumptions prevailing 
in oncologic clinical practice. Our findings suggest that this patient group could therefore 
profit considerably from the assessment of their preferences. In this process, a change in the 
behavorial culture of the medical community towards geriatric oncology is needed. More 
work is also needed on research level. Until then, the practical and policy recommendations 
mentioned in this thesis provide guidance to clinicians and policy makers, and contribute to 
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In Nederland werden in 2016 ongeveer 17.000 vrouwen gediagnosticeerd met borstkanker. 
Ongeveer 40% van de patiënten was 65 jaar of ouder ten tijde van de diagnose. Ondanks dat 
borstkanker een veelvoorkomend probleem is onder deze groep vrouwen, in het vervolg 
aangeduid als ‘oudere patiënten’, is de beste behandeling voor deze patiëntengroep 
vaak niet duidelijk. Het is belangrijk op te merken dat deze groep vaak wordt weggelaten 
uit klinische studies op basis van leeftijd of comorbiditeit. De behandeling van oudere 
patiënten met borstkanker wordt overigens bemoeilijkt doordat er geen leeftijdsspecifieke 
behandelrichtlijnen zijn en doordat de ouderenpopulatie zeer heterogeen is in termen van 
gezondheid, functioneren en sociaal welbevinden. Juist omdat er nog vrij weinig bekend 
is over de behandeleffecten, is het van belang om deze patiëntengroep zoveel mogelijk te 
betrekken in de besluitvorming, zodat deze een weloverwogen beslissing kan maken over de 
beste aanpak. Het proces waarbij arts en patiënt samen beslissen welk beleid het beste bij de 
patiënt past, oftewel de zogenaamde gedeelde besluitvorming, is in het bijzonder van belang 
bij beslissingen waarbij er meerdere behandelopties zijn. 
In dit proefschrift worden de voorkeuren van zowel de oudere patiëntengroep als de 
borstkankerspecialisten onderzocht om de huidige zorg voor deze patiëntengroep te 
verbeteren. Met het snel stijgend aantal borstkankerpatiënten boven de 65 neemt het belang 
van inzicht in hun voorkeuren toe. Al in een vroeg stadium van borstkanker moeten moeilijke 
beslissingen genomen worden, die betrekking hebben op de keuze tussen twee chirurgische 
opties en de keuze tussen het wel of niet ondergaan van een adjuvante systeembehandeling. 
Evenals jongere patiënten staan ook oudere patiënten vaak voor deze lastige keuzes. Beide 
groepen worden hierin bijgestaan door de arts. Bij borstkanker in een vroeg stadium verschilt 
de behandeling echter aanzienlijk tussen de jongere en de oudere patiëntengroep, wat 
mogelijk verklaard kan worden door de voorkeuren van de oudere patiëntengroep of door 
die van hun artsen. Op dit moment is nog weinig bekend over de voorkeuren van deze oudere 
patiëntengroep, terwijl kennis over de voorkeuren juist van grote waarde is.
Om te ontdekken hoe de huidige zorg voor de oudere patiëntengroep en de 
besluitvorming met deze patiëntengroep verbeterd kan worden, onderzoeken wij (i) 
wat de behandelingsvoorkeuren en overwegingen zijn van oudere patiënten met een 
vroeg stadium van borstkanker; (ii) of en hoe die behandelingsvoorkeuren en hun 
betrokkenheid in de besluitvorming verschillen met die van jongere patiënten; en (iii) wat de 
behandelingsvoorkeuren van borstkankerspecialisten zijn ten aanzien van oudere vrouwen 
met borstkanker. Dit hoofdstuk vat de inhoud van het proefschrift samen. 
Belangrijkste bevindingen 












borstverwijderende operatie en de chirurgische opties daarom vanuit medisch perspectief 
gelijkwaardig zijn, hangt de beste behandeling voornamelijk af van de waarden en 
preferenties van de patiënt. In hoofdstuk 2 beschrijven wij de resultaten van een systematisch 
literatuuronderzoek naar de behandelingsvoorkeuren van patiënten met een vroeg stadium 
van borstkanker. Het eerste doel van het literatuuronderzoek is om een overzicht te geven 
van de factoren die een rol spelen bij de patiëntvoorkeuren voor een borstsparende versus 
een borstverwijderende operatie. Wij hebben vijftien relevante studies gevonden. Uit ons 
overzicht blijkt dat zorgen over lichaamsbeeld en (ziektevrije) overleving doorslaggevende 
factoren zijn bij de beslissing voor een bepaald type operatie. Patiënten die lichaamsbeeld 
belangrijk vinden, geven de voorkeur aan een borstsparende therapie. Patiënten die zich 
zorgen maken om ziektevrije overleving prefereren daarentegen een borstverwijderende 
operatie. 
Het tweede deel van het literatuuronderzoek geeft een overzicht van de extra voordelen die 
patiënten met een vroeg stadium van borstkanker verlangen van een adjuvante behandeling 
om deze de moeite waard te vinden. Adjuvante systeembehandelingen, zoals chemotherapie 
en hormoontherapie, worden aan de behandeling toegevoegd met als doel de kans op 
ziektevrije of totale overleving te vergroten. Deze behandelingen hebben echter mogelijk 
bijwerkingen. Medisch gezien kan het niet ondergaan van een adjuvante behandeling dan 
ook een acceptabele keuze zijn, vooral als de kans relatief klein is op terugkeer van de ziekte 
of op overlijden door de ziekte. Zes studies blijken hiervoor relevant. De resultaten geven 
aan dat het extra voordeel dat de patiënten rapporteren over het algemeen klein is, maar 
dat de onderlinge voorkeuren sterk verschillen. Een deel van de patiënten zou namelijk 
voor de behandeling kiezen zonder enige voordeel, terwijl een ander deel de behandeling 
zou weigeren ondanks zeer veel voordeel. Verder komt in de meeste studies naar voren 
dat ‘de ervaren kwaliteit van leven tijdens de betreffende behandeling’ een voorspellende 
factor is. Patiënten die een betere kwaliteit van leven rapporteren kiezen namelijk eerder 
voor de behandeling. Een andere bevinding is dat de voorkeur voor een extra klein voordeel 
niet consistent samenhangt met sociaal-demografische kenmerken (bijv. leeftijd) of 
ziektekenmerken (bijv. stadium). 
Al met al geven de resultaten van het literatuuronderzoek aan dat het voor de dagelijkse 
praktijk van belang is dat clinici zich bewust zijn van de wensen en voorkeuren van individuele 
patiënten. Daarnaast dienen clinici vooraf naar deze wensen en voorkeuren te vragen om 
de behandeling beter aan te laten sluiten bij de voorkeuren van de patiënt. Uit hoofdstuk 
2 blijkt ook dat de meeste studies een retrospectief karakter hebben, waarbij de patiënten 
de chirurgische of adjuvante behandeling al hebben ondergaan. Maar ook in het merendeel 
van de prospectieve studies is de behandelingsbeslissing al gemaakt. Een beperking van 
deze studies is dat de patiënten mogelijk geneigd zijn te geloven dat hun keuze de beste is, 
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om zo de eventuele verschillen tussen de gekozen behandeling en hun mening daarover te 
beperken. De resultaten van deze studies weerspiegelen mogelijk dus niet de voorkeuren van 
patiënten die nog vóór de beslissing staan. Bovendien blijkt uit het literatuuronderzoek dat 
studies niet of nauwelijks zijn toegespitst op de oudere patiëntengroep: slechts één studie 
ging kort in op de voorkeuren van patiënten boven de 70 jaar. De voorkeuren van de oudere 
patiëntengroep zijn volgens clinici bekend, maar bewijs is er veelal nog niet. 
De resultaten van het literatuuroverzicht pleiten voor een prospectieve studieopzet 
(hoofdstuk 3, 4 en 5) waarbij nieuw-gediagnosticeerde patiënten met een vroeg stadium 
van borstkanker (0, I en II) worden geïncludeerd vlak na de voorlopige diagnose. Van 
januari 2012 tot en met december 2013 hebben wij een onderzoek uitgevoerd in meerdere 
onderzoekscentra. Nog strikter dan in eerdere prospectieve studies, werden in de analyses 
alleen de voorkeuren van patiënten meegenomen die vooraf aan het behandelplan gemeten 
waren. Het doel daarvan was het voorkomen van beïnvloeding van hun behandelend arts 
binnen het behandeladvies. In deze studies werd een vergelijking gemaakt tussen de jongere 
patiëntengroep (40 jaar tot en met 64 jaar) en de oudere patiëntengroep (gedefinieerd als 65 
jaar en ouder aan de hand van de criteria van de World Health Organization). 
Hoofdstuk 3 beschrijft de voorkeuren van beide patiëntengroepen voor een bepaald type 
operatie. Patiënten die in aanmerking kwamen voor zowel een borstsparende als een 
borstverwijderende operatie kregen na de diagnose een vragenlijst mee met een kort 
overzicht van beide type operaties, gevolgd door een vooraf gedefinieerde lijst van mogelijke 
beïnvloedbare factoren. Uit ons onderzoek blijkt dat beide patiëntengroepen voornamelijk 
een voorkeur hebben voor een borstsparende operatie: namelijk 56% van de oudere 
patiëntengroep en 69% van de jongere patiëntengroep. Wel heeft de oudere patiëntengroep 
vaker dan de jongere patiëntengroep een voorkeur voor een borstverwijderende operatie 
(40% versus 19%). Aan de andere kant heeft slechts 4% van de oudere patiëntengroep geen 
voorkeur of is hun voorkeur onbekend vergeleken met 12% van de jongere patiëntengroep. 
Deze verschillen zijn niet significant. Daarnaast blijkt dat voor beide patiëntengroepen het 
behandeladvies van de chirurg de belangrijkste factor is. Andere factoren die belangrijk 
worden geacht zijn angst voor terugkeer van de ziekte en het mogelijk missen van een borst. 
De mening van anderen (zoals de partner en familieleden) en angst voor radiotherapie worden 
door beide patiëntengroepen als het minst belangrijk beschouwd. Opmerkelijk is dat de 
oudere patiëntengroep significant vaker heeft aangegeven op te zien tegen de mogelijkheid 
dat er opnieuw geopereerd zou moeten worden. Mogelijk spelen factoren met betrekking 
tot de behandeling een grotere rol in de besluitvorming bij de oudere patiëntengroep en 
kan dit een doorslaggevende factor zijn in de voorkeur voor een borstverwijderende 
operatie. Ook zien we bij de oudere patiëntengroep de trend dat zij de bijwerkingen van 












laat meewegen dan de jongere patiëntengroep. Tevens hecht zij minder waarde aan de 
mogelijkheid tot borstreconstructie dan de jongere patiëntengroep. Dit bleek nogmaals toen 
een lager percentage van de oudere patiëntengroep aangaf dat zij hoogstwaarschijnlijk voor 
een borstreconstructie na een mastectomie zou kiezen (40% versus 77%). Naar aanleiding van 
deze resultaten concluderen wij dat het bij oudere patiënten – net als bij jongere patiënten 
- ook van belang is om beide chirurgische opties (met hun voor- en nadelen) te bespreken, 
zodat zij een geïnformeerde voorkeur kunnen ontwikkelen. Gezien de variatie in voorkeuren 
binnen de oudere patiëntengroep, is het belangrijk om inzicht te krijgen in de beweegredenen 
van de oudere patiënten op individueel niveau. Ook adviseren wij dat oudere patiënten in 
ieder geval geïnformeerd moeten worden over de mogelijkheid tot een borstreconstructie, 
zodat zij van deze optie afweten. 
Hoofdstuk 4 beschrijft een studie die als doel had te onderzoeken of er een verschil is in 
de bereidheid van de jongere en oudere patiëntengroep om een adjuvante systeemtherapie 
te ondergaan. Hiervoor gebruikten we gegevens uit zowel vragenlijsten als interviews. 
Patiënten met invasieve borstkanker (uit dezelfde patiëntengroep als in hoofdstuk 3) werden 
in de week na hun operatie geïnterviewd, maar nog voordat zij geïnformeerd werden over 
een mogelijke indicatie voor adjuvante systeemtherapie. Voorafgaand aan het telefonisch 
interview ontvingen zij een overzicht met twee hypothetische scenario’s. In het eerste 
scenario werd de keuze tussen wel of geen nabehandeling met chemotherapie beschreven 
en in het tweede scenario tussen wel of geen nabehandeling met hormoontherapie. In elk 
scenario werden de algemene kansen op terugkeer van de ziekte binnen tien jaar (met of 
zonder aanvullende behandeling) en de mogelijke bijwerkingen beschreven. Het interview 
bestond uit de volgende onderdelen: het extra voordeel dat de patiënt wilde hebben van 
de behandeling om deze de moeite waard te vinden (aan de hand van een veelgebruikte 
probability trade-off methode) en de factoren die de patiënt zou laten meewegen bij 
deze afweging. Uit de analyses blijkt dat de oudere patiëntengroep vaker een adjuvante 
systeemtherapie zou weigeren dan de jongere patiëntengroep (een significant verschil 
wordt alleen gevonden voor chemotherapie). Ook blijkt uit ons onderzoek dat een groter 
percentage van de oudere patiëntengroep het voordeel niet weet aan te geven. Drie op de 
vijf oudere patiënten zou echter kiezen voor beide aanvullende behandelingen. Toen men 
bij deze groep navroeg hoeveel voordeel (extra kans op tien-jaars ziektevrije overleving) 
de behandeling minimaal zou moeten opleveren, bleek het extra voordeel voor beide 
therapieën niet significant te verschillen met die van jongere patiënten (minimaal 4% en 
5% extra kans bij chemotherapie; 8% en 10% bij hormoontherapie). Toen men vroeg naar de 
factoren die een rol speelden bij de voorkeur van beide patiëntengroepen, beschouwden 
zowel de jongere als oudere patiëntengroep dezelfde factoren relevant (o.a. de wens om te 
overleven/geen recidief te krijgen) om voor een nabehandeling te kiezen. Uit ons onderzoek 
blijkt echter dat er grote verschillen zijn in de redenen om niet voor chemotherapie te kiezen. 
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Waar de jongere patiëntengroep de bijwerkingen als voornaamste reden noemt om niet voor 
chemotherapie te kiezen, noemt de oudere patiëntengroep bovendien als reden de wens 
hun onafhankelijkheid en huidige kwaliteit van leven te behouden. In de voorlichting aan 
oudere vrouwen dienen deze factoren meer aandacht te krijgen. Ook blijkt uit ons onderzoek 
dat patiënten die alleenstaand zijn, een geriatrische conditie hebben, of een actieve rol in de 
besluitvorming wensen een hoger voordeel van de chemotherapie willen om deze de moeite 
waard te vinden. Uit dit onderzoek concluderen wij dat de meerderheid van de oudere 
patiënten bereid is om een adjuvante systeemtherapie te ondergaan. Omdat er nog weinig 
wetenschappelijk bewijs is of chemotherapie bij oudere patiënten aanslaat, is het extra van 
belang om de verschillende behandelopties expliciet te bespreken (ook het niet ondergaan 
van behandeling) en naar hun overwegingen en voorkeuren te vragen, zoals al opgemerkt 
is in hoofdstuk 3. In aanvulling daarop constateren wij dat de leeftijd van de patiënt niet 
bepalend is voor het minimale voordeel en dat clinici zich hiervan bewust moeten zijn. Omdat 
voorkeuren kunnen verschillen tussen de jongere en oudere patiënten, tussen patiënten met 
verschillende persoonlijke kenmerken, maar ook binnen de oudere patiëntgroep zelf, is het 
van groot belang om de behandeling zoveel mogelijk af te stemmen op de individuele patiënt.
Hoofdstuk 5 onderzoekt in hoeverre jongere en oudere patiënten willen meebeslissen 
over hun behandeling. Hierbij zijn vragenlijstdata ingezet. Patiënten kregen voorafgaand 
aan het behandeladvies van de arts informatie uitgereikt over een borstsparende of 
borstverwijderende operatie (dezelfde informatie als in hoofdstuk 3) en over een 
nabehandeling met chemotherapie of hormoontherapie (wederom dezelfde informatie als 
in hoofdstuk 4). In de vragenlijsten werd de patiënt vervolgens gevraagd om per beslissing 
aan te geven of zijzelf die beslissing zou willen nemen, de arts wou laten beslissen of zij 
samen met de arts de beslissing wou nemen. Een klein aantal van de oudere patiëntengroep 
kiest ervoor de arts te laten beslissen, maar de meeste oudere patiënten hebben, net als 
jongere patiëntengroep, de voorkeur om deze beslissingen alleen of gezamenlijk met hun 
behandelend arts te nemen. Hoewel uit ons onderzoek blijkt dat jongere patiënten vaker dan 
oudere patiënten de beslissing zelf willen nemen of die aan de arts willen overlaten, zijn deze 
verschillen niet significant. We vergeleken ook per beslissing of er verschillen waren in de 
ervaren rol (vanuit het perspectief van de patiënt) tussen jongere en oudere patiënten. Onze 
analyses laten geen opvallende verschillen zien met betrekking tot de beslissing over het type 
operatie: beide patiëntgroepen geven aan dat zij vaak een actieve rol ervaren in de beslissing 
over het type operatie. Er blijken opvallende verschillen te zijn in de beslissingen over de 
nabehandeling. Oudere patiënten geven vaker aan een passieve rol te ervaren dan jongere 
patiënten, maar deze verschillen zijn niet statistisch significant. Onze resultaten maken 
duidelijk dat oudere patiënten betrokken moeten worden in het besluitvormingsproces en 
dat zij deze rol ook wensen. Een andere conclusie is dat oudere patiënten met name bij de 












grotere rol wensen. Daarnaast suggereren wij dat de verantwoordelijkheid voor het vergroten 
van deelname aan de besluitvorming van oudere patiënten met borstkanker voornamelijk 
bij clinici ligt, aangezien zij bepalen welke onderwerpen in het consult besproken worden. 
Het is belangrijk om tijdens het consult na te vragen of patiënten zelf een beslissing kunnen/
willen nemen, zodat de besluitvorming beter kan worden afgestemd op de voorkeuren van 
de individuele patiënt. Tot slot benadrukken wij dat er ook een rol voor de patiënt zelf is 
weggelegd om meer betrokken te zijn in beslissingen over hun behandeling. 
Ons laatste onderzoek, dat beschreven staat in hoofdstuk 6, heeft als doel inzicht te krijgen 
in de voorkeuren van verschillende borstkankerspecialisten voor het type behandeling bij 
oudere patiënten boven de zeventig jaar. Het is van belang bij de implementatie van nieuwe 
voorstellen of richtlijnen inzicht te hebben in de ideeën die onder clinici leven, om eventuele 
barrières weg te kunnen nemen. Hiertoe zijn de leden van de Nederlandse Verenigingen 
voor Chirurgische Oncologie, Radiotherapie en Oncologie, en voor Medische Oncologie via 
een online nieuwsbrief benaderd voor het invullen van een korte vragenlijst. De deelnemers 
werd een viertal scenario’s voorgelegd, waarbij hen gevraagd werd hun behandeladvies aan 
te geven. De resultaten laten zien dat patiëntkenmerken een significante invloed hebben 
op het behandeladvies van de artsen. Specialisten zouden minder vaak een borstsparende 
behandeling met radiotherapie adviseren voor een 84-jarige patiënte dan voor een 76-jarige 
patiënte met dezelfde tumorkenmerken. Ook zouden de specialisten vaker radiotherapie na 
een borstsparende operatie achterwege laten, indien de 84-jarige patiënte deze nabehandeling 
niet wenste te ondergaan. Voor chirurgisch en medisch oncologen blijkt de leeftijd van de 
patiënt van relatief groot belang, in tegenstelling tot radiotherapeut-oncologen die hetzelfde 
advies zouden geven ongeacht de leeftijd. In de drie andere casussen komt bij de specialisten 
duidelijke consensus naar voren over de beste behandeling. De algemene gezondheid van de 
patiënt is significant bepalend voor het behandeladvies. Het merendeel van de specialisten 
blijkt aanvullende hormoontherapie met of zonder chemotherapie aan te raden voor een 
oudere patiënte in goede algemene conditie, terwijl voor eenzelfde patiënte in matige of 
slechte conditie alleen hormoontherapie wordt aanbevolen. Ook komt naar voren dat één op 
de vier specialisten pre-operatieve hormoontherapie zou adviseren voor een patiënte met 
een grote, hormoongevoelige tumor, waarbij een borstsparende ingreep in eerste instantie 
niet mogelijk is. Vier van de vijf deelnemers geeft aan een aanvullende chemotherapie te 
overwegen in geval van een triple-negatieve borstkanker. Wij merken op dat de adviezen van 
de specialisten sterk verschillen met de huidige behandeling van de oudere patiëntengroep 
op basis van data van de Nederlandse Kankerregistratie. Een conclusie die wij hieruit trekken 
is dat er meer onderzoek nodig is om veranderingen in de bestaande behandelrichtlijnen te 




Algemene discussie en slotopmerkingen 
Ondanks dat de oudere patiëntengroep met borstkanker in de klinische praktijk steeds meer 
aandacht krijgt, is er momenteel nog vrij weinig bekend over hun voorkeuren. De voorkeuren 
van borstkankerpatiënten worden momenteel geregeld onderzocht, maar met de bestaande 
kennis lijkt het raadzaam om de focus te verschuiven naar de oudere patiëntengroep, 
aangezien het aantal oudere patiënten met borstkanker sterk zal stijgen de komende jaren. 
Gezien de grote heterogeniteit binnen deze patiëntengroep, ondervinden oudere patiënten 
moeilijkheden bij beslissingen over hun behandeling. Daarom is er voor deze groep nog veel 
te winnen bij een onderzoek naar hun voorkeuren. In de onderzoeken in dit proefschrift is 
in kaart gebracht wat de specifieke voorkeuren zijn en welke factoren belangrijk worden 
geacht (bij het maken van beslissingen over type operatie en nabehandeling) en in hoeverre 
de voorkeuren van oudere patiënten verschillen met die van jongere patiënten. Ook is 
onderzocht welke patiënt- en artskenmerken bepalend zijn voor het behandeladvies van 
borstkankerspecialisten. Dit proefschrift beschrijft resultaten waarin zowel patiënten als 
clinici, waaronder oncologisch chirurgen, radiotherapeut-oncologen en medisch oncologen, 
zijn betrokken. Ook de prospectieve studieopzet onder nieuw-gediagnosticeerde patiënten 
die nog geen beslissing hebben genomen, is van grote meerwaarde voor de klinische praktijk. 
Door het kleiner aantal oudere patiënten (leeftijd >65 jaar), zijn enkele methodologische 
uitdagingen ondervonden bij het vergelijken van de twee leeftijdsgroepen. 
Uit de resultaten van de studies blijkt de noodzaak om de oudere patiënt te betrekken bij de 
besluitvorming en deze de ruimte te bieden om haar individuele voorkeuren aan te geven. 
De resultaten in dit proefschrift kunnen gebruikt worden bij het vormgeven van toekomstige 
studies over besluitvorming bij oudere patiënten. De aanbevelingen voor de praktijk en 
beleid bevatten bruikbare aanknopingspunten om het huidige besluitvormingsproces met 
oudere borstkankerpatiënten in de dagelijkse praktijk te optimaliseren. In de algemene 
discussie pleiten wij er ook voor dat clinici meer kennis zouden moeten hebben van de 
verschillende voorkeuren en overwegingen van oudere patiënten, maar ook dat er meer 
aandacht moet worden besteed aan de impliciete verwachtingen van artsen over (de 
behandelingsvoorkeuren van) de oudere patiënt. Een investering in laatstgenoemde en het 
vergroten van het bewustzijn van bepaalde denkbeelden over deze patiëntengroep, zal van 
belang zijn om gedeelde besluitvorming te stimuleren. De behandelrichtlijn kan hier aandacht 
aan besteden door modules op te nemen met betrekking tot de oudere patiëntengroep en 
gezamenlijke besluitvorming. Daarnaast kan het aanbieden van communicatietrainingen aan 
clinici het besluitvormingsproces met de oudere patiëntengroep optimaliseren. Bovendien 
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